<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Kidney transplantation</title><meta name="description" content="Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis. The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="kidney transplant, renal transplantation, renal transplant, KT"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Kidney_transplantation"/><meta property="og:title" content="Kidney transplantation"/><meta property="og:description" content="Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis. The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding..."/><meta property="og:url" content="https://grokipedia.com/page/Kidney_transplantation"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Kidney transplantation"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:42.967Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Kidney transplantation"/><meta name="twitter:description" content="Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis. The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="d93c0b37899a85889cc33d986f3a70f4-62c37e3d0ce62b34-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=d93c0b37899a85889cc33d986f3a70f4,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.3072510647202047,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney-transplantation" class="transition-opacity hover:opacity-100 opacity-50">Kidney transplantation</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#historical-development" class="transition-opacity hover:opacity-100 opacity-50">Historical Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#early-attempts-and-immunological-challenges" class="transition-opacity hover:opacity-100 opacity-50">Early Attempts and Immunological Challenges</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mid-20th-century-milestones" class="transition-opacity hover:opacity-100 opacity-50">Mid-20th Century Milestones</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#late-20th-and-early-21st-century-advances" class="transition-opacity hover:opacity-100 opacity-50">Late 20th and Early 21st Century Advances</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recent-innovations-2010s2025" class="transition-opacity hover:opacity-100 opacity-50">Recent Innovations (2010sâ€“2025)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-indications-and-patient-selection" class="transition-opacity hover:opacity-100 opacity-50">Clinical Indications and Patient Selection</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#primary-indications" class="transition-opacity hover:opacity-100 opacity-50">Primary Indications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recipient-evaluation-process" class="transition-opacity hover:opacity-100 opacity-50">Recipient Evaluation Process</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#absolute-and-relative-contraindications" class="transition-opacity hover:opacity-100 opacity-50">Absolute and Relative Contraindications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#donor-sources-and-procurement" class="transition-opacity hover:opacity-100 opacity-50">Donor Sources and Procurement</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#living-donor-evaluation-and-surgery" class="transition-opacity hover:opacity-100 opacity-50">Living Donor Evaluation and Surgery</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#deceased-donor-criteria-and-retrieval" class="transition-opacity hover:opacity-100 opacity-50">Deceased Donor Criteria and Retrieval</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#expanding-donor-pools-through-policy-and-technology" class="transition-opacity hover:opacity-100 opacity-50">Expanding Donor Pools Through Policy and Technology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#xenotransplantation-and-bioengineered-options" class="transition-opacity hover:opacity-100 opacity-50">Xenotransplantation and Bioengineered Options</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#compatibility-and-allocation" class="transition-opacity hover:opacity-100 opacity-50">Compatibility and Allocation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hla-matching-and-crossmatching" class="transition-opacity hover:opacity-100 opacity-50">HLA Matching and Crossmatching</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#organ-allocation-algorithms" class="transition-opacity hover:opacity-100 opacity-50">Organ Allocation Algorithms</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#challenges-in-matching-and-prioritization" class="transition-opacity hover:opacity-100 opacity-50">Challenges in Matching and Prioritization</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#surgical-procedures" class="transition-opacity hover:opacity-100 opacity-50">Surgical Procedures</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recipient-implantation-technique" class="transition-opacity hover:opacity-100 opacity-50">Recipient Implantation Technique</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#variants-including-combined-transplants" class="transition-opacity hover:opacity-100 opacity-50">Variants Including Combined Transplants</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#postoperative-management" class="transition-opacity hover:opacity-100 opacity-50">Postoperative Management</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#acute-phase-care-and-monitoring" class="transition-opacity hover:opacity-100 opacity-50">Acute Phase Care and Monitoring</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#immunosuppressive-regimens" class="transition-opacity hover:opacity-100 opacity-50">Immunosuppressive Regimens</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-follow-up-protocols" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Follow-Up Protocols</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dietary-and-lifestyle-recommendations" class="transition-opacity hover:opacity-100 opacity-50">Dietary and Lifestyle Recommendations</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#complications-and-risks" class="transition-opacity hover:opacity-100 opacity-50">Complications and Risks</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#surgical-and-perioperative-complications" class="transition-opacity hover:opacity-100 opacity-50">Surgical and Perioperative Complications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#rejection-mechanisms-and-treatment" class="transition-opacity hover:opacity-100 opacity-50">Rejection Mechanisms and Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#infectious-and-malignancy-risks" class="transition-opacity hover:opacity-100 opacity-50">Infectious and Malignancy Risks</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cardiovascular-and-other-systemic-issues" class="transition-opacity hover:opacity-100 opacity-50">Cardiovascular and Other Systemic Issues</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prognosis-and-outcomes" class="transition-opacity hover:opacity-100 opacity-50">Prognosis and Outcomes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#graft-survival-metrics" class="transition-opacity hover:opacity-100 opacity-50">Graft Survival Metrics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#patient-survival-and-quality-of-life" class="transition-opacity hover:opacity-100 opacity-50">Patient Survival and Quality of Life</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#determinants-of-long-term-success" class="transition-opacity hover:opacity-100 opacity-50">Determinants of Long-Term Success</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ethical-legal-and-societal-dimensions" class="transition-opacity hover:opacity-100 opacity-50">Ethical, Legal, and Societal Dimensions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#the-organ-shortage-crisis-and-waitlist-deaths" class="transition-opacity hover:opacity-100 opacity-50">The Organ Shortage Crisis and Waitlist Deaths</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#allocation-fairness-and-geographic-disparities" class="transition-opacity hover:opacity-100 opacity-50">Allocation Fairness and Geographic Disparities</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#debates-on-organ-markets-vs-altruism" class="transition-opacity hover:opacity-100 opacity-50">Debates on Organ Markets vs. Altruism</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#access-inequities-and-systemic-biases" class="transition-opacity hover:opacity-100 opacity-50">Access Inequities and Systemic Biases</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiological-statistics" class="transition-opacity hover:opacity-100 opacity-50">Epidemiological Statistics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#global-transplant-trends-and-volumes" class="transition-opacity hover:opacity-100 opacity-50">Global Transplant Trends and Volumes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#national-variations-and-policy-impacts" class="transition-opacity hover:opacity-100 opacity-50">National Variations and Policy Impacts</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#recent-data-20202025-and-projections" class="transition-opacity hover:opacity-100 opacity-50">Recent Data (2020â€“2025) and Projections</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="kidney-transplantation" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Kidney transplantation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><br/>
The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding rejection due to genetic identity without the need for immunosuppression at the time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_100qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_140qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><br/>
Murray&#x27;s pioneering work, which earned him the 1990 Nobel Prize in Physiology or Medicine shared with E. Donnall Thomas, laid the foundation for modern transplantation, with subsequent developments in immunosuppressive drugs like cyclosporine in the 1980s dramatically expanding donor-recipient matching possibilities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><br/>
Despite these advances, kidney transplants face significant challenges, including immunological rejectionâ€”acute cellular or antibody-mediated, and chronic allograft nephropathyâ€”necessitating lifelong immunosuppression that increases risks of opportunistic infections, cardiovascular disease, and malignancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_200qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_240qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_280qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><br/>
One-year patient and graft survival rates typically exceed 95% and 90%, respectively, with living donor kidneys outperforming deceased donor grafts in longevity, though persistent organ shortages result in waitlist mortality rates of 5-10% annually in many regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2o0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2s0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="historical-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Historical Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="early-attempts-and-immunological-challenges" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Early Attempts and Immunological Challenges<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The initial experiments in kidney transplantation began with animal models in the early 20th century, building on Alexis Carrel&#x27;s pioneering work in vascular anastomosis in 1902, which enabled surgical connection of blood vessels but revealed rapid graft failure due to the host&#x27;s immune response against foreign tissue.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> In dogs, Emerich Ullmann&#x27;s 1902 attempt at heterotopic kidney autotransplantation succeeded temporarily, but allografts from other animals failed within hours to days, demonstrating the immunological barrier of tissue incompatibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Human attempts commenced in 1906 when Mathieu Jaboulay performed two xenotransplants using kidneys from a pig and a goat, respectively, anastomosed to the brachial artery and vein; both grafts thrombosed immediately, underscoring vascular and immunological incompatibilities across species.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> The first human-to-human allograft occurred on April 3, 1933, when Ukrainian surgeon Yuriy Voronoy transplanted a kidney from a deceased donor (dead 6 hours prior) into a 26-year-old woman dying of acute mercury poisoning; the graft produced urine briefly but ceased function within 48 hours, with autopsy revealing thrombosis and early necrotic changes attributable to immune-mediated rejection rather than solely technical issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Voronoy conducted a few additional transplants in the 1930s and 1940s, all failing rapidly, as did parallel efforts by surgeons like Jean Hamburger in France, where grafts lasted mere days amid uremic recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These failures stemmed primarily from acute allograft rejection, an unrecognized T-cell-driven process targeting major histocompatibility complex (MHC) antigens mismatched between donor and recipient, causing vascular damage, interstitial inflammation, and tubular necrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Without effective immunosuppressionâ€”limited to rudimentary measures like radiation or corticosteroids, which proved inadequate or toxicâ€”non-identical grafts universally rejected, as evidenced by Peter Medawar&#x27;s 1940s studies on skin grafts in rabbits, which established acquired immunological tolerance as the core obstacle and laid groundwork for understanding adaptive immunity&#x27;s role in transplant rejection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Early postoperative biopsies, when performed, showed lymphocytic infiltration and edema consistent with cellular rejection, but the absence of human leukocyte antigen (HLA) typing until the 1950s precluded matching, exacerbating outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> A 1950 deceased-donor transplant by Richard Lawler in Chicago functioned for about a week before rejection, highlighting that even short-term viability was exceptional without immunological compatibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_103abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The 1954 success of Joseph Murray&#x27;s team at Brigham Hospitalâ€”transplanting a kidney between identical twins, yielding over 5 years of functionâ€”conclusively proved that surgical technique alone sufficed when immune barriers were absent, isolating rejection as the paramount challenge limiting early transplantation to experimental failures or syngeneic cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> This immunological hurdle persisted until azathioprine&#x27;s introduction in 1960 enabled broader allograft survival, but pre-1950s efforts underscored the causal primacy of host-versus-graft immunity in graft demise, independent of procurement delays or ischemia, as postmortem analyses rarely implicated those factors over rejection pathology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="mid-20th-century-milestones" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mid-20th Century Milestones<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
In 1950, surgeon Richard Lawler at Mercy Hospital in Chicago performed the first intrabdominal kidney transplant from a cadaver donor to recipient Ruth Tucker, a 44-year-old woman with chronic kidney disease; the graft functioned for several weeks before rejection, marking an early step toward clinical viability despite limited immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Concurrently, David Hume at Peter Bent Brigham Hospital in Boston conducted pioneering human kidney allografts in the early 1950s, including a 1946 transplant to the arm vessels that briefly restored function, highlighting surgical feasibility but underscoring acute rejection as the primary barrier without effective immune control.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> These efforts laid groundwork amid experimental canine models in Paris and Boston during the 1940s, which demonstrated vascular anastomosis techniques essential for human application.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The breakthrough came on December 23, 1954, when Joseph E. Murray and J. Hartwell Harrison at Peter Bent Brigham Hospital successfully transplanted a kidney from Ronald Herrick to his identical twin brother Richard, who suffered from chronic glomerulonephritis; the absence of genetic disparity prevented rejection, enabling the graft to function for eight years until the recipient&#x27;s death from unrelated causes, establishing proof-of-principle for organ replacement therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> This identical twin procedure, later replicated including Hume&#x27;s 1957 transplant at Medical College of Virginia, confirmed long-term graft survival without immunosuppression, shifting focus to non-identical donor challenges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> By 1958, initial human kidney transplants incorporating corticosteroids and total body irradiation as immunosuppression demonstrated partial rejection mitigation, though with high complication rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The 1960s advanced immunosuppression with azathioprine, an antimetabolite derived from 6-mercaptopurine; Roy Calne in the UK first applied it clinically in 1960 for kidney recipients, reducing rejection incidence when combined with steroids, which improved one-year graft survival from under 50% to over 60% in early series.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Concurrent developments included tissue typing by leukocyte antigens in 1962, pioneered by teams like those at the University of Colorado, enabling donor-recipient matching to minimize histocompatibility mismatches and hyperacute rejection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> These innovations, validated in centers like Edinburgh where Michael Woodruff achieved the UK&#x27;s first long-term success in 1960, expanded transplantation beyond twins, though cadaver donor outcomes remained variable due to imperfect immune suppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<h3 id="late-20th-and-early-21st-century-advances" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Late 20th and Early 21st Century Advances<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The introduction of cyclosporine as an immunosuppressive agent in clinical renal transplantation in 1978, with widespread adoption by 1983, represented a major breakthrough by selectively inhibiting calcineurin to suppress T-cell activation and interleukin-2 production, thereby reducing acute rejection rates from over 50% to below 20% in the first year post-transplant and improving one-year graft survival to approximately 80-90%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Prior regimens relying on azathioprine and corticosteroids had limited efficacy, with graft survival often below 50% at one year due to uncontrolled rejection; cyclosporine&#x27;s specificity minimized broad immunosuppression-related infections while enabling broader donor-recipient matching.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the 1990s, tacrolimus emerged as a potent alternative calcineurin inhibitor, gaining U.S. Food and Drug Administration approval for kidney transplantation in 1997 after demonstrating superior prevention of acute rejection compared to cyclosporine in randomized trials, with equivalent long-term graft outcomes but a different side-effect profile including lower rates of cosmetic disturbances like hirsutism and gingival hyperplasia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Concurrently, mycophenolate mofetil was approved in 1995, replacing azathioprine in triple-drug regimens (calcineurin inhibitor, antimetabolite, and steroids) by more effectively inhibiting purine synthesis in lymphocytes, which further decreased rejection episodes by 20-30% and allowed steroid minimization or withdrawal in select low-risk patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Surgical innovations included the first laparoscopic living-donor nephrectomy performed in 1995, which reduced postoperative pain, hospital stays from 4-5 days to 1-2 days, and convalescence time by weeks compared to open procedures, thereby increasing living donation rates by addressing donor disincentives without compromising graft quality or recipient outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Induction therapies advanced with interleukin-2 receptor antagonists such as basiliximab, approved in 1998, providing targeted prophylaxis against early rejection in high-risk recipients when combined with maintenance regimens, achieving rejection rates under 15% in the initial post-transplant period.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Into the early 2000s, kidney paired donation programs gained traction, with initial small-scale exchanges in single centers matching incompatible donor-recipient pairs as early as the late 1990s, expanding nationally by the mid-2000s to facilitate over 100 transplants annually in the U.S. by 2010 through algorithms optimizing compatibility chains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> These developments collectively tripled the annual U.S. kidney transplant volume from about 7,000 in 1980 to over 17,000 by 2010, driven by enhanced graft longevity (median survival exceeding 10-15 years for living-donor kidneys) and reduced waitlist mortality, though chronic allograft nephropathy from calcineurin inhibitor nephrotoxicity remained a persistent challenge necessitating regimen refinements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<h3 id="recent-innovations-2010s2025" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Recent Innovations (2010sâ€“2025)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the 2010s, hypothermic machine perfusion (HMP) emerged as a key innovation for preserving deceased donor kidneys, particularly marginal ones, by actively circulating cold preservation solutions to reduce ischemia-reperfusion injury and improve graft viability compared to static cold storage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Clinical trials demonstrated that HMP increased utilization rates of expanded criteria donor kidneys by mitigating cold ischemic damage, with meta-analyses showing reduced delayed graft function incidence by up to 20-30% in randomized studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> By the mid-2010s, devices like the LifePort system gained widespread adoption in the United States and Europe, enabling better assessment of organ quality through real-time flow and resistance monitoring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Normothermic machine perfusion (NMP), which maintains kidneys at body temperature with oxygenated blood-like solutions, advanced further in the late 2010s and 2020s, allowing functional assessment and potential repair ex vivo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> A 2025 study reported successful transplantation of 36 human kidneys after 2-24 hours of NMP following initial cold storage, achieving 100% 30-day patient and graft survival, highlighting its potential to extend preservation times and resuscitate initially discarded organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> NMP also facilitates therapeutic interventions, such as defatting steatotic kidneys or delivering targeted drugs, addressing limitations of hypothermic methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Immunosuppression protocols evolved with the broader use of costimulation blockade agents like belatacept, approved by the FDA in 2011 for kidney transplant maintenance, offering a calcineurin inhibitor-sparing alternative that preserves renal function longer-term while reducing chronic allograft nephropathy risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> Trials in the 2010s and 2020s explored minimization strategies, including IL-6 inhibitors like tocilizumab to promote regulatory T cells and dampen effector responses, though widespread adoption remains limited due to infection risks and variable efficacy in diverse populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> Emerging cell therapies, such as MDR-101, entered trials by 2025 aiming for one-time tolerance induction to eliminate lifelong immunosuppression needs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Xenotransplantation marked a breakthrough in the 2020s, with gene-edited porcine kidneys addressing donor shortages through CRISPR modifications to eliminate hyperacute rejection triggers like alpha-gal epitopes and porcine endogenous retroviruses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> In March 2024, a genetically modified pig kidney transplant at Massachusetts General Hospital functioned for 52 days in a brain-dead recipient, followed by a February 2025 case at NYU Langone where a 53-year-old woman with end-stage kidney disease achieved immediate graft function, normalizing creatinine without dialysis for over a month before complications arose.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> By mid-2025, phase 1/2 clinical trials for living recipients commenced under FDA oversight, targeting highly sensitized patients ineligible for allografts, though porcine-specific immune barriers and zoonotic risks necessitate rigorous long-term monitoring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> These developments, while promising, highlight ongoing challenges in achieving indefinite survival beyond initial hyperacute phases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h2 id="clinical-indications-and-patient-selection" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Indications and Patient Selection<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="primary-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Primary Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney transplantation is primarily indicated for patients with <strong>end-stage renal disease (ESRD)</strong>, a condition characterized by irreversible loss of kidney function with a glomerular filtration rate (GFR) typically below 15 mL/min/1.73 mÂ², necessitating renal replacement therapy to sustain life.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> Unlike dialysis, which serves as a temporary or lifelong bridge, transplantation restores near-normal renal function, yielding superior long-term survival ratesâ€”such as a 10-year post-transplant survival advantage over dialysisâ€”and improved quality of life by alleviating dietary restrictions, fatigue, and cardiovascular risks associated with chronic dialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ocabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_scabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The most prevalent etiologies of ESRD prompting transplantation are <strong>diabetic nephropathy</strong>, accounting for the leading cause due to progressive microvascular damage from longstanding diabetes mellitus (type 1 or 2), and <strong>hypertensive nephrosclerosis</strong>, resulting from chronic uncontrolled hypertension leading to vascular and parenchymal injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ocqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_scqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Other common primary indications include <strong>glomerular diseases</strong> (e.g., focal segmental glomerulosclerosis, IgA nephropathy), <strong>polycystic kidney disease</strong>, and <strong>tubulointerstitial nephritis</strong>, each contributing to cumulative glomerular scarring and functional decline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1scqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Less frequent but notable causes encompass renovascular diseases, congenital anomalies, and rare genetic disorders like Alport syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Preemptive transplantationâ€”performed before initiating dialysis in patients with advanced chronic kidney disease (stage 4 or 5, GFR 15â€“29 mL/min/1.73 mÂ²)â€”is increasingly recommended as the optimal timing to minimize dialysis-related complications such as vascular access failures and infections, though it requires early multidisciplinary evaluation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> In pediatric populations, indications mirror adult ESRD causes but emphasize congenital and inherited disorders, with transplantation preferred over prolonged dialysis to support growth and development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Overall, candidacy hinges not solely on ESRD etiology but on holistic assessment of comorbidities, as transplantation does not cure underlying systemic conditions like diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<h3 id="recipient-evaluation-process" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Recipient Evaluation Process<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The recipient evaluation process for kidney transplantation involves a comprehensive, multidisciplinary assessment to determine a candidate&#x27;s suitability, optimize modifiable risks, and estimate expected survival benefit compared to remaining on dialysis. This process is typically coordinated by a team including transplant nephrologists, surgeons, coordinators, social workers, dietitians, and psychologists, aiming to identify contraindications or conditions requiring intervention prior to listing. Evaluation is recommended for patients with chronic kidney disease stages 4-5 (eGFR &lt;30 mL/min/1.73 mÂ²) at least 6-12 months before anticipated dialysis initiation to allow time for preemptive transplantation or risk mitigation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A thorough medical history review covers the etiology of end-stage renal disease, comorbidities such as diabetes (for which transplantation is recommended, including simultaneous pancreas-kidney for type 1 diabetes where feasible), cardiovascular disease, prior surgeries, and family history, alongside a physical examination assessing body habitus, frailty, and organ systems. Laboratory evaluations include complete blood counts, serum chemistries (e.g., electrolytes, PTH for hyperparathyroidism management), urinalysis, and screening for glucose metabolism abnormalities via oral glucose tolerance testing in non-diabetics; severe hyperparathyroidism should be treated medically or surgically pretransplant to avoid complications. Nutritional status and adherence barriers are assessed, with interventions like weight loss counseling suggested for obesity without automatic exclusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiovascular risk stratification is critical, given its role as a leading cause of post-transplant mortality; all candidates undergo history, physical exam, and ECG, with non-invasive stress testing recommended for asymptomatic high-risk individuals (e.g., diabetes, prior cardiac events). Severe, uncorrectable symptomatic cardiac disease or New York Heart Association class III/IV heart failure warrants exclusion unless survival prognosis aligns with national benchmarks, while peripheral artery disease or aortic aneurysms may require pretransplant correction if feasible. Pulmonary assessment includes chest imaging for all, with CT for heavy smokers (â‰¥30 pack-years), and gastrointestinal issues like active peptic ulcers or diverticulitis necessitate resolution before proceeding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Infectious disease screening follows evidence-based protocols, testing for HIV, hepatitis B/C, CMV, EBV, varicella-zoster, syphilis, tuberculosis (including latent), and endemic pathogens like Strongyloides or Chagas disease based on risk factors; active infections (except chronic HCV) delay transplantation until treated, with full TB therapy preferred pretransplant and vaccination updates (e.g., MMR, influenza) per guidelines. Tobacco cessation is strongly advised with counseling, as ongoing use elevates risks. Malignancy screening adheres to age- and risk-appropriate protocols (e.g., colonoscopy, mammography, prostate exam), excluding active cancers except low-grade indolent types; candidates with prior malignancies may require observation periods post-remission (e.g., 2-5 years for most solid tumors).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Psychosocial evaluation assesses mental health stability, substance use history, social support, cognitive function, and medication adherence potential, excluding candidates with unstable psychiatric conditions or active substance abuse impairing decision-making or posttransplant compliance; prior nonadherence does not preclude listing if barriers are addressed through counseling. Financial, housing, and transportation stability are reviewed, though lack of traditional support does not disqualify if a self-management plan exists. Immunologic workup includes ABO blood typing, HLA antibody screening via solid-phase assays, and panel-reactive antibody quantification to inform sensitization risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Upon completion, the team reviews findings to approve listing on the national waitlist if benefits outweigh risks, with ongoing monitoring for changes in status; additional tests like dental clearance, gynecologic exams, or vascular imaging may be required based on individual profiles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<h3 id="absolute-and-relative-contraindications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Absolute and Relative Contraindications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Absolute contraindications to kidney transplantation encompass conditions where the procedure&#x27;s risks substantially exceed potential benefits, rendering transplantation unethical or futile, such as active untreated malignancies or severe irreversible comorbidities that preclude survival or rehabilitation post-surgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> Relative contraindications involve elevated perioperative or long-term risks that may be mitigated through management, allowing case-by-case consideration by multidisciplinary teams.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_khqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ohqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key absolute contraindications include:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Active malignancy, excluding curatively treated low-risk cases like non-melanoma skin cancer or prostate cancer with Gleason score â‰¤6, due to immunosuppression accelerating progression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">Untreated or ongoing severe infections, such as active tuberculosis, bacterial/fungal sepsis, or uncontrolled viral infections (e.g., chronic active hepatitis B in children), which heighten post-transplant mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">Severe irreversible cardiopulmonary disease, including decompensated heart failure (NYHA class III/IV with ejection fraction &lt;30%), advanced obstructive/restrictive lung disease, or significant cardiac amyloidosis confirmed by imaging, limiting surgical tolerance and survival.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6oiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">Demonstrated repeated noncompliance with medical regimens or active substance abuse/addiction impairing post-transplant adherence to immunosuppression and follow-up.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">Progressive neurodegenerative diseases (e.g., advanced Alzheimer&#x27;s or Parkinson&#x27;s) or severe neurologic deficits where transplantation would not meaningfully extend quality life.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">Conditions with life expectancy less than the anticipated graft function or waiting time, such as metastatic cancer or hepatic insufficiency without eligibility for combined liver-kidney transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Relative contraindications often require optimization prior to listing, with decisions informed by recurrence risk, frailty assessment, and expected survival benefit:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Obesity, particularly BMI â‰¥35 kg/mÂ² (class II/III), increasing surgical complications like wound infections and graft thrombosis, though no universal cutoff exists; programs may require weight loss protocols.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></li>
<li class="text-[1em]">History of treated malignancy, with waiting periods post-remission (e.g., 5 years for breast/colorectal cancer, 1-2 years for low-grade prostate or bladder cancers) to minimize recurrence under immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></li>
<li class="text-[1em]">Controlled chronic infections, such as HIV seropositivity with CD4 count &gt;200/ÂµL for â‰¥6 months, undetectable viral load, and stable antiretroviral therapy without opportunistic complications, or hepatitis C post-treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4ojqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6ojqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></li>
<li class="text-[1em]">Advanced age (&gt;75 years), frailty, or multiple comorbidities (e.g., diabetes, smoking &lt;1 month abstinent, or peripheral vascular disease with 5-year survival ~81%), assessed via comprehensive geriatric evaluation rather than age alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
<li class="text-[1em]">Unstable psychiatric disorders, poor social support, or potentially reversible nonadherence, warranting psychosocial intervention and support planning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></li>
<li class="text-[1em]">High-risk primary diseases like focal segmental glomerulosclerosis (FSGS) or atypical hemolytic uremic syndrome (aHUS) with recurrence potential &gt;50%, unless eculizumab or combined transplants are feasible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Evaluation involves multidisciplinary review, including cancer screening per local guidelines, infection serologies, cardiovascular stress testing for high-risk patients, and frailty metrics, to ensure equitable access while prioritizing outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> No single criterion is universally absolute across centers, reflecting variations in technology and expertise, but guidelines emphasize evidence-based risk stratification over blanket exclusions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_okabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<h2 id="donor-sources-and-procurement" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Donor Sources and Procurement<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="living-donor-evaluation-and-surgery" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Living Donor Evaluation and Surgery<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">The evaluation of potential living kidney donors involves a comprehensive multidisciplinary assessment to ensure donor safety and informed consent while confirming compatibility with the recipient. This process typically begins with an initial screening of medical history, including exclusions for active malignancies, uncontrolled hypertension (defined as blood pressure &gt;140/90 mmHg on multiple readings), diabetes mellitus, or glomerular filtration rate (GFR) below 80-90 mL/min/1.73 mÂ², with measured GFR preferred over estimated methods for precision.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> Laboratory tests assess renal function, hemoglobin levels, infectious disease serologies (e.g., HIV, hepatitis B/C), and urine analysis for proteinuria, while imaging via CT angiography or MR angiography evaluates vascular anatomy to minimize surgical risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Psychosocial evaluation verifies voluntarism, absence of coercion, and psychological readiness, emphasizing long-term risks such as a halved GFR post-donation and a small increased lifetime risk of end-stage renal disease (approximately 0.9% vs. 0.3% in healthy non-donors).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_smabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent updates to exclusion criteria, effective from 2022, align with evidence-based guidelines by removing absolute bans on certain conditions like treated hypertension or BMI up to 35 kg/mÂ² if other risks are mitigated, reflecting improved long-term outcome data from registries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Donors must be at least 18 years old, and upper age limits vary but often extend to 70 in low-risk candidates; family history of renal disease prompts genetic screening where indicated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> Informed consent includes discussion of perioperative mortality risk, estimated at 3.1 deaths per 10,000 donations based on U.S. data from 1994-2009 with trends showing decline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_omqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Living donor nephrectomy is predominantly performed via minimally invasive laparoscopic techniques, with hand-assisted variants for complex anatomy, to reduce recovery time and complications compared to open surgery. The procedure favors the left kidney due to longer renal vein length; under general anesthesia, 3-4 trocars are placed, pneumoperitoneum established, and the kidney mobilized after dissecting the ureter, gonadal vein, and renal artery/vein, which are clipped and divided to limit warm ischemia time to under 5 minutes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> The kidney is extracted through a 5-7 cm iliac fossa incision, with robotic-assisted approaches emerging since 2023 for enhanced precision in select centers, though laparoscopic remains standard with operative times of 2-4 hours and hospital stays of 1-3 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_knabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_onabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Postoperative outcomes demonstrate low complication rates (Clavien-Dindo grade â‰¥2 in &lt;5%), with most donors resuming normal activities in 2-4 weeks; long-term studies confirm no overall increase in mortality and potential survival benefit over non-donors, though hypertensive disorders in pregnancy rise slightly for female donors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> High satisfaction rates (86-98% would donate again) underscore the procedure&#x27;s safety when adhering to rigorous evaluation, with ongoing registry follow-up mandated up to 2 years post-donation per OPTN policy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_knqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_onqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup></span>
<h3 id="deceased-donor-criteria-and-retrieval" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Deceased Donor Criteria and Retrieval<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Deceased kidney donors are categorized primarily as donation after brain death (DBD) or donation after circulatory death (DCD), with eligibility determined by legal declaration of death, absence of active malignancies (except certain skin or primary brain cancers), and exclusion of uncontrolled infections such as active sepsis or untreated HIV without viral suppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> Donor kidneys are further stratified using the Kidney Donor Profile Index (KDPI), a score from 0 to 100 incorporating ten factors including age, height, weight, race, history of hypertension or diabetes, cause of death, serum creatinine, and hepatitis C status; kidneys with KDPI &lt;20% are considered optimal, while those &gt;85% carry higher discard risk due to inferior long-term function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Standard criteria donors (SCD) typically include individuals under age 50 without significant comorbidities, offering graft survival comparable to living donors, whereas expanded criteria donors (ECD)â€”defined as those with at least two of age &gt;60 years, age 50-59 with hypertension or creatinine &gt;1.5 mg/dL, or cerebrovascular cause of deathâ€”exhibit a 1.7-fold higher relative risk of graft failure but expand the donor pool for older or less urgent recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Under OPTN policy effective September 2022, organ procurement organizations (OPOs) must perform procurement biopsies on deceased donors meeting high-risk thresholds, such as age â‰¥60 years, terminal creatinine â‰¥1.5 mg/dL, or KDPI &gt;85% (excluding donors &lt;18 years), to inform allocation decisions and reduce discard rates; this applies to all U.S. deceased donor kidneys unless contraindicated by logistics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> Comprehensive donor evaluation includes serologic testing for transmissible diseases (e.g., HIV, hepatitis B/C, CMV, EBV), echocardiography for cardiac function, and abdominal imaging to assess renal anatomy and vascular patency, with hemodynamic optimization in the ICU to maintain mean arterial pressure &gt;65 mmHg and minimize vasopressor use prior to procurement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_opabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Organ retrieval begins with donor preparation in the operating room, where systemic heparinization precedes aortic cannulation for in situ perfusion with cold University of Wisconsin or histidine-tryptophan-ketoglulate solution to induce hypothermic preservation, minimizing ischemic injury; kidneys are excised en bloc with surrounding aorta and vena cava if multi-organ donation is pursued, followed by back-table preparation to trim vessels and assess for anomalies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> For DCD donors, rapid recovery within 60-90 minutes of circulatory arrest is critical to limit warm ischemia time, often employing normothermic regional perfusion techniques post-arrest to restore organ viability before cold storage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_opqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> Retrieved kidneys are typically stored in ice-cold solution for up to 24-36 hours or increasingly via hypothermic machine perfusion, which improves outcomes for marginal grafts by reducing delayed graft function rates compared to static cold storage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Post-retrieval, organs undergo quality assessment including biopsy if not done in situ, with allocation prioritized by match run algorithms balancing HLA compatibility, wait time, and geographic proximity to minimize cold ischemia time ideally below 18 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup></span>
<h3 id="expanding-donor-pools-through-policy-and-technology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Expanding Donor Pools Through Policy and Technology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Policies such as kidney paired donation (KPD) programs have significantly expanded living donor pools by facilitating exchanges between incompatible donor-recipient pairs. In the United States, the Organ Procurement and Transplantation Network (OPTN) operates the Kidney Paired Donation Pilot Program, which matches pairs nationally to overcome blood type or human leukocyte antigen incompatibilities, enabling transplants that would otherwise be impossible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> The National Kidney Registry (NKR), a nonprofit clearinghouse, reported facilitating 760 KPD transplants in 2019, a 22% increase from the prior year, with sensitized patients (calculated panel reactive antibody &gt;80%) experiencing a 38% lower three-year death-censored graft failure rate compared to non-NKR recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup> These programs leverage chain exchanges, including end-chain donations initiated by altruistic donors, to amplify matches, with 46% of NKR candidates transplanted within 12 months of registration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Shifts in organ donation consent frameworks, particularly from opt-in to presumed consent (opt-out) systems, have demonstrably increased deceased donor rates in adopting countries. Spain&#x27;s implementation of presumed consent via its National Transplant Organization in the late 1980s, combined with robust procurement infrastructure, yielded the world&#x27;s highest deceased donation rate of 48 donors per million population by 2018, far exceeding the U.S. opt-in average of around 20-30 donors per million.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> Empirical comparisons across Europe show presumed consent correlates with higher donation willingness and actual procurement rates, though outcomes vary by implementation quality rather than policy alone; for instance, Spain&#x27;s success stems from mandatory hospital reporting and coordinator training, not consent mechanics in isolation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_orabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> In the U.S., proposed policy expansions include financial assistance for living donors and incentives for organ procurement organizations to utilize marginal deceased donors, aiming to boost overall supply without altering consent paradigms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Technological advancements in organ preservation, notably machine perfusion systems, enable broader utilization of extended criteria donors (ECDs)â€”those with factors like advanced age or hypertension that previously increased discard risks. Hypothermic machine perfusion (HMP) pulsatilely circulates preservation solution through kidneys at 4Â°C, reducing ischemic injury and discard rates; a pharmacoeconomic model estimated HMP for ECDs could increase U.S. transplants by 1,123 annually while decreasing waitlist mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> Normothermic machine perfusion (NMP), maintaining kidneys at body temperature with oxygenated blood, allows real-time viability assessment and resuscitation of initially declined organs, with clinical trials demonstrating feasibility for ECD and donation-after-circulatory-death kidneys, potentially converting discarded grafts into viable transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_orqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> Retrospective data indicate NMP reduces delayed graft function and improves one-year outcomes compared to static cold storage, though randomized trials confirm variable benefits, particularly for high-risk donors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1grqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> These technologies complement policy by rehabilitating marginal organs, addressing the supply-demand gap where over 90,000 U.S. patients await kidneys as of 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1orqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup></span>
<h3 id="xenotransplantation-and-bioengineered-options" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Xenotransplantation and Bioengineered Options<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Xenotransplantation, the transplantation of organs from nonhuman species into humans, has emerged as a potential solution to the chronic shortage of human donor kidneys, with pigs serving as the primary source due to anatomical compatibility and reproductive efficiency. Advances in CRISPR-Cas9 gene editing have enabled the creation of porcine donors with up to 69 genomic modifications, including knockouts of three major glycan antigens (GGTA1, CMAH, B4GALNT2) to prevent hyperacute rejection triggered by natural antibodies, and insertions of seven human transgenes such as CD46, CD55, and CD59 for complement regulation, alongside thrombomodulin and endothelial protein C receptor for anticoagulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> These edits also incorporate porcine endogenous retrovirus (PERV) knockouts to mitigate viral transmission risks, addressing a long-standing barrier identified in preclinical studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gsqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinical progress accelerated in 2024â€“2025, with genetically edited pig kidneys transplanted into living human recipients under FDA-approved compassionate use or early investigational protocols. At Massachusetts General Hospital, the first such procedure in March 2024 involved a 62-year-old man with end-stage renal disease; the kidney produced urine immediately, maintained function for 52 days, and supported dialysis independence until the patient&#x27;s death from unrelated cardiac complications, with no evidence of hyperacute rejection or porcine virus transmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup> A second transplant at the same institution in February 2025 used a pig kidney from eGenesis with similar edits, demonstrating prompt graft function and reduced creatinine levels in the recipient.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Additional cases, including one at NYU Langone in December 2024, reported initial successes with six human transgenes added to enhance compatibility, though longer-term data remain limited by small sample sizes and patient comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_otabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup> United Therapeutics received FDA clearance in February 2025 for a phase 1/2 trial of xenokidneys, anticipating the first procedure mid-year, with endpoints focused on safety, function, and infection surveillance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Despite these milestones, challenges persist, including acute antibody-mediated rejection, thrombosis due to endothelial incompatibilities, and potential chronic xenograft vasculopathy, which preclinical pig-to-nonhuman primate models have shown can limit graft survival beyond months even with optimized immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> Gene editing has largely overcome hyperacute rejection, but incomplete understanding of innate immune responses and complement activation necessitates tailored regimens, such as anti-CD40 monoclonal antibodies combined with costimulation blockade, which have extended survival in nonhuman primate recipients to over a year in some studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> Regulatory and ethical hurdles include zoonotic disease monitoring and equitable access, with ongoing debates over trial design emphasizing rigorous endpoints like creatinine clearance and biopsy-proven rejection rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_otqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bioengineered kidney options, distinct from xenotransplantation, involve reconstructing functional renal tissue using decellularized scaffolds, stem cell-derived organoids, or 3D bioprinting to create patient-specific organs devoid of immunological barriers. Decellularization removes cellular components from porcine or human cadaveric kidneys while preserving extracellular matrix architecture, followed by recellularization with human progenitor cells; a July 2025 preclinical study demonstrated vascularized bioengineered kidneys using human placenta-derived angiogenic stem cells and kidney organoids perfused in a bioreactor, achieving glomerular-like structures and basic filtration in rodent models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> Surface modifications, such as heparinization of scaffolds reported in December 2024, enhance endothelialization and reduce thrombosis during recellularization, addressing vascular patency issues central to whole-organ viability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Progress in stem cell technologies includes induced pluripotent stem cell (iPSC)-derived nephron progenitors forming organoids with tubular and vascular components, though scaling to full-sized kidneys remains constrained by nephrogenesis complexity and vascular integration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> As of 2025, these approaches are confined to in vitro and small-animal models, with no human implants reported; challenges encompass incomplete maturation of nephrons, insufficient nephron density (human kidneys contain ~1 million glomeruli), and the absence of a functional urinary collecting system.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup> Hybrid strategies combining scaffolds with organoids show promise for bridging to clinical translation, potentially offering immunocompatible alternatives without donor sourcing limitations, but require advances in bioreactors for uniform recellularization and long-term functionality assessments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ouqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup></span>
<h2 id="compatibility-and-allocation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Compatibility and Allocation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="hla-matching-and-crossmatching" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">HLA Matching and Crossmatching<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Human leukocyte antigen (HLA) matching assesses compatibility between donor and recipient at key HLA loci, primarily HLA-A, HLA-B, and HLA-DR, to minimize immune-mediated rejection in kidney transplantation. These antigens, encoded by genes in the major histocompatibility complex on chromosome 6, present peptides to T cells, triggering allograft recognition as foreign if mismatched. Mismatches increase the risk of acute cellular rejection and antibody-mediated rejection, with studies showing that zero-mismatch kidneys yield superior long-term graft survival rates, such as a 10-year survival advantage of approximately 10-15% over highly mismatched grafts in deceased donor transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> Even in the era of potent immunosuppression, HLA mismatching correlates with higher rates of de novo donor-specific antibodies (DSA) and reduced 20-year graft survival, emphasizing its causal role in chronic allograft nephropathy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">HLA typing employs molecular methods like polymerase chain reaction-sequence-specific oligonucleotide probes or next-generation sequencing for high-resolution (allele-level) identification, though deceased donor allocation often relies on initial low- or intermediate-resolution typing for efficiency, with confirmatory high-resolution testing post-offer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> In the United States, the Organ Procurement and Transplantation Network allocates kidneys prioritizing zero HLA-A, -B, and -DR mismatches for broadly sensitized patients, but broader policies have de-emphasized matching due to prolonged wait times, leading to debates on diminished outcomes like increased financial burdens from re-transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> Living donor programs, such as paired exchanges, leverage high-resolution matching to optimize outcomes, reducing DSA formation and rejection episodes by up to 50% in well-matched pairs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Crossmatching complements HLA matching by detecting recipient preformed antibodies against donor HLA or non-HLA antigens, preventing hyperacute rejection via complement activation and thrombosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> Standard techniques include complement-dependent cytotoxicity (CDC) crossmatch, which mixes recipient serum with donor lymphocytes to observe cell lysis, and flow cytometry crossmatch (FCXM), a more sensitive assay quantifying antibody binding via fluorescence, often using pronase-treated cells to reduce false positives from autoantibodies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup> Virtual crossmatching, an in silico alternative, predicts compatibility by comparing donor HLA typing against the recipient&#x27;s unacceptable antigen list from solid-phase antibody screening (e.g., Luminex assays), accelerating allocation in deceased donor scenarios while correlating strongly with physical crossmatch results.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A positive crossmatch, indicating high immunologic risk, historically contraindicated transplantation but now permits desensitization protocols like plasmapheresis and rituximab for select living donor cases, achieving 5-year graft survival rates exceeding 80% in rigorously selected patients despite elevated early rejection risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup> Both T-cell (cytotoxic) and B-cell crossmatches are routine, with B-cell FCXM particularly sensitive to class II mismatches like HLA-DQ, which independently predict poorer outcomes if ignored.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup> In deceased donor contexts, rapid crossmatch turnaroundâ€”ideally under 4 hoursâ€”balances rejection prevention with cold ischemia time limits, though false negatives from epitope-level mismatches underscore the need for integrated DSA monitoring post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup> Overall, stringent HLA matching and negative crossmatching reduce acute rejection incidence by 20-30% and enhance half-life expectancy of grafts to over 15 years in optimal scenarios.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_111qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup></span>
<h3 id="organ-allocation-algorithms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Organ Allocation Algorithms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Organ allocation algorithms for deceased donor kidneys prioritize recipients based on a combination of biological compatibility, medical urgency, expected post-transplant survival, and wait time to optimize graft longevity and equitable access while minimizing discard rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> These systems employ computerized match runs that sequence candidates within geographic zones, typically starting locally and expanding regionally or nationally for broader sharing of high-quality or hard-to-match organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> Core criteria include ABO blood type compatibility, human leukocyte antigen (HLA) matchingâ€”primarily at the DR locusâ€”sensitization levels measured by calculated panel reactive antibody (CPRA), and donor kidney quality assessed via the Kidney Donor Profile Index (KDPI), which ranges from 0% (best) to 100% (worst) based on 10 donor factors like age, height, and serum creatinine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> Recipient factors, such as the Estimated Post-Transplant Survival (EPTS) score incorporating age, diabetes status, and prior transplants, guide pairing of longer-surviving kidneys with longer-surviving recipients to extend overall graft utility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_112qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, the Organ Procurement and Transplantation Network (OPTN), contracted to the United Network for Organ Sharing (UNOS), administers the Kidney Allocation System (KAS), implemented on December 4, 2014, to address pre-existing issues like geographic disparities in wait times and underutilization of marginal kidneys.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> KAS generates match runs in sequences prioritizing 20% of kidneys with KDPI &gt;20% for recipients with EPTS &gt;20%, followed by local (0-250 nautical miles), regional (up to 1500 nm), and national offers for categories like pediatric candidates or zero-HLA-mismatched pairs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> Allocation points are awarded as follows: full waiting time credit from dialysis initiation or listing (whichever earlier, accrued at 100% rate); sliding-scale points for CPRA â‰¥20% (e.g., 2 points at 20-79.9%, up to 8 at â‰¥99.9%); up to 2 points for HLA-DR matching (2 for 0 mismatches, 1 for 1); and proximity points favoring local candidates within sequences.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> Pediatric candidates receive absolute priority in local sequences, and highly sensitized patients (CPRA â‰¥98%) access national pools for better matches.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_113abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> Post-implementation, KAS increased transplants for sensitized patients by 13% in the first year but raised discard rates for high-KDPI kidneys by about 1.7 percentage points due to expanded sharing circles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_193abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Internationally, algorithms vary to balance utility, equity, and logistics. Eurotransplant&#x27;s Kidney Allocation System (ETKAS), serving seven European countries, emphasizes HLA-A/B/DR matching (full points for 000 mismatches), age-matching between donor and recipient, prospective crossmatch for sensitized patients, and wait time, with rescue allocation for unsent kidneys after 2 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> In France, the Agence de la BiomÃ©decine uses a stepwise system for donation after brain death, prioritizing HLA compatibility and urgency within zones, updated in recent years to incorporate KDPI equivalents and reduce geographic barriers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> Australia&#x27;s system, managed by states via the OrganMatch program, allocates based on blood type, HLA-DR matching, wait time, and clinical urgency, with national sharing for perfect matches or pediatric cases, aiming to minimize cold ischemia time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> These frameworks reflect causal trade-offs: stricter matching improves outcomes (e.g., 5-year graft survival 10-15% higher with 0-DR mismatches) but prolongs waits, while broader sharing enhances equity yet risks logistics delays.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_113qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Ongoing reforms address limitations like geographic inequities, with the U.S. OPTN piloting continuous distribution paradigms by 2025 to replace discrete circles with score-based prioritization using distance as a continuous variable weighted against biology, potentially reducing wait time variances from 1.5-fold to near parity across donation service areas.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup> KDPI calculations were updated May 21, 2025, incorporating recent donor data for accuracy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> Algorithmic simulations using multiobjective optimization have informed these shifts, prioritizing metrics like transplant rates, graft survival, and equity indices over rigid boundaries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> Despite evidence-based designs, debates persist on weightingâ€”e.g., utility-focused systems may disadvantage younger or minority recipients, per analyses showing persistent disparities post-KAS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_114abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> OPTN policies, grounded in empirical modeling, evolve via public comment but face criticism for not fully resolving out-of-sequence offers, which rose post-2021 due to expanded recovery pressures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_194abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup></span>
<h3 id="challenges-in-matching-and-prioritization" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Challenges in Matching and Prioritization<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Matching deceased donor kidneys to recipients presents significant challenges due to the imbalance between limited organ supply and high demand, with over 100,000 patients on U.S. kidney transplant waitlists as of recent data, where more than 30% wait over three years, contributing to elevated pre-transplant mortality rates exceeding 5% annually for active candidates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> This scarcity necessitates prioritization algorithms that weigh factors like wait time, calculated panel reactive antibody (cPRA) levels for sensitization, expected post-transplant survival (EPTS) scores, and kidney donor profile index (KDPI), but implementation often results in trade-offs between equity and utility, such as increased organ discards or prolonged cold ischemia times following the 2014 Kidney Allocation System (KAS) revisions that expanded sharing for high-cPRA patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Human leukocyte antigen (HLA) matching remains a core hurdle, as mismatchesâ€”particularly at HLA-DR and HLA-DQ lociâ€”correlate with reduced long-term graft survival, with studies showing HLA-mismatched kidneys experiencing higher rates of chronic rejection and graft loss, potentially sensitizing recipients and complicating future retransplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> While modern immunosuppression has diminished the acute impact of mismatches, evidenced by similar short-term graft survival rates across match levels (e.g., 90.6% at one year for matched vs. 89.9% for mismatched), disparities persist in extended outcomes, with only about 40% of transplants achieving favorable HLA compatibility in analyzed cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup> Highly sensitized patients (cPRA &gt;99%) face prolonged waits due to limited compatible donors, exacerbating inequities despite prioritization points, as molecular-level HLA typing reveals epitope mismatches that standard serologic methods overlook, yet adoption lags due to data scarcity on waitlist impacts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_115qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_155qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Prioritization algorithms, such as those managed by the United Network for Organ Sharing (UNOS), aim to optimize both immediate placement and longevity matching but encounter resistance from transplant centers, which frequently decline offers for top-ranked candidates in favor of lower-priority recipients perceived to yield better utility, occurring in up to substantial fractions of cases per data from 2010-2020.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> This practice, while potentially maximizing overall graft life-years, undermines waitlist equity and increases discard rates for marginal kidneys, particularly those with high KDPI (&gt;85%), where end-of-chain selection challenges arise from balancing adherence to allocation versus utility-driven choices like HLA or longevity optimization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup> Multi-organ transplant priorities further disadvantage solitary kidney candidates, correlating with higher delisting and death rates on waitlists, as simultaneous liver-kidney allocations preempt kidneys from standalone recipients without commensurate outcome gains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Geographic and demographic disparities compound these issues, with local allocation preferences historically favoring shorter transport but post-KAS national sharing for sensitized patients leading to longer ischemia times and variable access, disproportionately affecting pediatric or urgent cases despite targeted exceptions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup> Operations research highlights algorithmic inefficiencies, such as suboptimal pairing that could be mitigated by advanced modeling, yet persistent center-level deviations and opaque decision-making hinder equitable outcomes, underscoring the need for transparent, evidence-based refinements to reduce waitlist mortality without inflating discards.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup></span>
<h2 id="surgical-procedures" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Surgical Procedures<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="recipient-implantation-technique" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Recipient Implantation Technique<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
The recipient implantation technique in kidney transplantation employs a heterotopic approach, positioning the donor kidney in the iliac fossa of the lower abdomen without routine removal of the native kidneys, which are preserved unless affected by conditions such as recurrent infection or malignancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The surgery is conducted under general anesthesia and typically lasts 2 to 4 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> An open extraperitoneal incision, often via the Gibson technique in the iliac fossa (preferentially right-sided for primary transplants), exposes the iliac vessels after medial retraction of the peritoneum.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_118abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_158abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Vascular anastomoses prioritize minimizing ischemia; the renal vein is first connected end-to-side to the external iliac vein, followed by the renal artery anastomosed end-to-side to the external iliac artery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> For grafts with multiple renal arteries, techniques such as Carrel patch augmentation or sequential side-to-side anastomoses to the iliac artery are utilized during back-table preparation to ensure adequate perfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> Systemic heparin (30-60 IU/kg) may be administered, and graft reperfusion is assessed via the Hume test for viability before completing arterial connections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> Variations include end-to-end anastomosis to the internal iliac artery in cases of external iliac disease or for smaller pediatric grafts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_158qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Ureteral anastomosis involves an extravesical ureteroneocystostomy, with the Lich-Gregoir technique preferred to create an anti-reflux submucosal tunnel in the bladder dome, reducing vesicoureteral reflux risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> A double-J ureteral stent (typically 5 Fr, 12-16 cm) is routinely or selectively placed to prevent obstruction or leakage, such as urinoma formation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Alternative methods like pyeloureterostomy are reserved for anomalous ureters.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> The peritoneum is repositioned, and the incision closed in layers, with drains sometimes used postoperatively. Orthotopic implantation, anastomosing to native renal vessels, is an uncommon variant for recipients with iliac fossa occupation or severe atherosclerosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_159abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup> Robotic-assisted techniques are emerging for precision in complex vascular scenarios but involve longer operative times.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1d9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<h3 id="variants-including-combined-transplants" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Variants Including Combined Transplants<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Simultaneous pancreas-kidney (SPK) transplantation represents a key variant for patients with type 1 diabetes mellitus and end-stage renal disease (ESRD), addressing both insulin dependence and uremia through dual organ replacement from a single deceased donor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup> The pancreas graft corrects hyperglycemia by restoring endogenous insulin production, while the kidney graft replaces failed renal function, with systemic venous drainage typically used for the pancreas to manage exocrine secretions via enteric or bladder anastomosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> This approach yields superior long-term outcomes compared to kidney transplantation alone in diabetic ESRD patients, including reduced cardiovascular mortality; a propensity score-matched analysis reported hazard ratios favoring SPK for event-free survival.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_paqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> Patient and graft survival rates exceed 90% at one year and 70-80% at five years in contemporary series, though pancreas graft thrombosis remains a leading cause of early failure at 5-10%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pancreas after kidney (PAK) transplantation offers an alternative sequential variant, deferring pancreas placement until after a prior kidney transplant, suitable for select type 1 diabetics with stable renal allografts but ongoing glycemic instability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[150]</sup> Outcomes mirror SPK in insulin independence rates (around 80% at one year), but PAK carries higher immunological risks due to prior sensitization from the kidney graft.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[151]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Combined liver-kidney (SLK) transplantation addresses dual organ failure, primarily indicated in conditions like hepatorenal syndrome, polycystic kidney and liver disease (autosomal dominant polycystic kidney disease, ADPKD), or chronic glomerular disease with decompensated cirrhosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[152]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[153]</sup> The liver graft often ameliorates renal dysfunction via factors reducing vasoconstriction, enabling staged kidney transplantation in some cases, though simultaneous SLK predominates for acute needs; survival reaches 85-90% at one year and 70% at five years across centers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[154]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[155]</sup> Indications exclude isolated liver disease with reversible kidney injury per allocation policies, prioritizing true multi-organ necessity to conserve kidneys.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[156]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Less common variants include kidney-heart or kidney-lung combinations for patients with ESRD complicating advanced cardiac or pulmonary failure, where multi-organ procurement from the same donor mitigates ischemia-reperfusion injury across grafts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[157]</sup> These procedures demand meticulous donor-recipient matching and perioperative management, with outcomes varying by center volume but generally aligning with isolated transplant benchmarks when feasible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[154]</sup></span>
<h2 id="postoperative-management" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Postoperative Management<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="acute-phase-care-and-monitoring" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Acute Phase Care and Monitoring<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following kidney transplantation, patients are typically admitted to an intensive care unit for 24 to 48 hours for close monitoring of hemodynamic stability, graft perfusion, and early complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> Vital signs, including blood pressure (target &lt;130/80 mmHg), heart rate, and central venous pressure (8-12 mmHg if monitored), are assessed hourly initially to ensure adequate graft blood flow and prevent hypovolemia or hypertension-induced injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup> Urine output is measured hourly for at least 24 hours, with targets exceeding 0.5 mL/kg/hour indicating initial graft viability; oliguria prompts evaluation for obstruction, thrombosis, or acute tubular necrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Graft function is evaluated daily via serum creatinine levels, aiming for a decline to below 2 mg/dL by postoperative day 5 in uncomplicated cases; persistent elevation necessitates renal ultrasound and potential biopsy to differentiate delayed graft function from rejection or vascular issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup> Complete blood counts and electrolyte panels are checked daily for the first week to detect anemia, leukopenia from immunosuppression, or imbalances like hyperkalemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> Immunosuppressive therapy, typically comprising a calcineurin inhibitor (e.g., tacrolimus with trough levels of 5-10 ng/mL initially), mycophenolate, and corticosteroids, is initiated before or at transplantation, with drug levels monitored every other day until therapeutic targets are achieved to minimize rejection risk while avoiding toxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_peabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_teabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Fluid management emphasizes euvolemia through intravenous isotonic solutions adjusted to urine output and hemodynamic parameters, avoiding overload that could exacerbate cardiac strain in recipients with preexisting comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> Prophylaxis against infections begins immediately, including trimethoprim-sulfamethoxazole for Pneumocystis jirovecii (6 months) and valganciclovir for cytomegalovirus (3-6 months in at-risk patients), with weekly viral load monitoring if high risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup> Surveillance for acute rejection involves daily clinical exams and laboratory trends; any unexplained creatinine rise triggers protocol biopsy (e.g., 16-gauge needle, two cores) rather than empirical treatment, as histological confirmation guides therapy such as high-dose methylprednisolone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_peqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_teqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup> Doppler ultrasound is performed if vascular thrombosis is suspected, occurring in up to 1-2% of cases early post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Transition to ward care occurs once stable, with outpatient follow-up 2-3 times weekly in the first month, including tacrolimus level checks 3 times weekly and creatinine assessments to detect subclinical issues like BK polyomavirus viremia (screened monthly via PCR, reducing immunosuppression if &gt;10,000 copies/mL).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup> Pain is managed with multimodal analgesia avoiding nephrotoxic agents, and surgical wound inspection prevents hematoma or infection, which affect 5-10% of recipients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> These protocols, derived from consensus guidelines, prioritize empirical graft viability metrics over proxy indicators to optimize outcomes in the vulnerable acute phase.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup></span>
<h3 id="immunosuppressive-regimens" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Immunosuppressive Regimens<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Immunosuppressive regimens are essential in kidney transplantation to suppress the recipient&#x27;s immune response and prevent acute and chronic rejection of the allograft, which occurs due to T-cell mediated recognition of donor antigens. These regimens typically involve an initial high-intensity phase (induction) followed by long-term maintenance therapy, balancing efficacy against risks such as infection, malignancy, and drug toxicity. Standard protocols have evolved since the introduction of calcineurin inhibitors (CNIs) in the 1980s, reducing acute rejection rates from over 50% to under 15% in the first year, though long-term graft survival remains challenged by chronic allograft nephropathy and non-adherence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[160]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[161]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Induction therapy, administered perioperatively, intensifies immunosuppression to mitigate early rejection risk, particularly in high-immunological-risk patients (e.g., those with prior transplants or panel-reactive antibodies &gt;50%). Interleukin-2 receptor antagonists like basiliximab (two 20 mg doses on days 0 and 4) are used in low-risk cases for their targeted blockade of activated T-cells, achieving acute rejection rates of 10-20% without increased infection risk compared to no induction. Polyclonal anti-thymocyte globulin (ATG), such as rabbit ATG at 1-1.5 mg/kg daily for 3-5 days, provides broader lymphodepletion and superior efficacy in high-risk recipients, reducing biopsy-proven acute rejection by 20-30% versus basiliximab (e.g., 12% vs. 25% at 1 year), though it carries higher cytomegalovirus (CMV) and post-transplant lymphoproliferative disorder risks requiring prophylaxis. Low-dose ATG (e.g., single 3 mg/kg) offers a compromise with rejection prevention comparable to standard doses and fewer adverse events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[162]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[163]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[164]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Maintenance immunosuppression usually consists of triple therapy: a CNI (tacrolimus preferred over cyclosporine for lower rejection rates, targeting trough levels of 5-10 ng/mL initially), an antiproliferative agent like mycophenolate mofetil (MMF; 1-2 g/day), and corticosteroids (e.g., prednisone tapered to 5 mg/day). Tacrolimus-based regimens yield 1-year graft survival exceeding 90%, outperforming cyclosporine in reducing acute rejection (15% vs. 25%) and improving long-term function, though both CNIs cause dose-dependent nephrotoxicity via afferent arteriolar vasoconstriction and fibrosis, contributing to 20-30% of chronic graft losses. MMF inhibits purine synthesis in lymphocytes, reducing rejection by 50% versus azathioprine, but gastrointestinal toxicity affects 10-20% of patients. Steroids provide rapid anti-inflammatory effects but are often minimized or withdrawn after 3-6 months in low-risk patients to avoid metabolic complications, with steroid-free protocols showing equivalent 5-year graft survival (85-90%) and reduced diabetes incidence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[165]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[167]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Alternative strategies address CNI limitations: minimization protocols reduce tacrolimus exposure (e.g., to 3-5 ng/mL after year 1) with adjuncts like mammalian target of rapamycin inhibitors (mTORi; everolimus or sirolimus), preserving function but increasing rejection risk if not monitored closely. Belatacept, a costimulatory blockade agent infused monthly, enables CNI avoidance, yielding superior 7-year graft survival (80% vs. 70% with cyclosporine) and better renal function (eGFR +10-15 mL/min), though early acute rejection rates are higher (20-25%) and it requires vigilant CMV screening. Regimen selection considers donor type, recipient comorbidities, and HLA mismatch; for example, living-donor transplants favor basiliximab induction with tacrolimus-MMF without steroids. Therapeutic drug monitoring is critical, with tacrolimus levels adjusted to avoid under- or over-immunosuppression, as non-adherence causes 20-30% of late graft failures. Despite advances, no regimen halts chronic antibody-mediated rejection, and ongoing trials explore tolerance induction via regulatory T-cells or mixed chimerism.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[160]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[167]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[168]</sup></span>
<h3 id="long-term-follow-up-protocols" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Follow-Up Protocols<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term follow-up protocols for kidney transplant recipients emphasize serial assessment of allograft function, adjustment of immunosuppressive therapy, and vigilant screening for chronic complications to mitigate graft loss and improve survival rates, which remain challenged by chronic allograft nephropathy and cardiovascular events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> After the first post-transplant year, clinical evaluations occur every 3 months, with laboratory assessments every 6 weeks to detect subtle declines in function early.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[170]</sup> Key metrics include serum creatinine and eGFR, monitored every 2-3 months to track progressive deterioration, as stable eGFR beyond year 1 correlates with extended graft survival exceeding 15 years in low-risk cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_piqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[171]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> Urinalysis for proteinuria, quantified annually thereafter, identifies early markers of chronic damage, with levels above 0.5 g/day prompting biopsy consideration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Immunosuppressive drug levels, particularly tacrolimus trough concentrations (target 5-8 ng/mL in stable maintenance), are measured every 3 months or with any graft function change to balance rejection risk against nephrotoxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup> Adherence is evaluated at every visit using validated tools or as the &quot;fifth vital sign,&quot; given nonadherence accounts for up to 20% of late graft losses; interventions include regimen simplification to once-daily dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup> De novo donor-specific antibodies are screened via solid-phase immunoassay in cases of dysfunction or suspected underimmunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Complication screening integrates infection surveillance, with BK polyomavirus PCR tested every 3 months for the first 24 months and upon creatinine elevation, as viremia precedes nephropathy in 10-20% of cases without intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> Cardiovascular risk management targets blood pressure below 130/80 mmHg at each visit via ACE inhibitors or ARBs, alongside annual lipid profiles to guide statin use, addressing the leading cause of post-transplant mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> Malignancy surveillance includes annual skin examinations, given a 2-5-fold elevated skin cancer risk, and age-appropriate protocols for other cancers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> Bone mineral density assessment every 1-2 years in at-risk patients, with calcium and phosphorus checked every 6-12 months, counters osteoporosis from steroids and CKD-mineral bone disorder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Indication-based biopsies are performed for unexplained creatinine rises exceeding 20-30%, persistent proteinuria â‰¥3 g/day, or protocol-driven in high-risk protocols, revealing antibody-mediated rejection in up to 50% of late failures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> Complete blood counts and electrolytes are reviewed every 3-6 months to detect cytopenias or imbalances from medications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[170]</sup> These protocols, derived from consensus guidelines, underscore causal links between consistent monitoring and reduced half-life loss, though real-world adherence varies due to socioeconomic factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup></span>
<h3 id="dietary-and-lifestyle-recommendations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dietary and Lifestyle Recommendations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Post-kidney transplantation, recipients are advised to adopt a balanced diet emphasizing cardiovascular health and weight management, as immunosuppressive medications such as corticosteroids often contribute to rapid weight gain, hyperlipidemia, and new-onset diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> A low-sodium intake, typically limited to less than 2,300 mg per day, is recommended to control hypertension, which affects up to 80% of transplant patients within the first year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup> The Mediterranean dietary pattern, rich in fruits, vegetables, whole grains, and plant-based fats, has been associated with improved graft function and reduced cardiovascular events in observational studies of transplant recipients.00108-5/fulltext)</span>
<span class="mb-4 block break-words text-[1em] leading-7">Protein intake should be adequate to support recovery and muscle maintenance, generally 1.0-1.2 g/kg body weight daily, without the restrictions applied in chronic kidney disease, as the functioning graft tolerates higher levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[174]</sup> Carbohydrates should comprise approximately 50% of total energy, prioritizing low-glycemic-index sources with high dietary fiber to mitigate post-transplant hyperglycemia risks.30191-7/fulltext) Unlike pre-transplant renal diets, restrictions on potassium and phosphorus are typically lifted unless graft dysfunction recurs, allowing broader inclusion of fresh produce.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[174]</sup> Alcohol consumption should be limited to no more than one standard drink per day for women and two for men, with abstinence preferred during the early postoperative period due to interactions with immunosuppressants.00108-5/fulltext)</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Fruits and vegetables</strong>: Aim for 5-7 servings daily to provide antioxidants and fiber, supporting immune function without excess potassium load in stable grafts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_69mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[175]</sup></li>
<li class="text-[1em]"><strong>Lean proteins</strong>: Include fish, poultry, and plant sources like legumes to minimize saturated fats linked to dyslipidemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6hmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup></li>
<li class="text-[1em]"><strong>Fats</strong>: Favor unsaturated fats from nuts, seeds, and olive oil; plant sterols may help lower cholesterol levels elevated by calcineurin inhibitors.00108-5/fulltext)</li>
<li class="text-[1em]"><strong>Hydration</strong>: Maintain 2-3 liters of fluid daily unless contraindicated by edema or heart failure, to promote renal perfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[176]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Lifestyle modifications focus on mitigating immunosuppression-related risks, including infection, malignancy, and cardiovascular diseaseâ€”the leading cause of death post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[176]</sup> Regular physical activity is endorsed, with guidelines suggesting at least 150 minutes of moderate-intensity aerobic exercise per week, supplemented by resistance training twice weekly, to improve endothelial function, reduce fatigue, and enhance quality of life; randomized trials demonstrate feasibility and safety starting 4-6 weeks post-surgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[177]</sup> Smoking cessation is critical, as continued tobacco use doubles the risk of graft loss and triples cardiovascular mortality within five years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[178]</sup> Sun protection measures, including broad-spectrum sunscreen and protective clothing, are essential due to heightened skin cancer incidence from azathioprine and cyclosporine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup> Weight reduction through combined diet and exercise is prioritized for overweight recipients, targeting a BMI below 30 kg/mÂ² to lower allograft failure rates observed in obese cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1dmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup></span>
<h2 id="complications-and-risks" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Complications and Risks<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="surgical-and-perioperative-complications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Surgical and Perioperative Complications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Surgical complications in kidney transplantation encompass vascular, urological, and wound-related issues that arise during or immediately after the procedure, with overall early complication rates (within 90 days) reported at approximately 36% across studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[179]</sup> These events often necessitate reoperation and can jeopardize graft viability, particularly if vascular thrombosis occurs, which affects 2-3% of cases and typically leads to irreversible graft loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[180]</sup> Urological complications, such as urine leaks or ureteral strictures, occur in 3.4-11.2% of transplants, stemming from anastomotic failures or ischemia to the ureter.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_poabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[181]</sup> Bleeding requiring transfusion is common, seen in up to 36% of patients, while symptomatic hematomas develop in about 10%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[182]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Vascular complications, occurring in 3-15% of renal transplants, include renal artery thrombosis (less than 1% incidence), venous thrombosis (around 1.4%), and transplant renal artery stenosis, which often manifests 3-6 months postoperatively but can originate perioperatively from technical errors or hypoperfusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[183]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_doqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[184]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hoqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[185]</sup> These arise causally from factors like prolonged cold ischemia time, donor hypotension, or anastomotic kinking, with early detection via Doppler ultrasound critical to salvage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_poqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[184]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Perioperative complications extend to non-surgical issues like delayed graft function (DGF), defined as the need for dialysis within the first week post-transplant, affecting 20-50% of deceased-donor recipients due to ischemia-reperfusion injury, acute tubular necrosis, or calcineurin inhibitor toxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[186]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[187]</sup> DGF prolongs hospitalization and heightens rejection risk, though its direct impact on long-term graft survival varies by duration and management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[188]</sup> Surgical site infections occur in about 3.7% of cases, often linked to wound contamination or immunosuppression, while incisional hernias develop in 2.5-10%, influenced by obesity and surgical technique.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[189]</sup> Sepsis, at 3%, and urinary tract infections (8.6%) further compound perioperative morbidity, underscoring the need for vigilant monitoring and prophylactic antibiotics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[182]</sup></span>
<h3 id="rejection-mechanisms-and-treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Rejection Mechanisms and Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Rejection of kidney transplants occurs when the recipient&#x27;s immune system recognizes the donor graft as foreign, primarily due to mismatched human leukocyte antigens (HLA), triggering adaptive and innate immune responses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[190]</sup> Three main types are distinguished by timing and pathophysiology: hyperacute, acute, and chronic. Hyperacute rejection manifests within minutes to hours post-revascularization, mediated by preformed donor-specific antibodies (DSA) binding to vascular endothelium, activating complement and causing thrombosis, neutrophil infiltration, and rapid graft necrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> This type is now rare, occurring in less than 1% of cases due to pre-transplant cross-matching via complement-dependent cytotoxicity or flow cytometry, which detects anti-HLA or anti-endothelial antibodies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[191]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Acute rejection typically arises within days to months postoperatively and comprises two subtypes: T-cell-mediated (cellular) and antibody-mediated. T-cell-mediated rejection involves direct allorecognition by recipient CD4+ and CD8+ T cells, leading to cytokine release, macrophage recruitment, and tubulitis or vasculitis in the graft, confirmed histologically by Banff criteria showing lymphocytic infiltrates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[192]</sup> Antibody-mediated rejection (ABMR) results from de novo or anamnestic DSA targeting HLA or non-HLA antigens, causing C4d deposition in peritubular capillaries, endothelial injury, and microvascular inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup> Incidence of acute rejection has declined to 10-15% in the first year with modern immunosuppression, but it remains a leading cause of early graft loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_prabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[194]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Chronic allograft injury, previously termed chronic rejection or chronic allograft nephropathy, develops over years through intertwined immune and non-immune mechanisms, culminating in interstitial fibrosis, tubular atrophy, and vascular changes. Immune factors include persistent low-level DSA-driven ABMR and T-cell activity, while non-immune contributors encompass calcineurin inhibitor nephrotoxicity, hypertension, recurrent glomerular disease, and donor-derived factors like ischemia-reperfusion injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[195]</sup> This progressive process accounts for over 50% of long-term graft failures beyond the first decade.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[196]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Treatment strategies prioritize prevention through induction with agents like basiliximab or antithymocyte globulin and maintenance regimens including tacrolimus, mycophenolate mofetil, and corticosteroids, which suppress T-cell activation and proliferation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> For acute cellular rejection, first-line therapy involves high-dose intravenous methylprednisolone (250-500 mg daily for 3 days), achieving response rates of 70-80%; steroid-resistant cases receive lymphocyte-depleting agents such as rabbit antithymocyte globulin (ATG, 1.5 mg/kg daily for 7-14 days).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[197]</sup> Acute ABMR treatment combines plasmapheresis (to remove DSA), intravenous immunoglobulin (IVIG, 0.1-2 g/kg), and rituximab (375 mg/mÂ²), with adjuncts like bortezomib for plasma cell depletion or eculizumab for complement inhibition in severe cases, though evidence for long-term efficacy varies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_psabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[198]</sup> Hyperacute rejection mandates immediate graft nephrectomy, as no reversal is possible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Chronic injury management focuses on risk factor modification rather than reversal, including minimization of calcineurin inhibitor doses, blood pressure control below 130/80 mmHg, proteinuria reduction with ACE inhibitors, and protocol biopsies for early detection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[199]</sup> Emerging therapies target fibrosis pathways, but mTOR inhibitors like everolimus show mixed results in slowing progression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hsqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[200]</sup> Overall, timely diagnosis via surveillance biopsies, DSA monitoring, and protocolized immunosuppression adjustments is critical, as untreated rejection episodes double the risk of graft loss.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_psqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup></span>
<h3 id="infectious-and-malignancy-risks" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Infectious and Malignancy Risks<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Immunosuppressive therapy in kidney transplant recipients substantially elevates the risk of opportunistic infections by impairing T-cell mediated immunity and neutrophil function, with bacterial infections occurring in approximately 41% of recipients and overall infection rates reaching 44% within two years post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[201]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[202]</sup> Urinary tract infections represent the most frequent complication, affecting 20-43% of patients, often linked to surgical site vulnerabilities and indwelling catheters, while asymptomatic bacteriuria complicates up to 53% of cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ltqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[203]</sup> Viral infections, particularly cytomegalovirus (CMV), pose significant threats, with incidence reduced to 17-37% through antiviral prophylaxis like valganciclovir, though disease can still emerge beyond six months in high-risk donor-positive/recipient-negative mismatches.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ttqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[204]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">BK polyomavirus nephropathy affects 1-10% of recipients, typically manifesting within the first year due to intense immunosuppression, leading to viruria in 30-40%, viremia in 10-20%, and graft loss in up to 35% of affected cases without intervention such as dose reduction of calcineurin inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[205]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_duabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[206]</sup> Fungal infections, including candidiasis and aspergillosis, occur less frequently but carry high mortality, often necessitating preemptive antifungal strategies in endemic areas or prolonged neutropenia. Prophylaxis protocols, including trimethoprim-sulfamethoxazole for Pneumocystis jirovecii, have curtailed certain infections, yet surveillance via PCR monitoring for CMV and BK remains essential to mitigate graft dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_luabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[207]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Malignancy risk post-kidney transplantation is nearly fourfold higher than in the general population, driven by chronic immunosuppression disrupting immune surveillance of oncogenic viruses and DNA repair mechanisms, with cumulative solid organ cancer incidence reaching 10-15% at 15 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[208]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_duqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[209]</sup> Non-melanoma skin cancers predominate, alongside increased rates of post-transplant lymphoproliferative disorder (PTLD), which arises in EBV-seronegative recipients at elevated risk due to primary infection under immunosuppression, with overall de novo malignancy rates around 9% in large cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_luqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[210]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_puqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[211]</sup> Risk factors for PTLD include EBV mismatch, older recipient age, and potent induction therapies like antithymocyte globulin, contributing to mortality rates exceeding those of the general population by twofold.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[212]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[213]</sup> Management involves immunosuppression minimization, rituximab for CD20-positive lesions, and enhanced screening such as annual dermatologic exams and EBV viral load monitoring to detect early oncogenic changes. Despite these measures, cancer remains a leading cause of long-term graft loss and death, underscoring the causal trade-off between rejection prevention and oncologic vulnerability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1duqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[214]</sup></span>
<h3 id="cardiovascular-and-other-systemic-issues" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cardiovascular and Other Systemic Issues<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Cardiovascular disease constitutes the leading cause of death in kidney transplant recipients, responsible for a substantial proportion of both early and late mortality despite improvements in overall graft survival. In U.S. registry data, cardiovascular events predominate as the cause of death from 1 to 10 years post-transplant, with manifestations including coronary artery disease, heart failure, arrhythmias, and peripheral vascular disease. Transplant-specific factors exacerbate traditional risks such as age, diabetes, smoking, and dyslipidemia; these include acute and chronic rejection episodes, which in one cohort increased 10-year cardiovascular incidence threefold, delayed graft function, impaired renal allograft performance, new-onset diabetes after transplantation, and circulating donor-specific antibodies. Immunosuppressive agents like corticosteroids and calcineurin inhibitors contribute to hypertension, hyperlipidemia, and metabolic disturbances, accelerating atherosclerosis independently of pre-existing end-stage renal disease burdens.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-transplant hyperglycemia and new-onset diabetes mellitus, occurring in 10-30% of recipients within the first year, further heighten cardiovascular vulnerability through endothelial dysfunction and insulin resistance, often linked to steroid use and tacrolimus. Elevated uric acid levels post-transplant, observed in up to 80% of recipients, correlate with congestive heart failure and graft loss, compounding ischemic risks. Management emphasizes aggressive modification of modifiable risksâ€”such as statin therapy for LDL reduction and blood pressure control below 130/80 mmHgâ€”alongside routine screening for donor-specific antibodies to mitigate rejection-related cardiovascular escalation, though outcomes vary with recipient age and comorbidity burden.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond cardiovascular concerns, posttransplant bone disease affects up to 50% of recipients, featuring rapid bone mineral density loss of 4-10% in the lumbar spine and femoral neck during the first 6-18 months, driven by persistent secondary hyperparathyroidism, corticosteroid-induced osteoporosis, and mineral metabolism dysregulation. This predisposes to fractures, with hip fracture rates 4-14 times higher than in the general population, correlating with increased morbidity and mortality independent of graft function. Anemia persists in 20-50% of patients early post-transplant, multifactorially arising from iron deficiency, erythropoietin hyporesponsiveness, and drug toxicities, and associates with allograft failure and reduced survival; severe cases (hemoglobin &lt;10 g/dL) heighten cardiovascular strain via left ventricular hypertrophy.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Hyperuricemia and gout emerge as prevalent metabolic issues, with gout incidence reaching 10-15% within five years, attributed to calcineurin inhibitors, diuretics, and reduced urate excretion, independently predicting allograft dysfunction and cardiovascular events. Other systemic complications encompass neurological effects from calcineurin inhibitor neurotoxicity, manifesting as tremors or posterior reversible encephalopathy in 5-15% of cases, and persistent electrolyte derangements like hypomagnesemia from proton pump inhibitors or tacrolimus. These issues underscore the need for vigilant monitoring, as they collectively impair long-term quality of life and survival beyond infectious or rejection pathways.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[215]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[216]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[217]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[218]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[219]</sup></span>
<h2 id="prognosis-and-outcomes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prognosis and Outcomes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="graft-survival-metrics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Graft Survival Metrics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Graft survival in kidney transplantation refers to the duration from transplant to irreversible graft failure, typically defined as the need for chronic dialysis, retransplantation, or patient death with a functioning graft (unless death-censored analysis is specified).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[220]</sup> Metrics are derived from large registries like the Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR), which track outcomes adjusted for recipient and donor factors. One-year graft survival rates have improved substantially, exceeding 95% overall, with living donor kidney transplants (LDKT) achieving 97.8-98.1% for recipients transplanted in recent cohorts (2014-2017).08680-4/fulltext)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[221]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Five-year graft survival rates vary by donor type and recipient age, consistently higher for LDKT than deceased donor kidney transplants (DDKT). For adults aged 18-34 years, rates are approximately 90.0% for LDKT versus 82.2% for DDKT; for those aged 65 years and older, they drop to 80.2% versus 66.1%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup> Death-censored analyses, excluding deaths with functioning grafts, yield higher figures, such as 92% for LDKT and 86% for DDKT at five years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[223]</sup> Long-term outcomes beyond five years show greater attrition, influenced by chronic allograft nephropathy, immunosuppression-related toxicities, and comorbidities, though exact 10-year metrics are less uniformly reported in recent data due to cohort maturity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[224]</sup></span>





























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Metric</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Living Donor (%)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Deceased Donor (%)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Notes/Source</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1-Year Graft Survival</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">97.8-98.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">96</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Adjusted; recent cohorts (2014-2017)08680-4/fulltext)</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18q3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[223]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5-Year Graft Survival (18-34 yo)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">90.0</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">82.2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">OPTN/SRTR 2023</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19a3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5-Year Graft Survival (â‰¥65 yo)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">80.2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">66.1</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">OPTN/SRTR 2023</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19q3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">These metrics reflect advancements in immunosuppression, donor selection, and perioperative care, but disparities persist due to donor quality (e.g., expanded criteria donors in DDKT) and recipient factors like diabetes or prior transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[221]</sup> Registry data indicate LDKT provides an additional 0.36 years of graft function over seven years compared to DDKT in matched cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[225]</sup></span>
<h3 id="patient-survival-and-quality-of-life" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Patient Survival and Quality of Life<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney transplantation confers a substantial survival advantage over maintenance dialysis for most end-stage renal disease patients, with adjusted life expectancy gains estimated at several years depending on age and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[226]</sup> For recipients transplanted between 2016 and 2018, one-year patient survival reached 97.4%, while five-year survival was 86.6%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[227]</sup> These rates vary by donor type, with living donor kidney transplants yielding higher five-year patient survival of approximately 88% compared to 75-82% for deceased donor transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[223]</sup> Long-term outcomes show ten-year patient survival rates around 70-80% in select cohorts, though influenced by factors such as recipient age, with older patients (&gt;65 years) experiencing lower absolute survival but still outperforming dialysis equivalents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_125abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[228]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[229]</sup></span>





























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Time Post-Transplant</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Patient Survival (All Donors, 2016-2018 Cohort)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Living Donor 5-Year</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Deceased Donor 5-Year</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1-Year</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">97.4%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~97%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">92%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5-Year</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">86.6%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">88%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">75%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10-Year</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~70-80% (cohort-specific)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Data derived from U.S. registry analyses; rates uncensored at graft failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[227]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[223]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[221]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Health-related quality of life (HRQoL) improves markedly post-transplantation relative to dialysis, with recipients reporting higher scores across physical, mental, and social domains in validated instruments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[230]</sup> Meta-analyses and cohort studies confirm this elevation persists long-term, particularly in younger patients and those without heavy comorbidity burdens, enabling greater workforce participation and reduced symptom burden from uremia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[231]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[232]</sup> However, immunosuppressive therapies introduce trade-offs, including fatigue, cosmetic changes, and heightened vulnerability to infections or malignancies, which can attenuate HRQoL gains in subsets like elderly recipients (&gt;70 years).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_126qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[233]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[234]</sup> Overall, transplantation yields net positive HRQoL trajectories, with dialysis patients consistently scoring lower pre- and post-waitlist periods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1i6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[231]</sup></span>
<h3 id="determinants-of-long-term-success" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Determinants of Long-Term Success<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term success in kidney transplantation is primarily measured by sustained allograft function, typically beyond 5â€“10 years, with median graft half-lives reported at approximately 12â€“15 years for deceased donor transplants and 15â€“20 years for living donor transplants in recent U.S. data from the Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[235]</sup> Key determinants encompass immunological compatibility, donor organ quality, recipient characteristics, and post-transplant management, where imbalances in any domain accelerate chronic allograft nephropathy or failure through mechanisms like antibody-mediated injury and fibrosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[224]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Human leukocyte antigen (HLA) matching remains a critical immunological factor, with each additional mismatch at HLA-A, -B, or -DR loci increasing the hazard ratio for graft loss by 7â€“10% over 20 years in first deceased donor transplants, based on analysis of over 100,000 U.S. cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[236]</sup> Poor matching heightens risks of chronic antibody-mediated rejection, particularly in sensitized recipients with preformed donor-specific antibodies, though modern immunosuppression has attenuated but not eliminated this effect.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[237]</sup> Living donor transplants from HLA-identical siblings achieve superior 10-year graft survival rates exceeding 80%, compared to 60â€“70% for mismatched deceased donors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Donor-specific factors, including age and procurement conditions, profoundly influence durability; kidneys from donors over 60 years exhibit 20â€“30% lower 10-year survival versus those from donors under 40, due to intrinsic nephrosclerosis and reduced regenerative capacity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[238]</sup> Deceased donor grafts from expanded criteria (e.g., high Kidney Donor Profile Index &gt;85%) face heightened early ischemic injury, correlating with accelerated long-term decline, whereas living donors provide organs with lower cold ischemia times and better baseline function, extending median survival by 3â€“5 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[239]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recipient variables such as pre-transplant dialysis duration, exceeding 5 years, independently doubles the risk of graft loss through endothelial damage and sensitization, per multivariate analyses of registry data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[240]</sup> Comorbidities like cardiovascular disease and diabetes mellitus impair outcomes, with adjusted hazard ratios for death-censored graft failure rising 1.5â€“2.0-fold in recipients with multiple conditions, underscoring the need for optimized pre-transplant risk stratification.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[241]</sup> Older recipients (&gt;65 years) experience comparable conditional survival post-engraftment but higher absolute failure rates due to cumulative frailty.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[242]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-transplant adherence to immunosuppression regimens is paramount, with non-adherence accounting for up to 20% of late losses; protocolized monitoring of drug levels and biopsy surveillance detects subclinical rejection early, preserving function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup> Delayed graft function, occurring in 20â€“30% of deceased donor cases, triples the risk of chronic dysfunction via ischemia-reperfusion pathways, while vigilant infection prophylaxis mitigates opportunistic pathogens that exacerbate allograft stress.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[243]</sup> Overall, integrating these factors via refined allocation algorithms and personalized care has incrementally boosted 10-year graft survival from 50% in the 1990s to over 65% today, though non-immunological barriers like donor scarcity persist.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[224]</sup></span>
<h2 id="ethical-legal-and-societal-dimensions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Ethical, Legal, and Societal Dimensions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="the-organ-shortage-crisis-and-waitlist-deaths" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">The Organ Shortage Crisis and Waitlist Deaths<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The persistent imbalance between the supply of donor kidneys and the demand from patients with end-stage renal disease constitutes a fundamental barrier to kidney transplantation in the United States. As of 2023, approximately 88,500 individuals were active on the kidney transplant waiting list, with 44,560 new candidates added that year, reflecting rising incidences of kidney failure driven by factors such as diabetes and hypertension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ababav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[244]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ebabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[245]</sup> In contrast, only 27,332 kidney transplants were performed in 2023, including about 6,290 from living donors, leaving a net growth in the waitlist despite incremental increases in deceased donor recoveries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[245]</sup> This supply-demand gap has widened over time, as annual transplant volumes, while reaching records like 26,309 in 2022, fail to match the expanding pool of eligible patients added to the list each year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ubabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[235]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Waitlist mortality underscores the human cost of this shortage, with thousands of patients dying annually while awaiting a transplant. In 2023, 4,002 individuals were removed from the kidney waitlist due to death, a decline from 5,371 in 2021 amid pandemic disruptions but still equating to roughly 11 deaths per day.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[246]</sup> Estimates indicate 12 to 17 kidney candidates die daily across the U.S., often from complications of dialysis or disease progression, as median wait times exceed three to five years depending on blood type, tissue match, and geographic factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ibqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[244]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[247]</sup> One-year post-waitlisting survival data show that only about 16.6% receive a deceased donor kidney, while 1.7% die within that period, highlighting how prolonged dialysisâ€”while life-sustainingâ€”carries inferior outcomes compared to transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ubqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[221]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Contributing to the shortage are multifaceted supply constraints, including insufficient deceased donor rates due to opt-in consent systems, cultural reluctance toward donation, and donor organ discard from perceived quality issues like extended ischemia or marginal viability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[248]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ecabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[249]</sup> In 2023, organ procurement organizations recovered twice the kidneys needed to save waitlisted patients who died, yet many were discarded, pointing to inefficiencies in utilization alongside demographic shifts toward older donors with comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[249]</sup> Living donation, which accounts for about 20-25% of transplants, has plateaued due to regulatory barriers and family-based limitations, failing to offset the deceased donor shortfall.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ucabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[250]</sup> These dynamics persist despite policy efforts like the 2014 Kidney Allocation System revisions, as demand continues to outpace even record donation levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_16cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[251]</sup></span>
<h3 id="allocation-fairness-and-geographic-disparities" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Allocation Fairness and Geographic Disparities<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, kidney allocation is managed by the Organ Procurement and Transplantation Network (OPTN) under policies designed to balance medical urgency, biological compatibility, and equitable access while maximizing graft utility. Priority is given first to zero human leukocyte antigen (HLA) mismatch candidates within a 250-nautical-mile radius of the donor hospital, followed by national zero-mismatch offers, pediatric candidates, highly sensitized patients (calculated panel reactive antibody &gt;98%), blood type compatibility, wait time, and other factors like donor-specific antibodies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_idabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[252]</sup> These criteria aim for fairness by prioritizing life-saving potential over geographic proximity, but longstanding debates question whether the system adequately weighs equity against efficiency, with critics arguing that local procurement inefficiencies exacerbate unequal outcomes without sufficient accountability for organ procurement organizations (OPOs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[253]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Geographic disparities in access to deceased donor kidney transplantation (DDKT) have persisted since the national system&#x27;s inception, driven by variations in OPO performance, donor recovery rates, and local demand-supply imbalances. Median wait times for kidney transplant candidates exceed 3 years nationally but range up to 10 years in high-demand regions, with transplant rates per 100 dialysis patients varying more than twofold across donation service areas (DSAs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[245]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_idqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[254]</sup> For instance, Scientific Registry of Transplant Recipients (SRTR) data indicate that areas with high end-stage kidney disease burdens, often urban centers, experience lower transplant rates post-policy updates due to constrained local supply and discard rates influenced by transport logistics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[255]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[256]</sup> In 2022, the OPTN/SRTR Annual Data Report highlighted stable but unequal graft survival metrics across regions, attributing part of the variance to OPO-level differences in deceased donor kidney recovery, where some DSAs recover kidneys from only 40-50% of eligible donors compared to over 70% in others.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1adqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[235]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Policy reforms have targeted these inequities, notably the 2014 Kidney Allocation System (KAS), which expanded sharing for highly sensitized patients and prioritized longevity matching, and the 2021 KAS250 update, which eliminated DSA and regional boundaries in favor of distance-based circles to promote broader distribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[254]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[257]</sup> The 2021 change increased cold ischemia times by an average of 1-2 hours but reduced geographic barriers, leading to a modest decline in waitlist mortality disparities in some analyses; however, SRTR evaluations show persistent unacceptably high variation, with the OPTN Board noting in 2012â€”and reaffirmed in subsequent reportsâ€”that access inequities remain a core failure mode tied to OPO metrics rather than allocation algorithms alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[253]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[258]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Fairness concerns extend to intersections with demographics, where geographic clustering of minority populations amplifies wait times; for example, non-Hispanic Black candidates, disproportionately in high-disparity DSAs, face 14% lower waitlisting odds even after KAS implementation, prompting 2023 waiting time modification policies that have awarded 1-3 years of credit to over 14,700 Black candidates to rectify historical HLA sensitization biases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[259]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[260]</sup> While these adjustments address calculable inequities, broader causal factors like variable OPO consent rates and discard practicesâ€”unmitigated by allocation tweaksâ€”underscore that fairness requires supply-side reforms, as evidenced by stagnant national waitlist growth despite record 28,142 transplants in 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup> Empirical data from SRTR prioritize OPO accountability over further algorithmic shifts to achieve causal equity in outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[261]</sup></span>
<h3 id="debates-on-organ-markets-vs-altruism" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Debates on Organ Markets vs. Altruism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The debate over introducing regulated markets for kidneys versus relying solely on altruistic donation stems from persistent organ shortages, with over 100,000 patients awaiting kidneys in the United States as of 2023, leading to approximately 17 deaths per day on waitlists.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[262]</sup> Proponents argue that economic incentives would substantially increase supply by aligning human motivations with basic self-interest, as altruism alone has failed to meet demand despite public campaigns and opt-out policies in some countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ifqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[263]</sup> In contrast, opponents contend that markets risk exploiting vulnerable sellers, commodifying human body parts, and eroding societal norms of gift-giving in medicine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[264]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Economists Gary Becker and Julio Elias proposed in 2007 that payments of around $15,000 to $40,000 per kidney could eliminate U.S. transplant queues by boosting live donor supply fivefold or more, based on econometric modeling of willingness-to-donate under incentives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[263]</sup> This approach would also yield net savings of $100,000 or more per transplant by averting dialysis costs, which exceed $80,000 annually per patient.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_igabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[265]</sup> Empirical support draws from Iran&#x27;s regulated compensated donation system, operational since 1988, where donors receive government-fixed payments of approximately $1,200 to $4,500 plus lifelong health insurance, resulting in over 40,000 kidney transplants by 2022 and the elimination of domestic waitlists.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[266]</sup> Studies of Iranian donors indicate high satisfaction rates (over 85%) and low regret (under 2%), with transplant volumes rising steadily without evidence of widespread coercion when regulated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[267]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Critics of organ markets emphasize ethical risks of exploitation, particularly for low-income individuals who may sell kidneys out of desperation rather than true voluntariness, potentially exacerbating global inequalities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[268]</sup> Bioethicists argue that even regulated payments undermine human dignity by treating organs as commodities, drawing parallels to historical bans on slavery or servitude, and warn of slippery slopes toward broader bodily commodification.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_igqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[269]</sup> Evidence from unregulated black markets, such as in Pakistan or via transplant tourism, shows higher infection rates and poorer graft survival (e.g., over 50% complication rates in some recipient cohorts), fueling concerns that incentives could incentivize substandard practices.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[270]</sup> However, proponents counter that prohibition drives underground tradeâ€”estimated at 10% of global transplantsâ€”where sellers receive far less (often under $1,000) and face greater harms without oversight, suggesting regulation could mitigate these issues more effectively than altruism&#x27;s status quo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[271]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent analyses, including a 2022 review, highlight that while Iran&#x27;s model has increased supply, donor long-term health outcomes remain understudied, with some evidence of higher hypertension risks among sellers, though not exceeding those in altruistic donors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[266]</sup> Proposals for Western markets often include safeguards like fixed prices, independent oversight, and bans on foreign sales to prevent exploitation, with pilot studies suggesting public support rises to 70% if supply gains are projected.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ihabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[272]</sup> Despite these, opposition persists in institutions like the World Health Organization, which in 2023 reiterated bans on payments citing dignity over utilitarian gains, reflecting a preference for deontological ethics amid debates on whether altruism&#x27;s moral framing truly enhances donation rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[273]</sup> Causal evidence indicates that incentives outperform purely voluntary systems in high-demand contexts, as human behavior responds predictably to compensation, challenging assumptions that markets inherently corrupt benevolence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[274]</sup></span>
<h3 id="access-inequities-and-systemic-biases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Access Inequities and Systemic Biases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Racial disparities persist in access to kidney transplantation in the United States, with Black patients facing lower rates of waitlisting and transplantation despite higher incidence of end-stage renal disease (ESRD). Black individuals are approximately 25% less likely to be waitlisted for transplant compared to White patients, even after adjusting for demographic, clinical, and socioeconomic factors. In 2020, White patients comprised 43% of kidney transplant recipients, while Black patients accounted for 26%, despite Blacks representing a disproportionate share of the ESRD population. Post-transplant, Black recipients experience worse graft survival rates compared to Whites. These patterns vary by age and region, with some studies indicating divergent trends where younger Black patients show narrowing gaps in waitlisting but persistent delays in transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[275]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[276]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[277]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_miabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[278]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Gender inequities also affect transplant access, with women consistently less likely than men to receive kidneys at multiple stages of the process. Women with ESRD are up to 20% less likely to be referred for evaluation, activated on waitlists after referral, or receive living donor transplants. By 2017â€“2020, the disparity in living donor kidney transplantation had widened, with women 21% less likely to receive one compared to men (hazard ratio 0.79). Intersectional analyses reveal that White men exhibit the highest access across referral, waitlisting, and receipt of both living and deceased donor kidneys, while Black women face compounded barriers. Nephrologists have identified potential contributors including implicit biases in referral decisions and women&#x27;s lower likelihood of pursuing living donation due to family roles, though empirical data underscores persistent gaps post-adjustment for clinical factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[279]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[280]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[281]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_miqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[282]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Socioeconomic status exacerbates these inequities, correlating with reduced preemptive transplantation, prolonged dialysis dependence, and inferior graft outcomes. Patients from lower socioeconomic neighborhoods, as measured by indices like HOUSES, show significantly lower rates of preemptive kidney transplants, particularly among children. Low income, lack of private insurance, and residence in high-poverty areas independently predict delayed access, with Black patients disproportionately affected due to higher poverty prevalence (four-fold greater than Whites). Insurance status further influences outcomes, as publicly insured patients encounter barriers in evaluation and listing. These patterns hold after controlling for race, suggesting socioeconomic factors drive causal chains in referral and donor matching independent of, yet intertwined with, racial dynamics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[283]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ejabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[284]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ijabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[285]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[286]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Geographic disparities amplify access barriers through uneven organ supply and demand across United Network for Organ Sharing (UNOS) regions, resulting in wait times ranging from under 3 years in some areas to over 10 years in others. Regional variations account for a substantial portion of racial differences in waiting times, with minority-heavy areas like the Southeast exhibiting &quot;hot spots&quot; of prolonged delays. The 2014 Kidney Allocation System aimed to mitigate this by awarding points for multi-listing at distant centers, yet geographic mismatches persist, disproportionately impacting Black candidates whose distribution correlates with longer queues. Supply-demand imbalances, rather than solely policy flaws, underlie these inequities, as evidenced by modeling showing wait times extending to 52.6 months under expanded waitlists without supply increases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ejqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[245]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ijqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[287]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[288]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Systemic biases manifest in allocation and evaluation processes, including historical use of race-adjusted glomerular filtration rate (eGFR) formulas that delayed Black patients&#x27; eligibility, now addressed by race-neutral alternatives. Disparities arise early, with Black patients less likely to receive timely referrals despite nephrologist awareness, potentially reflecting institutional inertia or unmeasured clinical hesitancy. Allocation prioritizes factors like wait time and expected post-transplant survival, inadvertently perpetuating inequities tied to dialysis duration and comorbidities more prevalent in disadvantaged groups. While some attribute gaps to overt discrimination, adjusted analyses reveal multifactorial origins, including HLA mismatch challenges in diverse populations and compliance variations, underscoring the need for causal dissection beyond correlative claims of bias. Peer-reviewed data from registries like UNOS provide robust evidence, though academic interpretations warrant scrutiny for overemphasizing social constructs over biological and logistical realities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_akabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[289]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ekabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[290]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ikabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[291]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[292]</sup></span>
<h2 id="epidemiological-statistics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiological Statistics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="global-transplant-trends-and-volumes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Global Transplant Trends and Volumes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney transplantation accounts for the majority of solid organ transplants worldwide, comprising approximately 65% of the total in 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_alqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[293]</sup> In that year, 111,135 kidney transplants were reported across 91 of 93 participating countries in the Global Observatory on Donation and Transplantation (GODT), reflecting data from regions covering a substantial portion of the global population.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ilqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[294]</sup> This volume marked a notable rise from 102,090 kidney transplants in 2022, as documented in the prior GODT report covering 90 of 91 countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[295]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Global volumes have shown consistent growth over the past decade, with kidney transplants increasing from around 80,000â€“90,000 annually in the mid-2010s to exceeding 100,000 by 2022, driven by expansions in both deceased and living donor programs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_amabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[296]</sup> Deceased donor kidney transplants constitute about 61% of the global total, though this proportion varies sharply by region: higher in high-income countries like the United States (where 28,142 kidney transplants occurred in 2023, predominantly deceased donor-derived) and lower in areas reliant on living donation, such as India, which performs 25% of worldwide living donor kidney transplants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_imabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[297]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[298]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[299]</sup> Living donor rates average a median of 5 per million population globally, with extremes from near zero in some low-capacity nations to over 30 per million in outliers like Turkey.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1amabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[300]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Despite the upward trend, coverage remains uneven, with Africa contributing only about 1% of global transplants in recent years due to infrastructural and regulatory limitations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_amqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[301]</sup> The overall 9% year-over-year increase in kidney transplant activity from 2022 to 2023 aligns with broader solid organ growth, attributed to policy enhancements in donor recruitment and allocation efficiency in reporting jurisdictions, though underreporting from non-participating or informal systems may underestimate true volumes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_imqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[302]</sup> Projections suggest continued modest expansion through 2030, contingent on addressing deceased donor shortages in developing regions, but empirical data indicate persistent gaps relative to the estimated 2â€“3 million annual end-stage kidney disease cases worldwide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[303]</sup></span>
<h3 id="national-variations-and-policy-impacts" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">National Variations and Policy Impacts<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney transplant rates vary substantially across nations, influenced by policies on donor consent, allocation systems, and infrastructure. In 2023, Spain achieved the highest rate in Europe at 77.7 transplants per million population (pmp), attributed to its presumed consent (opt-out) system implemented since 1979, coupled with robust coordination via the National Transplant Organization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_anqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[304]</sup> In contrast, the United States recorded 77.0 pmp in 2021, leading globally in deceased donor rates at 38.0 pmp and deceased-donor kidney transplants at 55.6 pmp, driven by explicit consent (opt-in) policies but supported by advanced paired exchange programs and the Organ Procurement and Transplantation Network (OPTN).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_inqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[305]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[306]</sup> Southeast Asian countries, however, averaged only 3.8 pmp in 2014, reflecting limited deceased donor frameworks and reliance on living donors amid cultural and regulatory barriers to posthumous donation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[307]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Opt-out policies correlate with higher deceased donor rates in some analyses, yet causal evidence remains inconclusive, as confounding factors like public awareness campaigns and healthcare infrastructure play significant roles. For instance, opt-out nations exhibit elevated overall donation but lower living kidney donor transplants (4.5 pmp versus 15.2 pmp in opt-in countries), potentially due to greater emphasis on deceased procurement reducing incentives for living donation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[308]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ioabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[309]</sup> Recent longitudinal studies, including evaluations post-policy shifts in countries like England (opting out since 2020), find no significant increase in donation rates attributable solely to defaults, underscoring that implementation quality and family override ratesâ€”often exceeding 40% even in opt-out systemsâ€”mitigate presumed consent effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[310]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[311]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Policy reforms have demonstrably impacted access and equity. In the US, 2019â€“2021 OPTN revisions prioritizing longevity matching over wait time reduced geographic disparities and boosted transplants across demographics, with overall kidney transplants rising post-implementation without favoring specific groups.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[312]</sup> European rates grew more modestly (+1.9% annually from 2012â€“2019) compared to the US (+4.3%), partly due to varied national allocation models emphasizing equity over utility in some regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ioqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[305]</sup> In Asia, heterogeneous deceased donor lawsâ€”ranging from prohibition in some nations to regulated systems in othersâ€”constrain transplant volumes, particularly in lower-income settings where living donor chains predominate but raise ethical concerns over coercion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qoqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[313]</sup> These variations highlight how policy design, independent of consent type, affects waitlist mortality, with higher-transplant nations like Spain and the US achieving lower per-capita dialysis burdens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[294]</sup></span>
<h3 id="recent-data-20202025-and-projections" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Recent Data (2020â€“2025) and Projections<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, kidney transplant volumes declined to 23,642 in 2020, primarily due to disruptions from the COVID-19 pandemic, which reduced deceased donor recoveries and elective procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_apqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[314]</sup> Recovery followed, with 25,549 transplants in 2021, rising to a record 26,309 in 2022 amid increased deceased donor activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ipqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[315]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[235]</sup> Volumes peaked at 28,142 in 2023 before a slight dip to 27,759 in 2024, reflecting sustained growth in deceased donor kidneys (over 70% of totals) despite living donor numbers stabilizing around 6,000 annually.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_upqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[251]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Year</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Total Kidney Transplants (US)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Deceased Donor Share (Approx.)</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2020</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">23,642</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~80%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2021</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">25,549</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~77%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2022</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">26,309</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~75%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2023</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">28,142</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~75%</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2024</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">27,759</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">~75%</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Globally, kidney transplants totaled approximately 102,149 in 2022, with kidneys comprising the majority of solid organ procedures amid uneven reporting from over 90 countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[296]</sup> The transplant rate reached 18.5 per million population in 2023, up from 11 per million in 2011, driven by expansions in living and deceased donation in regions like Europe and Asia, though coverage remains limited to about 70% of countries with underdeveloped programs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[316]</sup> Living donor kidney transplants alone numbered 43,101 worldwide in 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[317]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Projections indicate modest volume growth through 2030, constrained by persistent organ shortages; U.S. analyses suggest policy reforms in organ procurement could add up to 5,000 annual transplants by targeting underperforming centers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_arabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[318]</sup> Globally, kidney replacement therapy needs are forecasted to affect 14.5 million people by 2030, with transplants meeting only a fraction due to supply limits, though conservative rate increases could avert 290,000 chronic kidney disease deaths yearly via expanded access.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_irabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[319]</sup>00222-0/fulltext) Market analyses project the kidney transplant sector to grow at 4-6% CAGR to 2030, fueled by immunosuppression advances and paired exchange programs, but waitlist mortality underscores the need for supply-side innovations over demand-side expansions alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qrabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[320]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_urabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[321]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.ncbi.nlm.nih.gov/books/NBK567755/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK567755/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK567755/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8643514/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8643514/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8643514/</a></span></div></li><li id="https://www.nobelprize.org/prizes/medicine/1990/murray/facts/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nobelprize.org/prizes/medicine/1990/murray/facts/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nobelprize.org/prizes/medicine/1990/murray/facts/</a></span></div></li><li id="https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962883-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962883-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962883-8/fulltext</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK553074/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK553074/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK553074/</a></span></div></li><li id="https://www.uptodate.com/contents/kidney-transplantation-in-adults-management-of-the-patient-with-a-failed-kidney-transplant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uptodate.com/contents/kidney-transplantation-in-adults-management-of-the-patient-with-a-failed-kidney-transplant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uptodate.com/contents/kidney-transplantation-in-adults-management-of-the-patient-with-a-failed-kidney-transplant</a></span></div></li><li id="https://journals.lww.com/cjasn/fulltext/2022/02000/long_term_infectious_complications_of_kidney.17.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/cjasn/fulltext/2022/02000/long_term_infectious_complications_of_kidney.17.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/cjasn/fulltext/2022/02000/long_term_infectious_complications_of_kidney.17.aspx</a></span></div></li><li id="https://vascularsurgery.ucsf.edu/procedure/kidney-transplant-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://vascularsurgery.ucsf.edu/procedure/kidney-transplant-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://vascularsurgery.ucsf.edu/procedure/kidney-transplant-0</a></span></div></li><li id="https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/</a></span></div></li><li id="https://www.eujtransplantation.com/article/view/403" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.eujtransplantation.com/article/view/403" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.eujtransplantation.com/article/view/403</a></span></div></li><li id="https://unos.org/transplant/history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/transplant/history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/transplant/history/</a></span></div></li><li id="https://www.life-source.org/latest/early-organ-transplant/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.life-source.org/latest/early-organ-transplant/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.life-source.org/latest/early-organ-transplant/</a></span></div></li><li id="https://news.harvard.edu/gazette/story/2011/09/a-transplant-makes-history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.harvard.edu/gazette/story/2011/09/a-transplant-makes-history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.harvard.edu/gazette/story/2011/09/a-transplant-makes-history/</a></span></div></li><li id="https://waring.library.musc.edu/exhibits/kidney/Transplantation.php" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://waring.library.musc.edu/exhibits/kidney/Transplantation.php" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://waring.library.musc.edu/exhibits/kidney/Transplantation.php</a></span></div></li><li id="https://www.uspharmacist.com/article/immunosuppressants-used-in-solid-organ-transplantation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uspharmacist.com/article/immunosuppressants-used-in-solid-organ-transplantation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uspharmacist.com/article/immunosuppressants-used-in-solid-organ-transplantation</a></span></div></li><li id="https://abdominalkey.com/kidney-transplantation-a-history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://abdominalkey.com/kidney-transplantation-a-history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://abdominalkey.com/kidney-transplantation-a-history/</a></span></div></li><li id="https://edren.org/ren/unit/history/history-of-kidney-transplation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://edren.org/ren/unit/history/history-of-kidney-transplation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://edren.org/ren/unit/history/history-of-kidney-transplation/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3259474/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3259474/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3259474/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0041134504001320" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0041134504001320" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0041134504001320</a></span></div></li><li id="https://www.intechopen.com/chapters/41518" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.intechopen.com/chapters/41518" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.intechopen.com/chapters/41518</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/18312164/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/18312164/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/18312164/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7034519/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7034519/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7034519/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6165704/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6165704/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6165704/</a></span></div></li><li id="https://www.mdpi.com/2673-8236/5/3/37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2673-8236/5/3/37" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2673-8236/5/3/37</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2825%2900048-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2825%2900048-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2825%2900048-4/fulltext</a></span></div></li><li id="https://www.kireports.org/article/S2468-0249%2825%2900413-9/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kireports.org/article/S2468-0249%2825%2900413-9/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kireports.org/article/S2468-0249%2825%2900413-9/fulltext</a></span></div></li><li id="https://www.nature.com/articles/s41467-025-59829-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-025-59829-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-025-59829-5</a></span></div></li><li id="https://www.nature.com/articles/s41467-025-60410-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-025-60410-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-025-60410-3</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8968476/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8968476/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8968476/</a></span></div></li><li id="https://www.kidneyfund.org/kidney-health-innovations" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyfund.org/kidney-health-innovations" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyfund.org/kidney-health-innovations</a></span></div></li><li id="https://www.kidneymedicinejournal.org/article/S2590-0595%2825%2900077-9/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneymedicinejournal.org/article/S2590-0595%2825%2900077-9/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneymedicinejournal.org/article/S2590-0595%2825%2900077-9/fulltext</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2412747" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2412747" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2412747</a></span></div></li><li id="https://www.healio.com/news/nephrology/20250627/we-need-this-pigtohuman-kidney-transplants-enter-clinical-trials" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healio.com/news/nephrology/20250627/we-need-this-pigtohuman-kidney-transplants-enter-clinical-trials" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healio.com/news/nephrology/20250627/we-need-this-pigtohuman-kidney-transplants-enter-clinical-trials</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/iju.70173?af=R" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/iju.70173?af=R" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/iju.70173?af=R</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK499861/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK499861/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK499861/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/21883901/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/21883901/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/21883901/</a></span></div></li><li id="https://columbiasurgery.org/conditions-and-treatments/end-stage-renal-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://columbiasurgery.org/conditions-and-treatments/end-stage-renal-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://columbiasurgery.org/conditions-and-treatments/end-stage-renal-disease</a></span></div></li><li id="https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria</a></span></div></li><li id="https://www.myast.org/caregiver-toolkit/end-stage-kidney-disease-and-transplant-general-information" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.myast.org/caregiver-toolkit/end-stage-kidney-disease-and-transplant-general-information" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.myast.org/caregiver-toolkit/end-stage-kidney-disease-and-transplant-general-information</a></span></div></li><li id="https://my.clevelandclinic.org/departments/transplant/programs/kidney/candidate" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://my.clevelandclinic.org/departments/transplant/programs/kidney/candidate" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://my.clevelandclinic.org/departments/transplant/programs/kidney/candidate</a></span></div></li><li id="https://www.revistanefrologia.com/en-indications-contraindications-living-donor-kidney-transplantation-articulo-X2013251410051408" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.revistanefrologia.com/en-indications-contraindications-living-donor-kidney-transplantation-articulo-X2013251410051408" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.revistanefrologia.com/en-indications-contraindications-living-donor-kidney-transplantation-articulo-X2013251410051408</a></span></div></li><li id="https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/end-stage-renal-disease/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/end-stage-renal-disease/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/end-stage-renal-disease/</a></span></div></li><li id="https://emedicine.medscape.com/article/430128-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/430128-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/430128-overview</a></span></div></li><li id="https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx</a></span></div></li><li id="https://www.kidney.org/kidney-topics/evaluation-kidney-transplant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/evaluation-kidney-transplant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/evaluation-kidney-transplant</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5540357/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5540357/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5540357/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8786144/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8786144/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8786144/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2817%2931078-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2817%2931078-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2817%2931078-8/fulltext</a></span></div></li><li id="https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/guidance-for-the-development-of-program-specific-living-kidney-donor-medical-evaluation-protocols/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/guidance-for-the-development-of-program-specific-living-kidney-donor-medical-evaluation-protocols/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/guidance-for-the-development-of-program-specific-living-kidney-donor-medical-evaluation-protocols/</a></span></div></li><li id="https://www.annualreviews.org/content/journals/10.1146/annurev-med-050223-112648" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.annualreviews.org/content/journals/10.1146/annurev-med-050223-112648" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.annualreviews.org/content/journals/10.1146/annurev-med-050223-112648</a></span></div></li><li id="https://unos.org/news/policy-changes/updates-to-living-donor-exclusion-criteria-now-in-effect/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/news/policy-changes/updates-to-living-donor-exclusion-criteria-now-in-effect/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/news/policy-changes/updates-to-living-donor-exclusion-criteria-now-in-effect/</a></span></div></li><li id="https://kdigo.org/guidelines/living-kidney-donor/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/guidelines/living-kidney-donor/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/guidelines/living-kidney-donor/</a></span></div></li><li id="https://jamanetwork.com/journals/jama/article-abstract/2822922" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jama/article-abstract/2822922" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jama/article-abstract/2822922</a></span></div></li><li id="https://www.mayoclinic.org/tests-procedures/donor-nephrectomy/about/pac-20384867" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/tests-procedures/donor-nephrectomy/about/pac-20384867" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/tests-procedures/donor-nephrectomy/about/pac-20384867</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S240545692200075X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S240545692200075X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S240545692200075X</a></span></div></li><li id="https://health.ucdavis.edu/news/headlines/uc-davis-health-performs-first-robotic-nephrectomy-on-living-kidney-donor/2023/04" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://health.ucdavis.edu/news/headlines/uc-davis-health-performs-first-robotic-nephrectomy-on-living-kidney-donor/2023/04" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://health.ucdavis.edu/news/headlines/uc-davis-health-performs-first-robotic-nephrectomy-on-living-kidney-donor/2023/04</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7607668/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7607668/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7607668/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/long-term-risks-living-donation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/long-term-risks-living-donation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/long-term-risks-living-donation</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11896807/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11896807/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11896807/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/new-living-kidney-donor-program-requirements-standardizing-patient-care/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/new-living-kidney-donor-program-requirements-standardizing-patient-care/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/new-living-kidney-donor-program-requirements-standardizing-patient-care/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/</a></span></div></li><li id="https://www.uptodate.com/contents/management-of-the-deceased-organ-donor" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uptodate.com/contents/management-of-the-deceased-organ-donor" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uptodate.com/contents/management-of-the-deceased-organ-donor</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4116061/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4116061/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4116061/</a></span></div></li><li id="https://health.ucdavis.edu/transplant/nonlivingdonors/standard-criteria-donors.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://health.ucdavis.edu/transplant/nonlivingdonors/standard-criteria-donors.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://health.ucdavis.edu/transplant/nonlivingdonors/standard-criteria-donors.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC1356277/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1356277/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC1356277/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/establish-minimum-kidney-donor-criteria-to-require-biopsy/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/establish-minimum-kidney-donor-criteria-to-require-biopsy/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/establish-minimum-kidney-donor-criteria-to-require-biopsy/</a></span></div></li><li id="https://unos.org/news/implementation-minimum-kidney-donor-biopsy-criteria/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/news/implementation-minimum-kidney-donor-biopsy-criteria/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/news/implementation-minimum-kidney-donor-biopsy-criteria/</a></span></div></li><li id="https://teachmesurgery.com/transplant-surgery/core-concepts/organ-retrieval/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://teachmesurgery.com/transplant-surgery/core-concepts/organ-retrieval/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://teachmesurgery.com/transplant-surgery/core-concepts/organ-retrieval/</a></span></div></li><li id="https://unos.org/transplant/deceased-donation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/transplant/deceased-donation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/transplant/deceased-donation/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0263931923001485" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0263931923001485" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0263931923001485</a></span></div></li><li id="https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf</a></span></div></li><li id="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/update-kidney-paired-donation-policy/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/update-kidney-paired-donation-policy/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/update-kidney-paired-donation-policy/</a></span></div></li><li id="https://www.kidneyregistry.com/news/national-kidney-registrys-2025-outcomes-report-highlights-superior-kidney-transplant-success-rates/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyregistry.com/news/national-kidney-registrys-2025-outcomes-report-highlights-superior-kidney-transplant-success-rates/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyregistry.com/news/national-kidney-registrys-2025-outcomes-report-highlights-superior-kidney-transplant-success-rates/</a></span></div></li><li id="https://www.kidneyregistry.com/news-category/quarterly-reports/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyregistry.com/news-category/quarterly-reports/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyregistry.com/news-category/quarterly-reports/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6082363/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6082363/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6082363/</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2819%2930298-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2819%2930298-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2819%2930298-4/fulltext</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23684" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23684" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23684</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7822792/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7822792/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7822792/</a></span></div></li><li id="https://www.weforum.org/stories/2018/06/spain-leads-the-world-in-organ-donation-what-s-stopping-other-countries-catching-up/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.weforum.org/stories/2018/06/spain-leads-the-world-in-organ-donation-what-s-stopping-other-countries-catching-up/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.weforum.org/stories/2018/06/spain-leads-the-world-in-organ-donation-what-s-stopping-other-countries-catching-up/</a></span></div></li><li id="https://www.kidney.org/press-room/nkf-applauds-new-proposed-rules-to-increase-organ-donation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/press-room/nkf-applauds-new-proposed-rules-to-increase-organ-donation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/press-room/nkf-applauds-new-proposed-rules-to-increase-organ-donation</a></span></div></li><li id="https://www.organ-recovery.com/use-of-machine-perfusion-to-increase-the-number-of-expanded-criteria-deceased-donor-kidney-transplants-a-pharmacoeconomic-analysis/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.organ-recovery.com/use-of-machine-perfusion-to-increase-the-number-of-expanded-criteria-deceased-donor-kidney-transplants-a-pharmacoeconomic-analysis/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.organ-recovery.com/use-of-machine-perfusion-to-increase-the-number-of-expanded-criteria-deceased-donor-kidney-transplants-a-pharmacoeconomic-analysis/</a></span></div></li><li id="https://journals.lww.com/transplantationdirect/fulltext/2024/08000/use_of_machine_perfusion_to_increase_the_number_of.3.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantationdirect/fulltext/2024/08000/use_of_machine_perfusion_to_increase_the_number_of.3.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantationdirect/fulltext/2024/08000/use_of_machine_perfusion_to_increase_the_number_of.3.aspx</a></span></div></li><li id="https://thelimbic.com/nephrology/normothermic-machine-perfusion-expands-kidney-donor-pool/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://thelimbic.com/nephrology/normothermic-machine-perfusion-expands-kidney-donor-pool/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://thelimbic.com/nephrology/normothermic-machine-perfusion-expands-kidney-donor-pool/</a></span></div></li><li id="https://health.ucdavis.edu/news/headlines/new-technology-could-increase-donor-kidneys-for-transplants/2024/09" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://health.ucdavis.edu/news/headlines/new-technology-could-increase-donor-kidneys-for-transplants/2024/09" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://health.ucdavis.edu/news/headlines/new-technology-could-increase-donor-kidneys-for-transplants/2024/09</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12446984/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12446984/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12446984/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2825%2900047-2/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2825%2900047-2/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2825%2900047-2/fulltext</a></span></div></li><li id="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14807/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14807/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14807/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9846288/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9846288/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9846288/</a></span></div></li><li id="https://hms.harvard.edu/news/surgeons-perform-second-pig-kidney-transplant-massachusetts-general-hospital" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://hms.harvard.edu/news/surgeons-perform-second-pig-kidney-transplant-massachusetts-general-hospital" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://hms.harvard.edu/news/surgeons-perform-second-pig-kidney-transplant-massachusetts-general-hospital</a></span></div></li><li id="https://www.massgeneral.org/news/press-release/mgh-performs-second-xenotransplant-of-genetically-edited-pig-kidney-into-living-recipient" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.massgeneral.org/news/press-release/mgh-performs-second-xenotransplant-of-genetically-edited-pig-kidney-into-living-recipient" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.massgeneral.org/news/press-release/mgh-performs-second-xenotransplant-of-genetically-edited-pig-kidney-into-living-recipient</a></span></div></li><li id="https://nyulangone.org/news/gene-edited-pig-kidney-gives-living-donor-new-lease-life" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nyulangone.org/news/gene-edited-pig-kidney-gives-living-donor-new-lease-life" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nyulangone.org/news/gene-edited-pig-kidney-gives-living-donor-new-lease-life</a></span></div></li><li id="https://ir.unither.com/press-releases/2025/02-03-2025-120011819" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ir.unither.com/press-releases/2025/02-03-2025-120011819" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ir.unither.com/press-releases/2025/02-03-2025-120011819</a></span></div></li><li id="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13475/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13475/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13475/full</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0966327425000127" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0966327425000127" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0966327425000127</a></span></div></li><li id="https://www.nature.com/articles/s41591-025-03855-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41591-025-03855-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41591-025-03855-9</a></span></div></li><li id="https://www.biorxiv.org/content/10.1101/2025.07.10.664023v1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biorxiv.org/content/10.1101/2025.07.10.664023v1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biorxiv.org/content/10.1101/2025.07.10.664023v1</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39674100/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39674100/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39674100/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11816546/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11816546/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11816546/</a></span></div></li><li id="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1476510/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1476510/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1476510/full</a></span></div></li><li id="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1621641/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1621641/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1621641/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8966965/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8966965/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8966965/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0966327423000783" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0966327423000783" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0966327423000783</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0198885924000739" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0198885924000739" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0198885924000739</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/tan.15784" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/tan.15784" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/tan.15784</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2821%2900657-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2821%2900657-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2821%2900657-8/fulltext</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0010482524005365" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0010482524005365" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0010482524005365</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7462663/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7462663/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7462663/</a></span></div></li><li id="https://www.uptodate.com/contents/kidney-transplantation-in-adults-overview-of-hla-sensitization-and-crossmatch-testing" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uptodate.com/contents/kidney-transplantation-in-adults-overview-of-hla-sensitization-and-crossmatch-testing" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uptodate.com/contents/kidney-transplantation-in-adults-overview-of-hla-sensitization-and-crossmatch-testing</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9171621/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9171621/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9171621/</a></span></div></li><li id="https://www.amjtransplant.org/article/S1600-6135%2822%2907334-8/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.amjtransplant.org/article/S1600-6135%2822%2907334-8/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.amjtransplant.org/article/S1600-6135%2822%2907334-8/fulltext</a></span></div></li><li id="https://journals.lww.com/md-journal/fulltext/2023/12150/crossmatch_assays_in_transplantation__physical_or.85.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/md-journal/fulltext/2023/12150/crossmatch_assays_in_transplantation__physical_or.85.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/md-journal/fulltext/2023/12150/crossmatch_assays_in_transplantation__physical_or.85.aspx</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0198885925000941" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0198885925000941" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0198885925000941</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7701071/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7701071/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7701071/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/the-new-kidney-allocation-system-kas-frequently-asked-questions/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/the-new-kidney-allocation-system-kas-frequently-asked-questions/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/the-new-kidney-allocation-system-kas-frequently-asked-questions/</a></span></div></li><li id="https://unos.org/kidney-allocation-system-kas-data_dec-2015/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/kidney-allocation-system-kas-data_dec-2015/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/kidney-allocation-system-kas-data_dec-2015/</a></span></div></li><li id="https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009248" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009248" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009248</a></span></div></li><li id="https://www.ovid.com/journals/ajtr/fulltext/10.1111/ajt.17180~the-new-french-kidney-allocation-system-for-donations-after" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ovid.com/journals/ajtr/fulltext/10.1111/ajt.17180~the-new-french-kidney-allocation-system-for-donations-after" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ovid.com/journals/ajtr/fulltext/10.1111/ajt.17180~the-new-french-kidney-allocation-system-for-donations-after</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0270929522000560" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0270929522000560" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0270929522000560</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0085253817300753" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0085253817300753" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0085253817300753</a></span></div></li><li id="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/continuous-distribution-of-kidneys-winter-2025/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/continuous-distribution-of-kidneys-winter-2025/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/continuous-distribution-of-kidneys-winter-2025/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/news/may-2025-annual-kidney-allocation-calculator-updates/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/news/may-2025-annual-kidney-allocation-calculator-updates/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/news/may-2025-annual-kidney-allocation-calculator-updates/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377324/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377324/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12377324/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9558035/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9558035/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9558035/</a></span></div></li><li id="https://journals.lww.com/kidney360/fulltext/2025/01000/increasing_incidence_of_out_of_sequence_allocation.19.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/kidney360/fulltext/2025/01000/increasing_incidence_of_out_of_sequence_allocation.19.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/kidney360/fulltext/2025/01000/increasing_incidence_of_out_of_sequence_allocation.19.aspx</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0041134524004470" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0041134524004470" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0041134524004470</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1362-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1362-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1362-6</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3203330/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3203330/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3203330/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10833597/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10833597/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10833597/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6218811/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6218811/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6218811/</a></span></div></li><li id="https://www.amjtransplant.org/article/S1600-6135%2822%2907940-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.amjtransplant.org/article/S1600-6135%2822%2907940-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.amjtransplant.org/article/S1600-6135%2822%2907940-0/fulltext</a></span></div></li><li id="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14716/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14716/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14716/full</a></span></div></li><li id="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/identify-priority-shares-in-kidney-multi-organ-allocation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/identify-priority-shares-in-kidney-multi-organ-allocation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/identify-priority-shares-in-kidney-multi-organ-allocation/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805570" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805570" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805570</a></span></div></li><li id="https://www.amjtransplant.org/article/S1600-6135%2824%2900678-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.amjtransplant.org/article/S1600-6135%2824%2900678-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.amjtransplant.org/article/S1600-6135%2824%2900678-6/fulltext</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39490413/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39490413/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39490413/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1600613522085914" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1600613522085914" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1600613522085914</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10065754/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10065754/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10065754/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10000664/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10000664/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10000664/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40040564/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40040564/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40040564/</a></span></div></li><li id="https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3087789/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3087789/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3087789/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12079050/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12079050/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12079050/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10514751/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10514751/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10514751/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/36029250/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/36029250/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/36029250/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/15387113/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/15387113/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/15387113/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8693781/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8693781/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8693781/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/36406897/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/36406897/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/36406897/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7643210/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7643210/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7643210/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4675492/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4675492/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4675492/</a></span></div></li><li id="https://www.ahajournals.org/doi/10.1161/CIR.0000000000001155" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000001155" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ahajournals.org/doi/10.1161/CIR.0000000000001155</a></span></div></li><li id="https://www.mdpi.com/2075-1729/14/10/1319" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2075-1729/14/10/1319" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2075-1729/14/10/1319</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10637446/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10637446/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10637446/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/multi-organ-transplantation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/multi-organ-transplantation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/multi-organ-transplantation/</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11943253/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11943253/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11943253/</a></span></div></li><li id="https://www.kidney.org/sites/default/files/2025-08/new-options-maintenance-immunosuppression_02-10-7138.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/sites/default/files/2025-08/new-options-maintenance-immunosuppression_02-10-7138.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/sites/default/files/2025-08/new-options-maintenance-immunosuppression_02-10-7138.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/38553819/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/38553819/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/38553819/</a></span></div></li><li id="https://academic.oup.com/ckj/article/17/9/sfae236/7756426" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/17/9/sfae236/7756426" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/17/9/sfae236/7756426</a></span></div></li><li id="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15321/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15321/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15321/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10946132/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10946132/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10946132/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2952470/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2952470/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2952470/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa1506027" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1506027" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa1506027</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7080294/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7080294/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7080294/</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf</a></span></div></li><li id="https://www.tts.org/images/stories/practical_protocols/Practical_Protocols_ENG.PDF" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tts.org/images/stories/practical_protocols/Practical_Protocols_ENG.PDF" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tts.org/images/stories/practical_protocols/Practical_Protocols_ENG.PDF</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03504-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03504-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03504-2</a></span></div></li><li id="https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8258457/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8258457/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8258457/</a></span></div></li><li id="https://www.ucsfbenioffchildrens.org/education/nutrition-after-kidney-transplant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ucsfbenioffchildrens.org/education/nutrition-after-kidney-transplant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ucsfbenioffchildrens.org/education/nutrition-after-kidney-transplant</a></span></div></li><li id="https://www.kidney.org/kidney-topics/diet-after-kidney-transplant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/diet-after-kidney-transplant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/diet-after-kidney-transplant</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3540789/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3540789/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3540789/</a></span></div></li><li id="https://karger.com/kbr/article/49/1/548/909773/Physical-Exercise-in-Kidney-Renal-Recipients-Where" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/kbr/article/49/1/548/909773/Physical-Exercise-in-Kidney-Renal-Recipients-Where" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/kbr/article/49/1/548/909773/Physical-Exercise-in-Kidney-Renal-Recipients-Where</a></span></div></li><li id="https://newsnetwork.mayoclinic.org/discussion/lifestyle-changes-can-be-critical-for-kidney-transplant-patients-long-term-survival/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://newsnetwork.mayoclinic.org/discussion/lifestyle-changes-can-be-critical-for-kidney-transplant-patients-long-term-survival/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://newsnetwork.mayoclinic.org/discussion/lifestyle-changes-can-be-critical-for-kidney-transplant-patients-long-term-survival/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40912061/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40912061/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40912061/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10276531/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10276531/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10276531/</a></span></div></li><li id="https://tau.amegroups.org/article/view/23349/html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://tau.amegroups.org/article/view/23349/html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://tau.amegroups.org/article/view/23349/html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11098183/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11098183/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11098183/</a></span></div></li><li id="https://www.ectrx.org/detail/current/2022/20/4/0/333/0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ectrx.org/detail/current/2022/20/4/0/333/0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ectrx.org/detail/current/2022/20/4/0/333/0</a></span></div></li><li id="https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2023.1150331/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2023.1150331/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2023.1150331/full</a></span></div></li><li id="https://journals.lww.com/transplantationdirect/fulltext/2022/06000/vascular_complications_in_renal_transplantation_.12.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantationdirect/fulltext/2022/06000/vascular_complications_in_renal_transplantation_.12.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantationdirect/fulltext/2022/06000/vascular_complications_in_renal_transplantation_.12.aspx</a></span></div></li><li id="https://www.kidney-international.org/article/S2157-1716%2815%2932257-7/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S2157-1716%2815%2932257-7/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S2157-1716%2815%2932257-7/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9605016/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9605016/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9605016/</a></span></div></li><li id="https://journals.lww.com/transplantationdirect/fulltext/2023/02000/effects_of_delayed_graft_function_on_transplant.6.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantationdirect/fulltext/2023/02000/effects_of_delayed_graft_function_on_transplant.6.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantationdirect/fulltext/2023/02000/effects_of_delayed_graft_function_on_transplant.6.aspx</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40429301/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40429301/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40429301/</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2821%2901143-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2821%2901143-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2821%2901143-1/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4182006/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4182006/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4182006/</a></span></div></li><li id="https://emedicine.medscape.com/article/432209-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/432209-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/432209-overview</a></span></div></li><li id="https://www.mdpi.com/2077-0383/12/12/4130" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2077-0383/12/12/4130" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2077-0383/12/12/4130</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3808773/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3808773/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3808773/</a></span></div></li><li id="https://journals.lww.com/cjasn/fulltext/2021/11000/chronic_allograft_injury.16.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/cjasn/fulltext/2021/11000/chronic_allograft_injury.16.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/cjasn/fulltext/2021/11000/chronic_allograft_injury.16.aspx</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12024747/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12024747/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12024747/</a></span></div></li><li id="https://www.uptodate.com/contents/kidney-transplantation-in-adults-treatment-of-acute-t-cell-mediated-cellular-rejection" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uptodate.com/contents/kidney-transplantation-in-adults-treatment-of-acute-t-cell-mediated-cellular-rejection" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uptodate.com/contents/kidney-transplantation-in-adults-treatment-of-acute-t-cell-mediated-cellular-rejection</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10419508/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10419508/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10419508/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0955470X16300532" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0955470X16300532" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0955470X16300532</a></span></div></li><li id="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.660334/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.660334/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.660334/full</a></span></div></li><li id="https://academic.oup.com/ofid/article/9/7/ofac243/6585272" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ofid/article/9/7/ofac243/6585272" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ofid/article/9/7/ofac243/6585272</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1876034124002259" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1876034124002259" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1876034124002259</a></span></div></li><li id="https://www.mdpi.com/2077-0383/14/10/3307" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2077-0383/14/10/3307" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2077-0383/14/10/3307</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.2147/TRRM.S366213" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.2147/TRRM.S366213" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.2147/TRRM.S366213</a></span></div></li><li id="https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08043-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08043-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08043-z</a></span></div></li><li id="https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1309927/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1309927/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1309927/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12016247/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12016247/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12016247/</a></span></div></li><li id="https://academic.oup.com/ckj/article/18/4/sfaf077/8088413" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/18/4/sfaf077/8088413" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/18/4/sfaf077/8088413</a></span></div></li><li id="https://journals.lww.com/cjasn/fulltext/2022/03000/de_novo_malignancies_after_kidney_transplantation.16.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/cjasn/fulltext/2022/03000/de_novo_malignancies_after_kidney_transplantation.16.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/cjasn/fulltext/2022/03000/de_novo_malignancies_after_kidney_transplantation.16.aspx</a></span></div></li><li id="https://www.mdpi.com/2227-9059/13/10/2346" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2227-9059/13/10/2346" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2227-9059/13/10/2346</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4831913/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4831913/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4831913/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2821%2900501-1/pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2821%2900501-1/pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2821%2900501-1/pdf</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1600613525000413" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1600613525000413" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1600613525000413</a></span></div></li><li id="https://www.nature.com/articles/s41416-025-03086-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41416-025-03086-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41416-025-03086-2</a></span></div></li><li id="https://journals.lww.com/kidney360/fulltext/2025/07000/cardiovascular_risk_after_renal_transplantation_.5.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/kidney360/fulltext/2025/07000/cardiovascular_risk_after_renal_transplantation_.5.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/kidney360/fulltext/2025/07000/cardiovascular_risk_after_renal_transplantation_.5.aspx</a></span></div></li><li id="https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2024.1939" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2024.1939" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2024.1939</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10320602/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10320602/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10320602/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9904410/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9904410/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9904410/</a></span></div></li><li id="https://journals.lww.com/kidney360/fulltext/2025/01000/high_post_kidney_transplant_serum_uric_acid_levels.18.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/kidney360/fulltext/2025/01000/high_post_kidney_transplant_serum_uric_acid_levels.18.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/kidney360/fulltext/2025/01000/high_post_kidney_transplant_serum_uric_acid_levels.18.aspx</a></span></div></li><li id="https://srtr.transplant.hrsa.gov/adr/Chapter?name=Kidney&amp;year=2023" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://srtr.transplant.hrsa.gov/adr/Chapter?name=Kidney&amp;year=2023" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://srtr.transplant.hrsa.gov/adr/Chapter?name=Kidney&amp;year=2023</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/</a></span></div></li><li id="https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1600613522086804" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1600613522086804" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1600613522086804</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12362070/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12362070/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12362070/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181</a></span></div></li><li id="https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Introduction&amp;year=2023" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Introduction&amp;year=2023" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Introduction&amp;year=2023</a></span></div></li><li id="https://academic.oup.com/ndt/article/39/9/1483/7588854" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/39/9/1483/7588854" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/39/9/1483/7588854</a></span></div></li><li id="https://www.ectrx.org/class/pdfPreview.php?year=2024&amp;volume=22&amp;issue=1&amp;supplement=1&amp;spage_number=263&amp;makale_no=0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ectrx.org/class/pdfPreview.php?year=2024&amp;volume=22&amp;issue=1&amp;supplement=1&amp;spage_number=263&amp;makale_no=0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ectrx.org/class/pdfPreview.php?year=2024&amp;volume=22&amp;issue=1&amp;supplement=1&amp;spage_number=263&amp;makale_no=0</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8643597/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8643597/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8643597/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11057459/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11057459/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11057459/</a></span></div></li><li id="https://healthcare-bulletin.co.uk/article/quality-of-life-of-post-renal-transplant-patients-in-a-tertiary-corporate-hospital-in-bangalore-a-cross-sectional-study-3713/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://healthcare-bulletin.co.uk/article/quality-of-life-of-post-renal-transplant-patients-in-a-tertiary-corporate-hospital-in-bangalore-a-cross-sectional-study-3713/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://healthcare-bulletin.co.uk/article/quality-of-life-of-post-renal-transplant-patients-in-a-tertiary-corporate-hospital-in-bangalore-a-cross-sectional-study-3713/</a></span></div></li><li id="https://www.amjtransplant.org/article/S1600-6135%2823%2900578-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.amjtransplant.org/article/S1600-6135%2823%2900578-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.amjtransplant.org/article/S1600-6135%2823%2900578-6/fulltext</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z</a></span></div></li><li id="https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney&amp;year=2022" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney&amp;year=2022" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney&amp;year=2022</a></span></div></li><li id="https://journals.lww.com/transplantjournal/fulltext/2016/05000/the_risk_of_transplant_failure_with_hla_mismatch.25.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantjournal/fulltext/2016/05000/the_risk_of_transplant_failure_with_hla_mismatch.25.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantjournal/fulltext/2016/05000/the_risk_of_transplant_failure_with_hla_mismatch.25.aspx</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/37302557/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/37302557/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/37302557/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2589537021002601" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2589537021002601" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2589537021002601</a></span></div></li><li id="https://academic.oup.com/ndt/article/39/11/1846/7640868" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/39/11/1846/7640868" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/39/11/1846/7640868</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/24138291/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/24138291/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/24138291/</a></span></div></li><li id="https://bmjopen.bmj.com/content/12/5/e059631" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmjopen.bmj.com/content/12/5/e059631" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmjopen.bmj.com/content/12/5/e059631</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5120769/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5120769/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5120769/</a></span></div></li><li id="https://bmjopen.bmj.com/content/15/3/e087128" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmjopen.bmj.com/content/15/3/e087128" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmjopen.bmj.com/content/15/3/e087128</a></span></div></li><li id="https://kidneytransplantcollaborative.com/new-kidney-transplant-collaborative-ktc-analysis-of-data-reveals-alarming-surge-in-kidney-transplant-waitlists-in-swing-states/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kidneytransplantcollaborative.com/new-kidney-transplant-collaborative-ktc-analysis-of-data-reveals-alarming-surge-in-kidney-transplant-waitlists-in-swing-states/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kidneytransplantcollaborative.com/new-kidney-transplant-collaborative-ktc-analysis-of-data-reveals-alarming-surge-in-kidney-transplant-waitlists-in-swing-states/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874</a></span></div></li><li id="https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney&amp;year=2023" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney&amp;year=2023" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney&amp;year=2023</a></span></div></li><li id="https://www.kidney.org/kidney-topics/kidney-transplant-waitlist" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/kidney-transplant-waitlist" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/kidney-transplant-waitlist</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4149736/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4149736/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4149736/</a></span></div></li><li id="https://aopo.org/aopo-highlights-disturbing-crisis-thousands-of-kidney-patients-who-died-waiting-for-organs-in-2023-could-have-been-saved/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://aopo.org/aopo-highlights-disturbing-crisis-thousands-of-kidney-patients-who-died-waiting-for-organs-in-2023-could-have-been-saved/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://aopo.org/aopo-highlights-disturbing-crisis-thousands-of-kidney-patients-who-died-waiting-for-organs-in-2023-could-have-been-saved/</a></span></div></li><li id="https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961602-9/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961602-9/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961602-9/fulltext</a></span></div></li><li id="https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/removal-of-dsa-and-region-from-kidney-allocation-policy/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/removal-of-dsa-and-region-from-kidney-allocation-policy/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/removal-of-dsa-and-region-from-kidney-allocation-policy/</a></span></div></li><li id="https://www.srtr.org/media/1234/gustafson_geogdisp.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.srtr.org/media/1234/gustafson_geogdisp.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.srtr.org/media/1234/gustafson_geogdisp.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5992006/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5992006/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5992006/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2821%2901041-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2821%2901041-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2821%2901041-6/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6933455/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6933455/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6933455/</a></span></div></li><li id="https://link.springer.com/article/10.1007/s40472-022-00384-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s40472-022-00384-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s40472-022-00384-z</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1600613524000777" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1600613524000777" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1600613524000777</a></span></div></li><li id="https://www.kidneymedicinejournal.org/article/S2590-0595%2823%2900134-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneymedicinejournal.org/article/S2590-0595%2823%2900134-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneymedicinejournal.org/article/S2590-0595%2823%2900134-6/fulltext</a></span></div></li><li id="https://optn.transplant.hrsa.gov/news/over-14-700-waiting-time-modifications-completed-for-black-kidney-patients-one-year-after-policy-implementation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/news/over-14-700-waiting-time-modifications-completed-for-black-kidney-patients-one-year-after-policy-implementation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/news/over-14-700-waiting-time-modifications-completed-for-black-kidney-patients-one-year-after-policy-implementation/</a></span></div></li><li id="https://www.srtr.org/reports/opo-specific-reports/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.srtr.org/reports/opo-specific-reports/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.srtr.org/reports/opo-specific-reports/</a></span></div></li><li id="https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/</a></span></div></li><li id="https://www.aeaweb.org/articles?id=10.1257/jep.21.3.3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aeaweb.org/articles?id=10.1257/jep.21.3.3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aeaweb.org/articles?id=10.1257/jep.21.3.3</a></span></div></li><li id="https://meridian.allenpress.com/human-organization/article/77/4/323/72752/Against-a-Regulated-Market-in-Human-Organs-Ethical" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://meridian.allenpress.com/human-organization/article/77/4/323/72752/Against-a-Regulated-Market-in-Human-Organs-Ethical" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://meridian.allenpress.com/human-organization/article/77/4/323/72752/Against-a-Regulated-Market-in-Human-Organs-Ethical</a></span></div></li><li id="https://www.wsj.com/articles/SB10001424052702304149404579322560004817176" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wsj.com/articles/SB10001424052702304149404579322560004817176" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wsj.com/articles/SB10001424052702304149404579322560004817176</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9266983/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9266983/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9266983/</a></span></div></li><li id="https://ijkd.org/index.php/ijkd/article/download/9/8/8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ijkd.org/index.php/ijkd/article/download/9/8/8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ijkd.org/index.php/ijkd/article/download/9/8/8</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/28161761/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/28161761/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/28161761/</a></span></div></li><li id="https://plato.stanford.edu/entries/organs-sale/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://plato.stanford.edu/entries/organs-sale/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://plato.stanford.edu/entries/organs-sale/</a></span></div></li><li id="https://europepmc.org/article/med/19469028" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://europepmc.org/article/med/19469028" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://europepmc.org/article/med/19469028</a></span></div></li><li id="https://journalofethics.ama-assn.org/article/veneer-altruism/2012-03" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journalofethics.ama-assn.org/article/veneer-altruism/2012-03" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journalofethics.ama-assn.org/article/veneer-altruism/2012-03</a></span></div></li><li id="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12483/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12483/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12483/full</a></span></div></li><li id="https://jme.bmj.com/content/40/2/134" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jme.bmj.com/content/40/2/134" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jme.bmj.com/content/40/2/134</a></span></div></li><li id="https://engagedscholarship.csuohio.edu/cgi/viewcontent.cgi?referer=&amp;httpsredir=1&amp;article=1056&amp;context=tdr" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://engagedscholarship.csuohio.edu/cgi/viewcontent.cgi?referer=&amp;httpsredir=1&amp;article=1056&amp;context=tdr" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://engagedscholarship.csuohio.edu/cgi/viewcontent.cgi?referer=&amp;httpsredir=1&amp;article=1056&amp;context=tdr</a></span></div></li><li id="https://journals.lww.com/cjasn/fulltext/2021/02000/social_determinants_of_health_and_race_disparities.14.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/cjasn/fulltext/2021/02000/social_determinants_of_health_and_race_disparities.14.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/cjasn/fulltext/2021/02000/social_determinants_of_health_and_race_disparities.14.aspx</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12348215/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12348215/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12348215/</a></span></div></li><li id="https://www.kidneyfund.org/sites/default/files/media/documents/addressing-disparities-in-transplantation_1.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyfund.org/sites/default/files/media/documents/addressing-disparities-in-transplantation_1.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyfund.org/sites/default/files/media/documents/addressing-disparities-in-transplantation_1.pdf</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0966327425001170" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0966327425001170" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0966327425001170</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9174036/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9174036/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9174036/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2825%2900834-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2825%2900834-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2825%2900834-0/fulltext</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03453-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03453-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03453-2</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/37471097/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/37471097/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/37471097/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39703725/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39703725/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39703725/</a></span></div></li><li id="https://journals.lww.com/kidney360/fulltext/2025/07000/socioeconomic_disparities_in_preemptive_kidney.18.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/kidney360/fulltext/2025/07000/socioeconomic_disparities_in_preemptive_kidney.18.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/kidney360/fulltext/2025/07000/socioeconomic_disparities_in_preemptive_kidney.18.aspx</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2899%2970404-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2899%2970404-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2899%2970404-X/fulltext</a></span></div></li><li id="https://academic.oup.com/jamia/article/31/12/2781/7747707" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jamia/article/31/12/2781/7747707" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jamia/article/31/12/2781/7747707</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10078213/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10078213/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10078213/</a></span></div></li><li id="https://www.amjtransplant.org/article/S1600-6135%2822%2925661-5/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.amjtransplant.org/article/S1600-6135%2822%2925661-5/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.amjtransplant.org/article/S1600-6135%2822%2925661-5/fulltext</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMp2512030?af=R&amp;rss=currentIssue" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMp2512030?af=R&amp;rss=currentIssue" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMp2512030?af=R&amp;rss=currentIssue</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775070" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775070</a></span></div></li><li id="https://www.kireports.org/article/S2468-0249%2823%2901419-5/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kireports.org/article/S2468-0249%2823%2901419-5/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kireports.org/article/S2468-0249%2823%2901419-5/fulltext</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK580030/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK580030/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK580030/</a></span></div></li><li id="https://www.statista.com/topics/2389/organ-donations-and-transplants/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statista.com/topics/2389/organ-donations-and-transplants/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statista.com/topics/2389/organ-donations-and-transplants/</a></span></div></li><li id="https://www.transplant-observatory.org/wp-content/uploads/2025/02/2023-data-global-report-20022025.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.transplant-observatory.org/wp-content/uploads/2025/02/2023-data-global-report-20022025.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.transplant-observatory.org/wp-content/uploads/2025/02/2023-data-global-report-20022025.pdf</a></span></div></li><li id="https://www.transplant-observatory.org/wp-content/uploads/2023/11/2022-data-global-report_VF_2.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.transplant-observatory.org/wp-content/uploads/2023/11/2022-data-global-report_VF_2.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.transplant-observatory.org/wp-content/uploads/2023/11/2022-data-global-report_VF_2.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/</a></span></div></li><li id="https://journals.lww.com/transplantjournal/fulltext/2024/09001/405_5__the_need_for_rethinking_about_kidney.515.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/transplantjournal/fulltext/2024/09001/405_5__the_need_for_rethinking_about_kidney.515.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/transplantjournal/fulltext/2024/09001/405_5__the_need_for_rethinking_about_kidney.515.aspx</a></span></div></li><li id="https://www.amjtransplant.org/article/S1600-6135%2825%2900026-7/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.amjtransplant.org/article/S1600-6135%2825%2900026-7/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.amjtransplant.org/article/S1600-6135%2825%2900026-7/fulltext</a></span></div></li><li id="https://tts.org/news/tribune-pulse-weekly-newsletter/1520-tts-tribune-pulse-october-25-volume-viii-issue-42" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://tts.org/news/tribune-pulse-weekly-newsletter/1520-tts-tribune-pulse-october-25-volume-viii-issue-42" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://tts.org/news/tribune-pulse-weekly-newsletter/1520-tts-tribune-pulse-october-25-volume-viii-issue-42</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9128615/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9128615/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9128615/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10758520/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10758520/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10758520/</a></span></div></li><li id="https://www.transplant-observatory.org/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.transplant-observatory.org/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.transplant-observatory.org/</a></span></div></li><li id="https://pharm.ucsf.edu/kidney/need/statistics" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pharm.ucsf.edu/kidney/need/statistics" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pharm.ucsf.edu/kidney/need/statistics</a></span></div></li><li id="https://www.statista.com/statistics/537935/kidney-transplant-rate-in-europe/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statista.com/statistics/537935/kidney-transplant-rate-in-europe/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statista.com/statistics/537935/kidney-transplant-rate-in-europe/</a></span></div></li><li id="https://academic.oup.com/ndt/article/39/10/1593/7619140" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/39/10/1593/7619140" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/39/10/1593/7619140</a></span></div></li><li id="https://unos.org/news/in-focus/us-world-leader-deceased-donor-rates/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/news/in-focus/us-world-leader-deceased-donor-rates/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/news/in-focus/us-world-leader-deceased-donor-rates/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5481314/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5481314/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5481314/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9462118/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9462118/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9462118/</a></span></div></li><li id="https://www.kidney-international.org/article/S0085-2538%2819%2930185-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney-international.org/article/S0085-2538%2819%2930185-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney-international.org/article/S0085-2538%2819%2930185-1/fulltext</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S003335062400355X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S003335062400355X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S003335062400355X</a></span></div></li><li id="https://www.mpg.de/23726833/1113-bild-organ-donation-opt-out-defaults-do-not-increase-donation-rates-149835-x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mpg.de/23726833/1113-bild-organ-donation-opt-out-defaults-do-not-increase-donation-rates-149835-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mpg.de/23726833/1113-bild-organ-donation-opt-out-defaults-do-not-increase-donation-rates-149835-x</a></span></div></li><li id="https://unos.org/news/in-focus/kidney-transplants-increase-across-all-populations-following-policy-changes/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://unos.org/news/in-focus/kidney-transplants-increase-across-all-populations-following-policy-changes/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://unos.org/news/in-focus/kidney-transplants-increase-across-all-populations-following-policy-changes/</a></span></div></li><li id="https://www.thelancet.com/journals/lansea/article/PIIS2772-3682%2823%2900172-5/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lansea/article/PIIS2772-3682%2823%2900172-5/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lansea/article/PIIS2772-3682%2823%2900172-5/fulltext</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/35266618/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/35266618/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/35266618/</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/7-transplantation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/7-transplantation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/7-transplantation</a></span></div></li><li id="https://www.statista.com/statistics/1083404/rate-of-kidney-transplant-activities-worldwide/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statista.com/statistics/1083404/rate-of-kidney-transplant-activities-worldwide/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statista.com/statistics/1083404/rate-of-kidney-transplant-activities-worldwide/</a></span></div></li><li id="https://www.transplant-observatory.org/wp-content/uploads/2024/12/2023-data-global-report-17122024.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.transplant-observatory.org/wp-content/uploads/2024/12/2023-data-global-report-17122024.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.transplant-observatory.org/wp-content/uploads/2024/12/2023-data-global-report-17122024.pdf</a></span></div></li><li id="https://reconstrategy.com/2025/03/kidney-transplantation-improved-but-still-a-massive-missed-opportunity/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://reconstrategy.com/2025/03/kidney-transplantation-improved-but-still-a-massive-missed-opportunity/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://reconstrategy.com/2025/03/kidney-transplantation-improved-but-still-a-massive-missed-opportunity/</a></span></div></li><li id="https://khi.asn-online.org/roadmap/kidney-diseases.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://khi.asn-online.org/roadmap/kidney-diseases.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://khi.asn-online.org/roadmap/kidney-diseases.aspx</a></span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/kidney-transplant-market-report" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/kidney-transplant-market-report" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/kidney-transplant-market-report</a></span></div></li><li id="https://www.coherentmarketinsights.com/market-insight/kidney-transplant-market-4887" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.coherentmarketinsights.com/market-insight/kidney-transplant-market-4887" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.coherentmarketinsights.com/market-insight/kidney-transplant-market-4887</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1" id="_R_" async=""></script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Kidney_transplantation\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Kidney_transplantation\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Kidney_transplantation\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T24861,"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"# Kidney transplantation\n\n![Kidney transplant procedure](./_assets_/Kidtransplant.svg.png)  \nKidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis.[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643514/)  \nThe first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding rejection due to genetic identity without the need for immunosuppression at the time.[](https://www.nobelprize.org/prizes/medicine/1990/murray/facts/)[](https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962883-8/fulltext)  \nMurray's pioneering work, which earned him the 1990 Nobel Prize in Physiology or Medicine shared with E. Donnall Thomas, laid the foundation for modern transplantation, with subsequent developments in immunosuppressive drugs like cyclosporine in the 1980s dramatically expanding donor-recipient matching possibilities.[](https://www.nobelprize.org/prizes/medicine/1990/murray/facts/)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)  \nDespite these advances, kidney transplants face significant challenges, including immunological rejectionâ€”acute cellular or antibody-mediated, and chronic allograft nephropathyâ€”necessitating lifelong immunosuppression that increases risks of opportunistic infections, cardiovascular disease, and malignancy.[](https://www.ncbi.nlm.nih.gov/books/NBK553074/)[](https://www.uptodate.com/contents/kidney-transplantation-in-adults-management-of-the-patient-with-a-failed-kidney-transplant)[](https://journals.lww.com/cjasn/fulltext/2022/02000/long_term_infectious_complications_of_kidney.17.aspx)  \nOne-year patient and graft survival rates typically exceed 95% and 90%, respectively, with living donor kidneys outperforming deceased donor grafts in longevity, though persistent organ shortages result in waitlist mortality rates of 5-10% annually in many regions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643514/)[](https://vascularsurgery.ucsf.edu/procedure/kidney-transplant-0)[](https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/)\n\n## Historical Development\n\n### Early Attempts and Immunological Challenges\n\nThe initial experiments in kidney transplantation began with animal models in the early 20th century, building on Alexis Carrel's pioneering work in vascular anastomosis in 1902, which enabled surgical connection of blood vessels but revealed rapid graft failure due to the host's immune response against foreign tissue.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/) In dogs, Emerich Ullmann's 1902 attempt at heterotopic kidney autotransplantation succeeded temporarily, but allografts from other animals failed within hours to days, demonstrating the immunological barrier of tissue incompatibility.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/)\n\nHuman attempts commenced in 1906 when Mathieu Jaboulay performed two xenotransplants using kidneys from a pig and a goat, respectively, anastomosed to the brachial artery and vein; both grafts thrombosed immediately, underscoring vascular and immunological incompatibilities across species.[](https://www.eujtransplantation.com/article/view/403) The first human-to-human allograft occurred on April 3, 1933, when Ukrainian surgeon Yuriy Voronoy transplanted a kidney from a deceased donor (dead 6 hours prior) into a 26-year-old woman dying of acute mercury poisoning; the graft produced urine briefly but ceased function within 48 hours, with autopsy revealing thrombosis and early necrotic changes attributable to immune-mediated rejection rather than solely technical issues.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/) Voronoy conducted a few additional transplants in the 1930s and 1940s, all failing rapidly, as did parallel efforts by surgeons like Jean Hamburger in France, where grafts lasted mere days amid uremic recipients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/)\n\nThese failures stemmed primarily from acute allograft rejection, an unrecognized T-cell-driven process targeting major histocompatibility complex (MHC) antigens mismatched between donor and recipient, causing vascular damage, interstitial inflammation, and tubular necrosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/) Without effective immunosuppressionâ€”limited to rudimentary measures like radiation or corticosteroids, which proved inadequate or toxicâ€”non-identical grafts universally rejected, as evidenced by Peter Medawar's 1940s studies on skin grafts in rabbits, which established acquired immunological tolerance as the core obstacle and laid groundwork for understanding adaptive immunity's role in transplant rejection.[](https://unos.org/transplant/history/) Early postoperative biopsies, when performed, showed lymphocytic infiltration and edema consistent with cellular rejection, but the absence of human leukocyte antigen (HLA) typing until the 1950s precluded matching, exacerbating outcomes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/) A 1950 deceased-donor transplant by Richard Lawler in Chicago functioned for about a week before rejection, highlighting that even short-term viability was exceptional without immunological compatibility.[](https://www.life-source.org/latest/early-organ-transplant/)\n\nThe 1954 success of Joseph Murray's team at Brigham Hospitalâ€”transplanting a kidney between identical twins, yielding over 5 years of functionâ€”conclusively proved that surgical technique alone sufficed when immune barriers were absent, isolating rejection as the paramount challenge limiting early transplantation to experimental failures or syngeneic cases.[](https://news.harvard.edu/gazette/story/2011/09/a-transplant-makes-history/) This immunological hurdle persisted until azathioprine's introduction in 1960 enabled broader allograft survival, but pre-1950s efforts underscored the causal primacy of host-versus-graft immunity in graft demise, independent of procurement delays or ischemia, as postmortem analyses rarely implicated those factors over rejection pathology.[](https://unos.org/transplant/history/)\n\n### Mid-20th Century Milestones\n\n![The Herrick twins' kidney transplant in 1954](./_assets_/Herrick_kidney_transplant.jpg)\nIn 1950, surgeon Richard Lawler at Mercy Hospital in Chicago performed the first intrabdominal kidney transplant from a cadaver donor to recipient Ruth Tucker, a 44-year-old woman with chronic kidney disease; the graft functioned for several weeks before rejection, marking an early step toward clinical viability despite limited immunosuppression.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/) Concurrently, David Hume at Peter Bent Brigham Hospital in Boston conducted pioneering human kidney allografts in the early 1950s, including a 1946 transplant to the arm vessels that briefly restored function, highlighting surgical feasibility but underscoring acute rejection as the primary barrier without effective immune control.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/) These efforts laid groundwork amid experimental canine models in Paris and Boston during the 1940s, which demonstrated vascular anastomosis techniques essential for human application.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/)\n\nThe breakthrough came on December 23, 1954, when Joseph E. Murray and J. Hartwell Harrison at Peter Bent Brigham Hospital successfully transplanted a kidney from Ronald Herrick to his identical twin brother Richard, who suffered from chronic glomerulonephritis; the absence of genetic disparity prevented rejection, enabling the graft to function for eight years until the recipient's death from unrelated causes, establishing proof-of-principle for organ replacement therapy.[](https://www.nobelprize.org/prizes/medicine/1990/murray/facts/) This identical twin procedure, later replicated including Hume's 1957 transplant at Medical College of Virginia, confirmed long-term graft survival without immunosuppression, shifting focus to non-identical donor challenges.[](https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962883-8/fulltext) By 1958, initial human kidney transplants incorporating corticosteroids and total body irradiation as immunosuppression demonstrated partial rejection mitigation, though with high complication rates.[](https://waring.library.musc.edu/exhibits/kidney/Transplantation.php)\n\nThe 1960s advanced immunosuppression with azathioprine, an antimetabolite derived from 6-mercaptopurine; Roy Calne in the UK first applied it clinically in 1960 for kidney recipients, reducing rejection incidence when combined with steroids, which improved one-year graft survival from under 50% to over 60% in early series.[](https://www.uspharmacist.com/article/immunosuppressants-used-in-solid-organ-transplantation) Concurrent developments included tissue typing by leukocyte antigens in 1962, pioneered by teams like those at the University of Colorado, enabling donor-recipient matching to minimize histocompatibility mismatches and hyperacute rejection.[](https://abdominalkey.com/kidney-transplantation-a-history/) These innovations, validated in centers like Edinburgh where Michael Woodruff achieved the UK's first long-term success in 1960, expanded transplantation beyond twins, though cadaver donor outcomes remained variable due to imperfect immune suppression.[](https://edren.org/ren/unit/history/history-of-kidney-transplation/)\n\n### Late 20th and Early 21st Century Advances\n\nThe introduction of cyclosporine as an immunosuppressive agent in clinical renal transplantation in 1978, with widespread adoption by 1983, represented a major breakthrough by selectively inhibiting calcineurin to suppress T-cell activation and interleukin-2 production, thereby reducing acute rejection rates from over 50% to below 20% in the first year post-transplant and improving one-year graft survival to approximately 80-90%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3259474/)[](https://www.sciencedirect.com/science/article/abs/pii/S0041134504001320) Prior regimens relying on azathioprine and corticosteroids had limited efficacy, with graft survival often below 50% at one year due to uncontrolled rejection; cyclosporine's specificity minimized broad immunosuppression-related infections while enabling broader donor-recipient matching.[](https://www.intechopen.com/chapters/41518)\n\nIn the 1990s, tacrolimus emerged as a potent alternative calcineurin inhibitor, gaining U.S. Food and Drug Administration approval for kidney transplantation in 1997 after demonstrating superior prevention of acute rejection compared to cyclosporine in randomized trials, with equivalent long-term graft outcomes but a different side-effect profile including lower rates of cosmetic disturbances like hirsutism and gingival hyperplasia.[](https://pubmed.ncbi.nlm.nih.gov/18312164/) Concurrently, mycophenolate mofetil was approved in 1995, replacing azathioprine in triple-drug regimens (calcineurin inhibitor, antimetabolite, and steroids) by more effectively inhibiting purine synthesis in lymphocytes, which further decreased rejection episodes by 20-30% and allowed steroid minimization or withdrawal in select low-risk patients.[](https://www.intechopen.com/chapters/41518)\n\nSurgical innovations included the first laparoscopic living-donor nephrectomy performed in 1995, which reduced postoperative pain, hospital stays from 4-5 days to 1-2 days, and convalescence time by weeks compared to open procedures, thereby increasing living donation rates by addressing donor disincentives without compromising graft quality or recipient outcomes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7034519/) Induction therapies advanced with interleukin-2 receptor antagonists such as basiliximab, approved in 1998, providing targeted prophylaxis against early rejection in high-risk recipients when combined with maintenance regimens, achieving rejection rates under 15% in the initial post-transplant period.[](https://www.intechopen.com/chapters/41518)\n\nInto the early 2000s, kidney paired donation programs gained traction, with initial small-scale exchanges in single centers matching incompatible donor-recipient pairs as early as the late 1990s, expanding nationally by the mid-2000s to facilitate over 100 transplants annually in the U.S. by 2010 through algorithms optimizing compatibility chains.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6165704/) These developments collectively tripled the annual U.S. kidney transplant volume from about 7,000 in 1980 to over 17,000 by 2010, driven by enhanced graft longevity (median survival exceeding 10-15 years for living-donor kidneys) and reduced waitlist mortality, though chronic allograft nephropathy from calcineurin inhibitor nephrotoxicity remained a persistent challenge necessitating regimen refinements.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/)[](https://www.intechopen.com/chapters/41518)\n\n### Recent Innovations (2010sâ€“2025)\n\nIn the 2010s, hypothermic machine perfusion (HMP) emerged as a key innovation for preserving deceased donor kidneys, particularly marginal ones, by actively circulating cold preservation solutions to reduce ischemia-reperfusion injury and improve graft viability compared to static cold storage.[](https://www.mdpi.com/2673-8236/5/3/37) Clinical trials demonstrated that HMP increased utilization rates of expanded criteria donor kidneys by mitigating cold ischemic damage, with meta-analyses showing reduced delayed graft function incidence by up to 20-30% in randomized studies.[](https://www.ajkd.org/article/S0272-6386%2825%2900048-4/fulltext) By the mid-2010s, devices like the LifePort system gained widespread adoption in the United States and Europe, enabling better assessment of organ quality through real-time flow and resistance monitoring.[](https://www.mdpi.com/2673-8236/5/3/37)\n\nNormothermic machine perfusion (NMP), which maintains kidneys at body temperature with oxygenated blood-like solutions, advanced further in the late 2010s and 2020s, allowing functional assessment and potential repair ex vivo.[](https://www.kireports.org/article/S2468-0249%2825%2900413-9/fulltext) A 2025 study reported successful transplantation of 36 human kidneys after 2-24 hours of NMP following initial cold storage, achieving 100% 30-day patient and graft survival, highlighting its potential to extend preservation times and resuscitate initially discarded organs.[](https://www.nature.com/articles/s41467-025-59829-5) NMP also facilitates therapeutic interventions, such as defatting steatotic kidneys or delivering targeted drugs, addressing limitations of hypothermic methods.[](https://www.nature.com/articles/s41467-025-60410-3)\n\nImmunosuppression protocols evolved with the broader use of costimulation blockade agents like belatacept, approved by the FDA in 2011 for kidney transplant maintenance, offering a calcineurin inhibitor-sparing alternative that preserves renal function longer-term while reducing chronic allograft nephropathy risks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8968476/) Trials in the 2010s and 2020s explored minimization strategies, including IL-6 inhibitors like tocilizumab to promote regulatory T cells and dampen effector responses, though widespread adoption remains limited due to infection risks and variable efficacy in diverse populations.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8968476/) Emerging cell therapies, such as MDR-101, entered trials by 2025 aiming for one-time tolerance induction to eliminate lifelong immunosuppression needs.[](https://www.kidneyfund.org/kidney-health-innovations)\n\nXenotransplantation marked a breakthrough in the 2020s, with gene-edited porcine kidneys addressing donor shortages through CRISPR modifications to eliminate hyperacute rejection triggers like alpha-gal epitopes and porcine endogenous retroviruses.[](https://www.kidneymedicinejournal.org/article/S2590-0595%2825%2900077-9/fulltext) In March 2024, a genetically modified pig kidney transplant at Massachusetts General Hospital functioned for 52 days in a brain-dead recipient, followed by a February 2025 case at NYU Langone where a 53-year-old woman with end-stage kidney disease achieved immediate graft function, normalizing creatinine without dialysis for over a month before complications arose.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2412747) By mid-2025, phase 1/2 clinical trials for living recipients commenced under FDA oversight, targeting highly sensitized patients ineligible for allografts, though porcine-specific immune barriers and zoonotic risks necessitate rigorous long-term monitoring.[](https://www.healio.com/news/nephrology/20250627/we-need-this-pigtohuman-kidney-transplants-enter-clinical-trials) These developments, while promising, highlight ongoing challenges in achieving indefinite survival beyond initial hyperacute phases.[](https://onlinelibrary.wiley.com/doi/10.1111/iju.70173?af=R)\n\n## Clinical Indications and Patient Selection\n\n### Primary Indications\n\nKidney transplantation is primarily indicated for patients with **end-stage renal disease (ESRD)**, a condition characterized by irreversible loss of kidney function with a glomerular filtration rate (GFR) typically below 15 mL/min/1.73 mÂ², necessitating renal replacement therapy to sustain life.[](https://www.ncbi.nlm.nih.gov/books/NBK499861/) Unlike dialysis, which serves as a temporary or lifelong bridge, transplantation restores near-normal renal function, yielding superior long-term survival ratesâ€”such as a 10-year post-transplant survival advantage over dialysisâ€”and improved quality of life by alleviating dietary restrictions, fatigue, and cardiovascular risks associated with chronic dialysis.[](https://pubmed.ncbi.nlm.nih.gov/21883901/)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)\n\nThe most prevalent etiologies of ESRD prompting transplantation are **diabetic nephropathy**, accounting for the leading cause due to progressive microvascular damage from longstanding diabetes mellitus (type 1 or 2), and **hypertensive nephrosclerosis**, resulting from chronic uncontrolled hypertension leading to vascular and parenchymal injury.[](https://www.ncbi.nlm.nih.gov/books/NBK499861/)[](https://columbiasurgery.org/conditions-and-treatments/end-stage-renal-disease) Other common primary indications include **glomerular diseases** (e.g., focal segmental glomerulosclerosis, IgA nephropathy), **polycystic kidney disease**, and **tubulointerstitial nephritis**, each contributing to cumulative glomerular scarring and functional decline.[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria) Less frequent but notable causes encompass renovascular diseases, congenital anomalies, and rare genetic disorders like Alport syndrome.[](https://www.myast.org/caregiver-toolkit/end-stage-kidney-disease-and-transplant-general-information)\n\nPreemptive transplantationâ€”performed before initiating dialysis in patients with advanced chronic kidney disease (stage 4 or 5, GFR 15â€“29 mL/min/1.73 mÂ²)â€”is increasingly recommended as the optimal timing to minimize dialysis-related complications such as vascular access failures and infections, though it requires early multidisciplinary evaluation.[](https://my.clevelandclinic.org/departments/transplant/programs/kidney/candidate)[](https://www.revistanefrologia.com/en-indications-contraindications-living-donor-kidney-transplantation-articulo-X2013251410051408) In pediatric populations, indications mirror adult ESRD causes but emphasize congenital and inherited disorders, with transplantation preferred over prolonged dialysis to support growth and development.[](https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/end-stage-renal-disease/) Overall, candidacy hinges not solely on ESRD etiology but on holistic assessment of comorbidities, as transplantation does not cure underlying systemic conditions like diabetes.[](https://emedicine.medscape.com/article/430128-overview)\n\n### Recipient Evaluation Process\n\nThe recipient evaluation process for kidney transplantation involves a comprehensive, multidisciplinary assessment to determine a candidate's suitability, optimize modifiable risks, and estimate expected survival benefit compared to remaining on dialysis. This process is typically coordinated by a team including transplant nephrologists, surgeons, coordinators, social workers, dietitians, and psychologists, aiming to identify contraindications or conditions requiring intervention prior to listing. Evaluation is recommended for patients with chronic kidney disease stages 4-5 (eGFR \u003c30 mL/min/1.73 mÂ²) at least 6-12 months before anticipated dialysis initiation to allow time for preemptive transplantation or risk mitigation.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/)\n\nA thorough medical history review covers the etiology of end-stage renal disease, comorbidities such as diabetes (for which transplantation is recommended, including simultaneous pancreas-kidney for type 1 diabetes where feasible), cardiovascular disease, prior surgeries, and family history, alongside a physical examination assessing body habitus, frailty, and organ systems. Laboratory evaluations include complete blood counts, serum chemistries (e.g., electrolytes, PTH for hyperparathyroidism management), urinalysis, and screening for glucose metabolism abnormalities via oral glucose tolerance testing in non-diabetics; severe hyperparathyroidism should be treated medically or surgically pretransplant to avoid complications. Nutritional status and adherence barriers are assessed, with interventions like weight loss counseling suggested for obesity without automatic exclusion.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.kidney.org/kidney-topics/evaluation-kidney-transplant)\n\nCardiovascular risk stratification is critical, given its role as a leading cause of post-transplant mortality; all candidates undergo history, physical exam, and ECG, with non-invasive stress testing recommended for asymptomatic high-risk individuals (e.g., diabetes, prior cardiac events). Severe, uncorrectable symptomatic cardiac disease or New York Heart Association class III/IV heart failure warrants exclusion unless survival prognosis aligns with national benchmarks, while peripheral artery disease or aortic aneurysms may require pretransplant correction if feasible. Pulmonary assessment includes chest imaging for all, with CT for heavy smokers (â‰¥30 pack-years), and gastrointestinal issues like active peptic ulcers or diverticulitis necessitate resolution before proceeding.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.kidney.org/kidney-topics/evaluation-kidney-transplant)\n\nInfectious disease screening follows evidence-based protocols, testing for HIV, hepatitis B/C, CMV, EBV, varicella-zoster, syphilis, tuberculosis (including latent), and endemic pathogens like Strongyloides or Chagas disease based on risk factors; active infections (except chronic HCV) delay transplantation until treated, with full TB therapy preferred pretransplant and vaccination updates (e.g., MMR, influenza) per guidelines. Tobacco cessation is strongly advised with counseling, as ongoing use elevates risks. Malignancy screening adheres to age- and risk-appropriate protocols (e.g., colonoscopy, mammography, prostate exam), excluding active cancers except low-grade indolent types; candidates with prior malignancies may require observation periods post-remission (e.g., 2-5 years for most solid tumors).[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.kidney.org/kidney-topics/evaluation-kidney-transplant)\n\nPsychosocial evaluation assesses mental health stability, substance use history, social support, cognitive function, and medication adherence potential, excluding candidates with unstable psychiatric conditions or active substance abuse impairing decision-making or posttransplant compliance; prior nonadherence does not preclude listing if barriers are addressed through counseling. Financial, housing, and transportation stability are reviewed, though lack of traditional support does not disqualify if a self-management plan exists. Immunologic workup includes ABO blood typing, HLA antibody screening via solid-phase assays, and panel-reactive antibody quantification to inform sensitization risks.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/)[](https://www.kidney.org/kidney-topics/evaluation-kidney-transplant)\n\nUpon completion, the team reviews findings to approve listing on the national waitlist if benefits outweigh risks, with ongoing monitoring for changes in status; additional tests like dental clearance, gynecologic exams, or vascular imaging may be required based on individual profiles.[](https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/)[](https://www.kidney.org/kidney-topics/evaluation-kidney-transplant)\n\n### Absolute and Relative Contraindications\n\nAbsolute contraindications to kidney transplantation encompass conditions where the procedure's risks substantially exceed potential benefits, rendering transplantation unethical or futile, such as active untreated malignancies or severe irreversible comorbidities that preclude survival or rehabilitation post-surgery.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://emedicine.medscape.com/article/430128-overview) Relative contraindications involve elevated perioperative or long-term risks that may be mitigated through management, allowing case-by-case consideration by multidisciplinary teams.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)\n\nKey absolute contraindications include:\n\n- Active malignancy, excluding curatively treated low-risk cases like non-melanoma skin cancer or prostate cancer with Gleason score â‰¤6, due to immunosuppression accelerating progression.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria)\n- Untreated or ongoing severe infections, such as active tuberculosis, bacterial/fungal sepsis, or uncontrolled viral infections (e.g., chronic active hepatitis B in children), which heighten post-transplant mortality.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://emedicine.medscape.com/article/430128-overview)[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria)\n- Severe irreversible cardiopulmonary disease, including decompensated heart failure (NYHA class III/IV with ejection fraction \u003c30%), advanced obstructive/restrictive lung disease, or significant cardiac amyloidosis confirmed by imaging, limiting surgical tolerance and survival.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria)\n- Demonstrated repeated noncompliance with medical regimens or active substance abuse/addiction impairing post-transplant adherence to immunosuppression and follow-up.[](https://emedicine.medscape.com/article/430128-overview)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria)\n- Progressive neurodegenerative diseases (e.g., advanced Alzheimer's or Parkinson's) or severe neurologic deficits where transplantation would not meaningfully extend quality life.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria)\n- Conditions with life expectancy less than the anticipated graft function or waiting time, such as metastatic cancer or hepatic insufficiency without eligibility for combined liver-kidney transplant.[](https://emedicine.medscape.com/article/430128-overview)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)\n\nRelative contraindications often require optimization prior to listing, with decisions informed by recurrence risk, frailty assessment, and expected survival benefit:\n\n- Obesity, particularly BMI â‰¥35 kg/mÂ² (class II/III), increasing surgical complications like wound infections and graft thrombosis, though no universal cutoff exists; programs may require weight loss protocols.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)\n- History of treated malignancy, with waiting periods post-remission (e.g., 5 years for breast/colorectal cancer, 1-2 years for low-grade prostate or bladder cancers) to minimize recurrence under immunosuppression.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://emedicine.medscape.com/article/430128-overview)\n- Controlled chronic infections, such as HIV seropositivity with CD4 count \u003e200/ÂµL for â‰¥6 months, undetectable viral load, and stable antiretroviral therapy without opportunistic complications, or hepatitis C post-treatment.[](https://emedicine.medscape.com/article/430128-overview)[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)\n- Advanced age (\u003e75 years), frailty, or multiple comorbidities (e.g., diabetes, smoking \u003c1 month abstinent, or peripheral vascular disease with 5-year survival ~81%), assessed via comprehensive geriatric evaluation rather than age alone.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria)\n- Unstable psychiatric disorders, poor social support, or potentially reversible nonadherence, warranting psychosocial intervention and support planning.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)[](https://emedicine.medscape.com/article/430128-overview)\n- High-risk primary diseases like focal segmental glomerulosclerosis (FSGS) or atypical hemolytic uremic syndrome (aHUS) with recurrence potential \u003e50%, unless eculizumab or combined transplants are feasible.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)\n\nEvaluation involves multidisciplinary review, including cancer screening per local guidelines, infection serologies, cardiovascular stress testing for high-risk patients, and frailty metrics, to ensure equitable access while prioritizing outcomes.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://emedicine.medscape.com/article/430128-overview) No single criterion is universally absolute across centers, reflecting variations in technology and expertise, but guidelines emphasize evidence-based risk stratification over blanket exclusions.[](https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)\n\n## Donor Sources and Procurement\n\n### Living Donor Evaluation and Surgery\n\n![Kidney for transplant from live donor](./_assets_/Kidney_for_transplant_from_live_donor.jpg)\n\nThe evaluation of potential living kidney donors involves a comprehensive multidisciplinary assessment to ensure donor safety and informed consent while confirming compatibility with the recipient. This process typically begins with an initial screening of medical history, including exclusions for active malignancies, uncontrolled hypertension (defined as blood pressure \u003e140/90 mmHg on multiple readings), diabetes mellitus, or glomerular filtration rate (GFR) below 80-90 mL/min/1.73 mÂ², with measured GFR preferred over estimated methods for precision.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540357/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8786144/) Laboratory tests assess renal function, hemoglobin levels, infectious disease serologies (e.g., HIV, hepatitis B/C), and urine analysis for proteinuria, while imaging via CT angiography or MR angiography evaluates vascular anatomy to minimize surgical risks.[](https://www.ajkd.org/article/S0272-6386%2817%2931078-8/fulltext) Psychosocial evaluation verifies voluntarism, absence of coercion, and psychological readiness, emphasizing long-term risks such as a halved GFR post-donation and a small increased lifetime risk of end-stage renal disease (approximately 0.9% vs. 0.3% in healthy non-donors).[](https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/guidance-for-the-development-of-program-specific-living-kidney-donor-medical-evaluation-protocols/)[](https://www.annualreviews.org/content/journals/10.1146/annurev-med-050223-112648)\n\nRecent updates to exclusion criteria, effective from 2022, align with evidence-based guidelines by removing absolute bans on certain conditions like treated hypertension or BMI up to 35 kg/mÂ² if other risks are mitigated, reflecting improved long-term outcome data from registries.[](https://unos.org/news/policy-changes/updates-to-living-donor-exclusion-criteria-now-in-effect/) Donors must be at least 18 years old, and upper age limits vary but often extend to 70 in low-risk candidates; family history of renal disease prompts genetic screening where indicated.[](https://kdigo.org/guidelines/living-kidney-donor/) Informed consent includes discussion of perioperative mortality risk, estimated at 3.1 deaths per 10,000 donations based on U.S. data from 1994-2009 with trends showing decline.[](https://jamanetwork.com/journals/jama/article-abstract/2822922)\n\nLiving donor nephrectomy is predominantly performed via minimally invasive laparoscopic techniques, with hand-assisted variants for complex anatomy, to reduce recovery time and complications compared to open surgery. The procedure favors the left kidney due to longer renal vein length; under general anesthesia, 3-4 trocars are placed, pneumoperitoneum established, and the kidney mobilized after dissecting the ureter, gonadal vein, and renal artery/vein, which are clipped and divided to limit warm ischemia time to under 5 minutes.[](https://www.mayoclinic.org/tests-procedures/donor-nephrectomy/about/pac-20384867)[](https://www.sciencedirect.com/science/article/pii/S240545692200075X) The kidney is extracted through a 5-7 cm iliac fossa incision, with robotic-assisted approaches emerging since 2023 for enhanced precision in select centers, though laparoscopic remains standard with operative times of 2-4 hours and hospital stays of 1-3 days.[](https://health.ucdavis.edu/news/headlines/uc-davis-health-performs-first-robotic-nephrectomy-on-living-kidney-donor/2023/04)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7607668/)\n\nPostoperative outcomes demonstrate low complication rates (Clavien-Dindo grade â‰¥2 in \u003c5%), with most donors resuming normal activities in 2-4 weeks; long-term studies confirm no overall increase in mortality and potential survival benefit over non-donors, though hypertensive disorders in pregnancy rise slightly for female donors.[](https://www.kidney.org/kidney-topics/long-term-risks-living-donation)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11896807/) High satisfaction rates (86-98% would donate again) underscore the procedure's safety when adhering to rigorous evaluation, with ongoing registry follow-up mandated up to 2 years post-donation per OPTN policy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11896807/)[](https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/new-living-kidney-donor-program-requirements-standardizing-patient-care/)\n\n### Deceased Donor Criteria and Retrieval\n\nDeceased kidney donors are categorized primarily as donation after brain death (DBD) or donation after circulatory death (DCD), with eligibility determined by legal declaration of death, absence of active malignancies (except certain skin or primary brain cancers), and exclusion of uncontrolled infections such as active sepsis or untreated HIV without viral suppression.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/) [](https://www.uptodate.com/contents/management-of-the-deceased-organ-donor) Donor kidneys are further stratified using the Kidney Donor Profile Index (KDPI), a score from 0 to 100 incorporating ten factors including age, height, weight, race, history of hypertension or diabetes, cause of death, serum creatinine, and hepatitis C status; kidneys with KDPI \u003c20% are considered optimal, while those \u003e85% carry higher discard risk due to inferior long-term function.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4116061/) Standard criteria donors (SCD) typically include individuals under age 50 without significant comorbidities, offering graft survival comparable to living donors, whereas expanded criteria donors (ECD)â€”defined as those with at least two of age \u003e60 years, age 50-59 with hypertension or creatinine \u003e1.5 mg/dL, or cerebrovascular cause of deathâ€”exhibit a 1.7-fold higher relative risk of graft failure but expand the donor pool for older or less urgent recipients.[](https://health.ucdavis.edu/transplant/nonlivingdonors/standard-criteria-donors.html) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC1356277/)\n\nUnder OPTN policy effective September 2022, organ procurement organizations (OPOs) must perform procurement biopsies on deceased donors meeting high-risk thresholds, such as age â‰¥60 years, terminal creatinine â‰¥1.5 mg/dL, or KDPI \u003e85% (excluding donors \u003c18 years), to inform allocation decisions and reduce discard rates; this applies to all U.S. deceased donor kidneys unless contraindicated by logistics.[](https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/establish-minimum-kidney-donor-criteria-to-require-biopsy/) [](https://unos.org/news/implementation-minimum-kidney-donor-biopsy-criteria/) Comprehensive donor evaluation includes serologic testing for transmissible diseases (e.g., HIV, hepatitis B/C, CMV, EBV), echocardiography for cardiac function, and abdominal imaging to assess renal anatomy and vascular patency, with hemodynamic optimization in the ICU to maintain mean arterial pressure \u003e65 mmHg and minimize vasopressor use prior to procurement.[](https://www.uptodate.com/contents/management-of-the-deceased-organ-donor) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/)\n\nOrgan retrieval begins with donor preparation in the operating room, where systemic heparinization precedes aortic cannulation for in situ perfusion with cold University of Wisconsin or histidine-tryptophan-ketoglulate solution to induce hypothermic preservation, minimizing ischemic injury; kidneys are excised en bloc with surrounding aorta and vena cava if multi-organ donation is pursued, followed by back-table preparation to trim vessels and assess for anomalies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/) [](https://teachmesurgery.com/transplant-surgery/core-concepts/organ-retrieval/) For DCD donors, rapid recovery within 60-90 minutes of circulatory arrest is critical to limit warm ischemia time, often employing normothermic regional perfusion techniques post-arrest to restore organ viability before cold storage.[](https://unos.org/transplant/deceased-donation/) Retrieved kidneys are typically stored in ice-cold solution for up to 24-36 hours or increasingly via hypothermic machine perfusion, which improves outcomes for marginal grafts by reducing delayed graft function rates compared to static cold storage.[](https://www.sciencedirect.com/science/article/abs/pii/S0263931923001485) Post-retrieval, organs undergo quality assessment including biopsy if not done in situ, with allocation prioritized by match run algorithms balancing HLA compatibility, wait time, and geographic proximity to minimize cold ischemia time ideally below 18 hours.[](https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf)\n\n### Expanding Donor Pools Through Policy and Technology\n\nPolicies such as kidney paired donation (KPD) programs have significantly expanded living donor pools by facilitating exchanges between incompatible donor-recipient pairs. In the United States, the Organ Procurement and Transplantation Network (OPTN) operates the Kidney Paired Donation Pilot Program, which matches pairs nationally to overcome blood type or human leukocyte antigen incompatibilities, enabling transplants that would otherwise be impossible.[](https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/update-kidney-paired-donation-policy/) The National Kidney Registry (NKR), a nonprofit clearinghouse, reported facilitating 760 KPD transplants in 2019, a 22% increase from the prior year, with sensitized patients (calculated panel reactive antibody \u003e80%) experiencing a 38% lower three-year death-censored graft failure rate compared to non-NKR recipients.[](https://www.kidneyregistry.com/news/national-kidney-registrys-2025-outcomes-report-highlights-superior-kidney-transplant-success-rates/) [](https://www.kidneyregistry.com/news-category/quarterly-reports/) These programs leverage chain exchanges, including end-chain donations initiated by altruistic donors, to amplify matches, with 46% of NKR candidates transplanted within 12 months of registration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6082363/)\n\nShifts in organ donation consent frameworks, particularly from opt-in to presumed consent (opt-out) systems, have demonstrably increased deceased donor rates in adopting countries. Spain's implementation of presumed consent via its National Transplant Organization in the late 1980s, combined with robust procurement infrastructure, yielded the world's highest deceased donation rate of 48 donors per million population by 2018, far exceeding the U.S. opt-in average of around 20-30 donors per million.[](https://www.kidney-international.org/article/S0085-2538%2819%2930298-4/fulltext) [](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23684) Empirical comparisons across Europe show presumed consent correlates with higher donation willingness and actual procurement rates, though outcomes vary by implementation quality rather than policy alone; for instance, Spain's success stems from mandatory hospital reporting and coordinator training, not consent mechanics in isolation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7822792/) [](https://www.weforum.org/stories/2018/06/spain-leads-the-world-in-organ-donation-what-s-stopping-other-countries-catching-up/) In the U.S., proposed policy expansions include financial assistance for living donors and incentives for organ procurement organizations to utilize marginal deceased donors, aiming to boost overall supply without altering consent paradigms.[](https://www.kidney.org/press-room/nkf-applauds-new-proposed-rules-to-increase-organ-donation)\n\nTechnological advancements in organ preservation, notably machine perfusion systems, enable broader utilization of extended criteria donors (ECDs)â€”those with factors like advanced age or hypertension that previously increased discard risks. Hypothermic machine perfusion (HMP) pulsatilely circulates preservation solution through kidneys at 4Â°C, reducing ischemic injury and discard rates; a pharmacoeconomic model estimated HMP for ECDs could increase U.S. transplants by 1,123 annually while decreasing waitlist mortality.[](https://www.organ-recovery.com/use-of-machine-perfusion-to-increase-the-number-of-expanded-criteria-deceased-donor-kidney-transplants-a-pharmacoeconomic-analysis/) [](https://journals.lww.com/transplantationdirect/fulltext/2024/08000/use_of_machine_perfusion_to_increase_the_number_of.3.aspx) Normothermic machine perfusion (NMP), maintaining kidneys at body temperature with oxygenated blood, allows real-time viability assessment and resuscitation of initially declined organs, with clinical trials demonstrating feasibility for ECD and donation-after-circulatory-death kidneys, potentially converting discarded grafts into viable transplants.[](https://thelimbic.com/nephrology/normothermic-machine-perfusion-expands-kidney-donor-pool/) [](https://health.ucdavis.edu/news/headlines/new-technology-could-increase-donor-kidneys-for-transplants/2024/09) Retrospective data indicate NMP reduces delayed graft function and improves one-year outcomes compared to static cold storage, though randomized trials confirm variable benefits, particularly for high-risk donors.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446984/) [](https://www.ajkd.org/article/S0272-6386%2825%2900047-2/fulltext) These technologies complement policy by rehabilitating marginal organs, addressing the supply-demand gap where over 90,000 U.S. patients await kidneys as of 2023.[](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14807/full)\n\n### Xenotransplantation and Bioengineered Options\n\nXenotransplantation, the transplantation of organs from nonhuman species into humans, has emerged as a potential solution to the chronic shortage of human donor kidneys, with pigs serving as the primary source due to anatomical compatibility and reproductive efficiency. Advances in CRISPR-Cas9 gene editing have enabled the creation of porcine donors with up to 69 genomic modifications, including knockouts of three major glycan antigens (GGTA1, CMAH, B4GALNT2) to prevent hyperacute rejection triggered by natural antibodies, and insertions of seven human transgenes such as CD46, CD55, and CD59 for complement regulation, alongside thrombomodulin and endothelial protein C receptor for anticoagulation.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2412747) These edits also incorporate porcine endogenous retrovirus (PERV) knockouts to mitigate viral transmission risks, addressing a long-standing barrier identified in preclinical studies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9846288/)\n\nClinical progress accelerated in 2024â€“2025, with genetically edited pig kidneys transplanted into living human recipients under FDA-approved compassionate use or early investigational protocols. At Massachusetts General Hospital, the first such procedure in March 2024 involved a 62-year-old man with end-stage renal disease; the kidney produced urine immediately, maintained function for 52 days, and supported dialysis independence until the patient's death from unrelated cardiac complications, with no evidence of hyperacute rejection or porcine virus transmission.[](https://hms.harvard.edu/news/surgeons-perform-second-pig-kidney-transplant-massachusetts-general-hospital) A second transplant at the same institution in February 2025 used a pig kidney from eGenesis with similar edits, demonstrating prompt graft function and reduced creatinine levels in the recipient.[](https://www.massgeneral.org/news/press-release/mgh-performs-second-xenotransplant-of-genetically-edited-pig-kidney-into-living-recipient) Additional cases, including one at NYU Langone in December 2024, reported initial successes with six human transgenes added to enhance compatibility, though longer-term data remain limited by small sample sizes and patient comorbidities.[](https://nyulangone.org/news/gene-edited-pig-kidney-gives-living-donor-new-lease-life) United Therapeutics received FDA clearance in February 2025 for a phase 1/2 trial of xenokidneys, anticipating the first procedure mid-year, with endpoints focused on safety, function, and infection surveillance.[](https://ir.unither.com/press-releases/2025/02-03-2025-120011819)\n\nDespite these milestones, challenges persist, including acute antibody-mediated rejection, thrombosis due to endothelial incompatibilities, and potential chronic xenograft vasculopathy, which preclinical pig-to-nonhuman primate models have shown can limit graft survival beyond months even with optimized immunosuppression.[](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13475/full) Gene editing has largely overcome hyperacute rejection, but incomplete understanding of innate immune responses and complement activation necessitates tailored regimens, such as anti-CD40 monoclonal antibodies combined with costimulation blockade, which have extended survival in nonhuman primate recipients to over a year in some studies.[](https://www.sciencedirect.com/science/article/pii/S0966327425000127) Regulatory and ethical hurdles include zoonotic disease monitoring and equitable access, with ongoing debates over trial design emphasizing rigorous endpoints like creatinine clearance and biopsy-proven rejection rates.[](https://www.nature.com/articles/s41591-025-03855-9)\n\nBioengineered kidney options, distinct from xenotransplantation, involve reconstructing functional renal tissue using decellularized scaffolds, stem cell-derived organoids, or 3D bioprinting to create patient-specific organs devoid of immunological barriers. Decellularization removes cellular components from porcine or human cadaveric kidneys while preserving extracellular matrix architecture, followed by recellularization with human progenitor cells; a July 2025 preclinical study demonstrated vascularized bioengineered kidneys using human placenta-derived angiogenic stem cells and kidney organoids perfused in a bioreactor, achieving glomerular-like structures and basic filtration in rodent models.[](https://www.biorxiv.org/content/10.1101/2025.07.10.664023v1) Surface modifications, such as heparinization of scaffolds reported in December 2024, enhance endothelialization and reduce thrombosis during recellularization, addressing vascular patency issues central to whole-organ viability.[](https://pubmed.ncbi.nlm.nih.gov/39674100/)\n\nProgress in stem cell technologies includes induced pluripotent stem cell (iPSC)-derived nephron progenitors forming organoids with tubular and vascular components, though scaling to full-sized kidneys remains constrained by nephrogenesis complexity and vascular integration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11816546/) As of 2025, these approaches are confined to in vitro and small-animal models, with no human implants reported; challenges encompass incomplete maturation of nephrons, insufficient nephron density (human kidneys contain ~1 million glomeruli), and the absence of a functional urinary collecting system.[](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1476510/full) Hybrid strategies combining scaffolds with organoids show promise for bridging to clinical translation, potentially offering immunocompatible alternatives without donor sourcing limitations, but require advances in bioreactors for uniform recellularization and long-term functionality assessments.[](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1621641/full)\n\n## Compatibility and Allocation\n\n### HLA Matching and Crossmatching\n\nHuman leukocyte antigen (HLA) matching assesses compatibility between donor and recipient at key HLA loci, primarily HLA-A, HLA-B, and HLA-DR, to minimize immune-mediated rejection in kidney transplantation. These antigens, encoded by genes in the major histocompatibility complex on chromosome 6, present peptides to T cells, triggering allograft recognition as foreign if mismatched. Mismatches increase the risk of acute cellular rejection and antibody-mediated rejection, with studies showing that zero-mismatch kidneys yield superior long-term graft survival rates, such as a 10-year survival advantage of approximately 10-15% over highly mismatched grafts in deceased donor transplants.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8966965/)[](https://www.sciencedirect.com/science/article/abs/pii/S0966327423000783) Even in the era of potent immunosuppression, HLA mismatching correlates with higher rates of de novo donor-specific antibodies (DSA) and reduced 20-year graft survival, emphasizing its causal role in chronic allograft nephropathy.[](https://www.sciencedirect.com/science/article/pii/S0198885924000739)\n\nHLA typing employs molecular methods like polymerase chain reaction-sequence-specific oligonucleotide probes or next-generation sequencing for high-resolution (allele-level) identification, though deceased donor allocation often relies on initial low- or intermediate-resolution typing for efficiency, with confirmatory high-resolution testing post-offer.[](https://onlinelibrary.wiley.com/doi/10.1111/tan.15784) In the United States, the Organ Procurement and Transplantation Network allocates kidneys prioritizing zero HLA-A, -B, and -DR mismatches for broadly sensitized patients, but broader policies have de-emphasized matching due to prolonged wait times, leading to debates on diminished outcomes like increased financial burdens from re-transplants.[](https://www.kidney-international.org/article/S0085-2538%2821%2900657-8/fulltext) Living donor programs, such as paired exchanges, leverage high-resolution matching to optimize outcomes, reducing DSA formation and rejection episodes by up to 50% in well-matched pairs.[](https://www.sciencedirect.com/science/article/pii/S0010482524005365)\n\nCrossmatching complements HLA matching by detecting recipient preformed antibodies against donor HLA or non-HLA antigens, preventing hyperacute rejection via complement activation and thrombosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7462663/) Standard techniques include complement-dependent cytotoxicity (CDC) crossmatch, which mixes recipient serum with donor lymphocytes to observe cell lysis, and flow cytometry crossmatch (FCXM), a more sensitive assay quantifying antibody binding via fluorescence, often using pronase-treated cells to reduce false positives from autoantibodies.[](https://www.uptodate.com/contents/kidney-transplantation-in-adults-overview-of-hla-sensitization-and-crossmatch-testing) Virtual crossmatching, an in silico alternative, predicts compatibility by comparing donor HLA typing against the recipient's unacceptable antigen list from solid-phase antibody screening (e.g., Luminex assays), accelerating allocation in deceased donor scenarios while correlating strongly with physical crossmatch results.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9171621/)\n\nA positive crossmatch, indicating high immunologic risk, historically contraindicated transplantation but now permits desensitization protocols like plasmapheresis and rituximab for select living donor cases, achieving 5-year graft survival rates exceeding 80% in rigorously selected patients despite elevated early rejection risks.[](https://www.amjtransplant.org/article/S1600-6135%2822%2907334-8/fulltext) Both T-cell (cytotoxic) and B-cell crossmatches are routine, with B-cell FCXM particularly sensitive to class II mismatches like HLA-DQ, which independently predict poorer outcomes if ignored.[](https://journals.lww.com/md-journal/fulltext/2023/12150/crossmatch_assays_in_transplantation__physical_or.85.aspx) In deceased donor contexts, rapid crossmatch turnaroundâ€”ideally under 4 hoursâ€”balances rejection prevention with cold ischemia time limits, though false negatives from epitope-level mismatches underscore the need for integrated DSA monitoring post-transplant.[](https://www.sciencedirect.com/science/article/abs/pii/S0198885925000941) Overall, stringent HLA matching and negative crossmatching reduce acute rejection incidence by 20-30% and enhance half-life expectancy of grafts to over 15 years in optimal scenarios.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7701071/)\n\n### Organ Allocation Algorithms\n\nOrgan allocation algorithms for deceased donor kidneys prioritize recipients based on a combination of biological compatibility, medical urgency, expected post-transplant survival, and wait time to optimize graft longevity and equitable access while minimizing discard rates.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/) These systems employ computerized match runs that sequence candidates within geographic zones, typically starting locally and expanding regionally or nationally for broader sharing of high-quality or hard-to-match organs.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/) Core criteria include ABO blood type compatibility, human leukocyte antigen (HLA) matchingâ€”primarily at the DR locusâ€”sensitization levels measured by calculated panel reactive antibody (CPRA), and donor kidney quality assessed via the Kidney Donor Profile Index (KDPI), which ranges from 0% (best) to 100% (worst) based on 10 donor factors like age, height, and serum creatinine.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/) Recipient factors, such as the Estimated Post-Transplant Survival (EPTS) score incorporating age, diabetes status, and prior transplants, guide pairing of longer-surviving kidneys with longer-surviving recipients to extend overall graft utility.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/)\n\nIn the United States, the Organ Procurement and Transplantation Network (OPTN), contracted to the United Network for Organ Sharing (UNOS), administers the Kidney Allocation System (KAS), implemented on December 4, 2014, to address pre-existing issues like geographic disparities in wait times and underutilization of marginal kidneys.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/) KAS generates match runs in sequences prioritizing 20% of kidneys with KDPI \u003e20% for recipients with EPTS \u003e20%, followed by local (0-250 nautical miles), regional (up to 1500 nm), and national offers for categories like pediatric candidates or zero-HLA-mismatched pairs.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/) Allocation points are awarded as follows: full waiting time credit from dialysis initiation or listing (whichever earlier, accrued at 100% rate); sliding-scale points for CPRA â‰¥20% (e.g., 2 points at 20-79.9%, up to 8 at â‰¥99.9%); up to 2 points for HLA-DR matching (2 for 0 mismatches, 1 for 1); and proximity points favoring local candidates within sequences.[](https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/the-new-kidney-allocation-system-kas-frequently-asked-questions/) Pediatric candidates receive absolute priority in local sequences, and highly sensitized patients (CPRA â‰¥98%) access national pools for better matches.[](https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/the-new-kidney-allocation-system-kas-frequently-asked-questions/) Post-implementation, KAS increased transplants for sensitized patients by 13% in the first year but raised discard rates for high-KDPI kidneys by about 1.7 percentage points due to expanded sharing circles.[](https://unos.org/kidney-allocation-system-kas-data_dec-2015/)\n\nInternationally, algorithms vary to balance utility, equity, and logistics. Eurotransplant's Kidney Allocation System (ETKAS), serving seven European countries, emphasizes HLA-A/B/DR matching (full points for 000 mismatches), age-matching between donor and recipient, prospective crossmatch for sensitized patients, and wait time, with rescue allocation for unsent kidneys after 2 hours.[](https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009248) In France, the Agence de la BiomÃ©decine uses a stepwise system for donation after brain death, prioritizing HLA compatibility and urgency within zones, updated in recent years to incorporate KDPI equivalents and reduce geographic barriers.[](https://www.ovid.com/journals/ajtr/fulltext/10.1111/ajt.17180~the-new-french-kidney-allocation-system-for-donations-after) Australia's system, managed by states via the OrganMatch program, allocates based on blood type, HLA-DR matching, wait time, and clinical urgency, with national sharing for perfect matches or pediatric cases, aiming to minimize cold ischemia time.[](https://www.sciencedirect.com/science/article/pii/S0270929522000560) These frameworks reflect causal trade-offs: stricter matching improves outcomes (e.g., 5-year graft survival 10-15% higher with 0-DR mismatches) but prolongs waits, while broader sharing enhances equity yet risks logistics delays.[](https://www.sciencedirect.com/science/article/pii/S0085253817300753)\n\nOngoing reforms address limitations like geographic inequities, with the U.S. OPTN piloting continuous distribution paradigms by 2025 to replace discrete circles with score-based prioritization using distance as a continuous variable weighted against biology, potentially reducing wait time variances from 1.5-fold to near parity across donation service areas.[](https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/continuous-distribution-of-kidneys-winter-2025/) KDPI calculations were updated May 21, 2025, incorporating recent donor data for accuracy.[](https://optn.transplant.hrsa.gov/news/may-2025-annual-kidney-allocation-calculator-updates/) Algorithmic simulations using multiobjective optimization have informed these shifts, prioritizing metrics like transplant rates, graft survival, and equity indices over rigid boundaries.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12377324/) Despite evidence-based designs, debates persist on weightingâ€”e.g., utility-focused systems may disadvantage younger or minority recipients, per analyses showing persistent disparities post-KAS.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9558035/) OPTN policies, grounded in empirical modeling, evolve via public comment but face criticism for not fully resolving out-of-sequence offers, which rose post-2021 due to expanded recovery pressures.[](https://journals.lww.com/kidney360/fulltext/2025/01000/increasing_incidence_of_out_of_sequence_allocation.19.aspx)\n\n### Challenges in Matching and Prioritization\n\nMatching deceased donor kidneys to recipients presents significant challenges due to the imbalance between limited organ supply and high demand, with over 100,000 patients on U.S. kidney transplant waitlists as of recent data, where more than 30% wait over three years, contributing to elevated pre-transplant mortality rates exceeding 5% annually for active candidates.[](https://www.sciencedirect.com/science/article/pii/S0041134524004470)[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1362-6) This scarcity necessitates prioritization algorithms that weigh factors like wait time, calculated panel reactive antibody (cPRA) levels for sensitization, expected post-transplant survival (EPTS) scores, and kidney donor profile index (KDPI), but implementation often results in trade-offs between equity and utility, such as increased organ discards or prolonged cold ischemia times following the 2014 Kidney Allocation System (KAS) revisions that expanded sharing for high-cPRA patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3203330/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10833597/)\n\nHuman leukocyte antigen (HLA) matching remains a core hurdle, as mismatchesâ€”particularly at HLA-DR and HLA-DQ lociâ€”correlate with reduced long-term graft survival, with studies showing HLA-mismatched kidneys experiencing higher rates of chronic rejection and graft loss, potentially sensitizing recipients and complicating future retransplants.[](https://www.sciencedirect.com/science/article/abs/pii/S0966327423000783)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218811/) While modern immunosuppression has diminished the acute impact of mismatches, evidenced by similar short-term graft survival rates across match levels (e.g., 90.6% at one year for matched vs. 89.9% for mismatched), disparities persist in extended outcomes, with only about 40% of transplants achieving favorable HLA compatibility in analyzed cohorts.[](https://www.amjtransplant.org/article/S1600-6135%2822%2907940-0/fulltext)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8966965/) Highly sensitized patients (cPRA \u003e99%) face prolonged waits due to limited compatible donors, exacerbating inequities despite prioritization points, as molecular-level HLA typing reveals epitope mismatches that standard serologic methods overlook, yet adoption lags due to data scarcity on waitlist impacts.[](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14716/full)[](https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/identify-priority-shares-in-kidney-multi-organ-allocation/)\n\nPrioritization algorithms, such as those managed by the United Network for Organ Sharing (UNOS), aim to optimize both immediate placement and longevity matching but encounter resistance from transplant centers, which frequently decline offers for top-ranked candidates in favor of lower-priority recipients perceived to yield better utility, occurring in up to substantial fractions of cases per data from 2010-2020.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805570) This practice, while potentially maximizing overall graft life-years, undermines waitlist equity and increases discard rates for marginal kidneys, particularly those with high KDPI (\u003e85%), where end-of-chain selection challenges arise from balancing adherence to allocation versus utility-driven choices like HLA or longevity optimization.[](https://www.amjtransplant.org/article/S1600-6135%2824%2900678-6/fulltext)[](https://pubmed.ncbi.nlm.nih.gov/39490413/) Multi-organ transplant priorities further disadvantage solitary kidney candidates, correlating with higher delisting and death rates on waitlists, as simultaneous liver-kidney allocations preempt kidneys from standalone recipients without commensurate outcome gains.[](https://www.sciencedirect.com/science/article/pii/S1600613522085914)\n\nGeographic and demographic disparities compound these issues, with local allocation preferences historically favoring shorter transport but post-KAS national sharing for sensitized patients leading to longer ischemia times and variable access, disproportionately affecting pediatric or urgent cases despite targeted exceptions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10065754/) Operations research highlights algorithmic inefficiencies, such as suboptimal pairing that could be mitigated by advanced modeling, yet persistent center-level deviations and opaque decision-making hinder equitable outcomes, underscoring the need for transparent, evidence-based refinements to reduce waitlist mortality without inflating discards.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10000664/)[](https://pubmed.ncbi.nlm.nih.gov/40040564/)\n\n## Surgical Procedures\n\n### Recipient Implantation Technique\n\n![Kidney transplant implantation](./_assets_/Kidtransplant.svg.png)\nThe recipient implantation technique in kidney transplantation employs a heterotopic approach, positioning the donor kidney in the iliac fossa of the lower abdomen without routine removal of the native kidneys, which are preserved unless affected by conditions such as recurrent infection or malignancy.[](https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/) The surgery is conducted under general anesthesia and typically lasts 2 to 4 hours.[](https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777) An open extraperitoneal incision, often via the Gibson technique in the iliac fossa (preferentially right-sided for primary transplants), exposes the iliac vessels after medial retraction of the peritoneum.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/)\n\nVascular anastomoses prioritize minimizing ischemia; the renal vein is first connected end-to-side to the external iliac vein, followed by the renal artery anastomosed end-to-side to the external iliac artery.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/) For grafts with multiple renal arteries, techniques such as Carrel patch augmentation or sequential side-to-side anastomoses to the iliac artery are utilized during back-table preparation to ensure adequate perfusion.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/) Systemic heparin (30-60 IU/kg) may be administered, and graft reperfusion is assessed via the Hume test for viability before completing arterial connections.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/) Variations include end-to-end anastomosis to the internal iliac artery in cases of external iliac disease or for smaller pediatric grafts.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/)\n\nUreteral anastomosis involves an extravesical ureteroneocystostomy, with the Lich-Gregoir technique preferred to create an anti-reflux submucosal tunnel in the bladder dome, reducing vesicoureteral reflux risk.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/) A double-J ureteral stent (typically 5 Fr, 12-16 cm) is routinely or selectively placed to prevent obstruction or leakage, such as urinoma formation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/)[](https://www.ncbi.nlm.nih.gov/books/NBK567755/) Alternative methods like pyeloureterostomy are reserved for anomalous ureters.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/) The peritoneum is repositioned, and the incision closed in layers, with drains sometimes used postoperatively. Orthotopic implantation, anastomosing to native renal vessels, is an uncommon variant for recipients with iliac fossa occupation or severe atherosclerosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/) Robotic-assisted techniques are emerging for precision in complex vascular scenarios but involve longer operative times.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/)\n\n### Variants Including Combined Transplants\n\n![Schema of pancreas-kidney transplantation](./_assets_/lossy-page1-250px-Schema_der_Pankreas-Nierentransplantation_mit_portalven%C3%B6ser_Anastomose_des_Pankreastransplantats.tif.jpg)\n\nSimultaneous pancreas-kidney (SPK) transplantation represents a key variant for patients with type 1 diabetes mellitus and end-stage renal disease (ESRD), addressing both insulin dependence and uremia through dual organ replacement from a single deceased donor.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3087789/) The pancreas graft corrects hyperglycemia by restoring endogenous insulin production, while the kidney graft replaces failed renal function, with systemic venous drainage typically used for the pancreas to manage exocrine secretions via enteric or bladder anastomosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079050/) This approach yields superior long-term outcomes compared to kidney transplantation alone in diabetic ESRD patients, including reduced cardiovascular mortality; a propensity score-matched analysis reported hazard ratios favoring SPK for event-free survival.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10514751/) Patient and graft survival rates exceed 90% at one year and 70-80% at five years in contemporary series, though pancreas graft thrombosis remains a leading cause of early failure at 5-10%.[](https://pubmed.ncbi.nlm.nih.gov/36029250/)[](https://pubmed.ncbi.nlm.nih.gov/15387113/)\n\nPancreas after kidney (PAK) transplantation offers an alternative sequential variant, deferring pancreas placement until after a prior kidney transplant, suitable for select type 1 diabetics with stable renal allografts but ongoing glycemic instability.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8693781/) Outcomes mirror SPK in insulin independence rates (around 80% at one year), but PAK carries higher immunological risks due to prior sensitization from the kidney graft.[](https://pubmed.ncbi.nlm.nih.gov/36406897/)\n\nCombined liver-kidney (SLK) transplantation addresses dual organ failure, primarily indicated in conditions like hepatorenal syndrome, polycystic kidney and liver disease (autosomal dominant polycystic kidney disease, ADPKD), or chronic glomerular disease with decompensated cirrhosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7643210/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4675492/) The liver graft often ameliorates renal dysfunction via factors reducing vasoconstriction, enabling staged kidney transplantation in some cases, though simultaneous SLK predominates for acute needs; survival reaches 85-90% at one year and 70% at five years across centers.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001155)[](https://www.mdpi.com/2075-1729/14/10/1319) Indications exclude isolated liver disease with reversible kidney injury per allocation policies, prioritizing true multi-organ necessity to conserve kidneys.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10637446/)\n\nLess common variants include kidney-heart or kidney-lung combinations for patients with ESRD complicating advanced cardiac or pulmonary failure, where multi-organ procurement from the same donor mitigates ischemia-reperfusion injury across grafts.[](https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/multi-organ-transplantation/) These procedures demand meticulous donor-recipient matching and perioperative management, with outcomes varying by center volume but generally aligning with isolated transplant benchmarks when feasible.[](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001155)\n\n## Postoperative Management\n\n### Acute Phase Care and Monitoring\n\nFollowing kidney transplantation, patients are typically admitted to an intensive care unit for 24 to 48 hours for close monitoring of hemodynamic stability, graft perfusion, and early complications.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf) Vital signs, including blood pressure (target \u003c130/80 mmHg), heart rate, and central venous pressure (8-12 mmHg if monitored), are assessed hourly initially to ensure adequate graft blood flow and prevent hypovolemia or hypertension-induced injury.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/) Urine output is measured hourly for at least 24 hours, with targets exceeding 0.5 mL/kg/hour indicating initial graft viability; oliguria prompts evaluation for obstruction, thrombosis, or acute tubular necrosis.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf)\n\nGraft function is evaluated daily via serum creatinine levels, aiming for a decline to below 2 mg/dL by postoperative day 5 in uncomplicated cases; persistent elevation necessitates renal ultrasound and potential biopsy to differentiate delayed graft function from rejection or vascular issues.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/) Complete blood counts and electrolyte panels are checked daily for the first week to detect anemia, leukopenia from immunosuppression, or imbalances like hyperkalemia.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf) Immunosuppressive therapy, typically comprising a calcineurin inhibitor (e.g., tacrolimus with trough levels of 5-10 ng/mL initially), mycophenolate, and corticosteroids, is initiated before or at transplantation, with drug levels monitored every other day until therapeutic targets are achieved to minimize rejection risk while avoiding toxicity.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/)\n\nFluid management emphasizes euvolemia through intravenous isotonic solutions adjusted to urine output and hemodynamic parameters, avoiding overload that could exacerbate cardiac strain in recipients with preexisting comorbidities.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf) Prophylaxis against infections begins immediately, including trimethoprim-sulfamethoxazole for Pneumocystis jirovecii (6 months) and valganciclovir for cytomegalovirus (3-6 months in at-risk patients), with weekly viral load monitoring if high risk.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/) Surveillance for acute rejection involves daily clinical exams and laboratory trends; any unexplained creatinine rise triggers protocol biopsy (e.g., 16-gauge needle, two cores) rather than empirical treatment, as histological confirmation guides therapy such as high-dose methylprednisolone.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/) Doppler ultrasound is performed if vascular thrombosis is suspected, occurring in up to 1-2% of cases early post-transplant.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf)\n\nTransition to ward care occurs once stable, with outpatient follow-up 2-3 times weekly in the first month, including tacrolimus level checks 3 times weekly and creatinine assessments to detect subclinical issues like BK polyomavirus viremia (screened monthly via PCR, reducing immunosuppression if \u003e10,000 copies/mL).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/) Pain is managed with multimodal analgesia avoiding nephrotoxic agents, and surgical wound inspection prevents hematoma or infection, which affect 5-10% of recipients.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf) These protocols, derived from consensus guidelines, prioritize empirical graft viability metrics over proxy indicators to optimize outcomes in the vulnerable acute phase.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/)[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf)\n\n### Immunosuppressive Regimens\n\nImmunosuppressive regimens are essential in kidney transplantation to suppress the recipient's immune response and prevent acute and chronic rejection of the allograft, which occurs due to T-cell mediated recognition of donor antigens. These regimens typically involve an initial high-intensity phase (induction) followed by long-term maintenance therapy, balancing efficacy against risks such as infection, malignancy, and drug toxicity. Standard protocols have evolved since the introduction of calcineurin inhibitors (CNIs) in the 1980s, reducing acute rejection rates from over 50% to under 15% in the first year, though long-term graft survival remains challenged by chronic allograft nephropathy and non-adherence.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11943253/)[](https://www.kidney.org/sites/default/files/2025-08/new-options-maintenance-immunosuppression_02-10-7138.pdf)\n\nInduction therapy, administered perioperatively, intensifies immunosuppression to mitigate early rejection risk, particularly in high-immunological-risk patients (e.g., those with prior transplants or panel-reactive antibodies \u003e50%). Interleukin-2 receptor antagonists like basiliximab (two 20 mg doses on days 0 and 4) are used in low-risk cases for their targeted blockade of activated T-cells, achieving acute rejection rates of 10-20% without increased infection risk compared to no induction. Polyclonal anti-thymocyte globulin (ATG), such as rabbit ATG at 1-1.5 mg/kg daily for 3-5 days, provides broader lymphodepletion and superior efficacy in high-risk recipients, reducing biopsy-proven acute rejection by 20-30% versus basiliximab (e.g., 12% vs. 25% at 1 year), though it carries higher cytomegalovirus (CMV) and post-transplant lymphoproliferative disorder risks requiring prophylaxis. Low-dose ATG (e.g., single 3 mg/kg) offers a compromise with rejection prevention comparable to standard doses and fewer adverse events.[](https://pubmed.ncbi.nlm.nih.gov/38553819/)[](https://academic.oup.com/ckj/article/17/9/sfae236/7756426)[](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15321/full)\n\nMaintenance immunosuppression usually consists of triple therapy: a CNI (tacrolimus preferred over cyclosporine for lower rejection rates, targeting trough levels of 5-10 ng/mL initially), an antiproliferative agent like mycophenolate mofetil (MMF; 1-2 g/day), and corticosteroids (e.g., prednisone tapered to 5 mg/day). Tacrolimus-based regimens yield 1-year graft survival exceeding 90%, outperforming cyclosporine in reducing acute rejection (15% vs. 25%) and improving long-term function, though both CNIs cause dose-dependent nephrotoxicity via afferent arteriolar vasoconstriction and fibrosis, contributing to 20-30% of chronic graft losses. MMF inhibits purine synthesis in lymphocytes, reducing rejection by 50% versus azathioprine, but gastrointestinal toxicity affects 10-20% of patients. Steroids provide rapid anti-inflammatory effects but are often minimized or withdrawn after 3-6 months in low-risk patients to avoid metabolic complications, with steroid-free protocols showing equivalent 5-year graft survival (85-90%) and reduced diabetes incidence.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10946132/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2952470/)[](https://www.nejm.org/doi/full/10.1056/NEJMoa1506027)\n\nAlternative strategies address CNI limitations: minimization protocols reduce tacrolimus exposure (e.g., to 3-5 ng/mL after year 1) with adjuncts like mammalian target of rapamycin inhibitors (mTORi; everolimus or sirolimus), preserving function but increasing rejection risk if not monitored closely. Belatacept, a costimulatory blockade agent infused monthly, enables CNI avoidance, yielding superior 7-year graft survival (80% vs. 70% with cyclosporine) and better renal function (eGFR +10-15 mL/min), though early acute rejection rates are higher (20-25%) and it requires vigilant CMV screening. Regimen selection considers donor type, recipient comorbidities, and HLA mismatch; for example, living-donor transplants favor basiliximab induction with tacrolimus-MMF without steroids. Therapeutic drug monitoring is critical, with tacrolimus levels adjusted to avoid under- or over-immunosuppression, as non-adherence causes 20-30% of late graft failures. Despite advances, no regimen halts chronic antibody-mediated rejection, and ongoing trials explore tolerance induction via regulatory T-cells or mixed chimerism.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11943253/)[](https://www.nejm.org/doi/full/10.1056/NEJMoa1506027)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7080294/)\n\n### Long-Term Follow-Up Protocols\n\nLong-term follow-up protocols for kidney transplant recipients emphasize serial assessment of allograft function, adjustment of immunosuppressive therapy, and vigilant screening for chronic complications to mitigate graft loss and improve survival rates, which remain challenged by chronic allograft nephropathy and cardiovascular events.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) After the first post-transplant year, clinical evaluations occur every 3 months, with laboratory assessments every 6 weeks to detect subtle declines in function early.[](https://www.tts.org/images/stories/practical_protocols/Practical_Protocols_ENG.PDF) Key metrics include serum creatinine and eGFR, monitored every 2-3 months to track progressive deterioration, as stable eGFR beyond year 1 correlates with extended graft survival exceeding 15 years in low-risk cohorts.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03504-2) [](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) Urinalysis for proteinuria, quantified annually thereafter, identifies early markers of chronic damage, with levels above 0.5 g/day prompting biopsy consideration.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf)\n\nImmunosuppressive drug levels, particularly tacrolimus trough concentrations (target 5-8 ng/mL in stable maintenance), are measured every 3 months or with any graft function change to balance rejection risk against nephrotoxicity.[](https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx) Adherence is evaluated at every visit using validated tools or as the \"fifth vital sign,\" given nonadherence accounts for up to 20% of late graft losses; interventions include regimen simplification to once-daily dosing.[](https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx) De novo donor-specific antibodies are screened via solid-phase immunoassay in cases of dysfunction or suspected underimmunosuppression.[](https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx)\n\nComplication screening integrates infection surveillance, with BK polyomavirus PCR tested every 3 months for the first 24 months and upon creatinine elevation, as viremia precedes nephropathy in 10-20% of cases without intervention.[](https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx) [](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) Cardiovascular risk management targets blood pressure below 130/80 mmHg at each visit via ACE inhibitors or ARBs, alongside annual lipid profiles to guide statin use, addressing the leading cause of post-transplant mortality.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) Malignancy surveillance includes annual skin examinations, given a 2-5-fold elevated skin cancer risk, and age-appropriate protocols for other cancers.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) Bone mineral density assessment every 1-2 years in at-risk patients, with calcium and phosphorus checked every 6-12 months, counters osteoporosis from steroids and CKD-mineral bone disorder.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf)\n\nIndication-based biopsies are performed for unexplained creatinine rises exceeding 20-30%, persistent proteinuria â‰¥3 g/day, or protocol-driven in high-risk protocols, revealing antibody-mediated rejection in up to 50% of late failures.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) Complete blood counts and electrolytes are reviewed every 3-6 months to detect cytopenias or imbalances from medications.[](https://www.tts.org/images/stories/practical_protocols/Practical_Protocols_ENG.PDF) These protocols, derived from consensus guidelines, underscore causal links between consistent monitoring and reduced half-life loss, though real-world adherence varies due to socioeconomic factors.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) [](https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx)\n\n### Dietary and Lifestyle Recommendations\n\nPost-kidney transplantation, recipients are advised to adopt a balanced diet emphasizing cardiovascular health and weight management, as immunosuppressive medications such as corticosteroids often contribute to rapid weight gain, hyperlipidemia, and new-onset diabetes.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) A low-sodium intake, typically limited to less than 2,300 mg per day, is recommended to control hypertension, which affects up to 80% of transplant patients within the first year.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8258457/) The Mediterranean dietary pattern, rich in fruits, vegetables, whole grains, and plant-based fats, has been associated with improved graft function and reduced cardiovascular events in observational studies of transplant recipients.00108-5/fulltext)\n\nProtein intake should be adequate to support recovery and muscle maintenance, generally 1.0-1.2 g/kg body weight daily, without the restrictions applied in chronic kidney disease, as the functioning graft tolerates higher levels.[](https://www.ucsfbenioffchildrens.org/education/nutrition-after-kidney-transplant) Carbohydrates should comprise approximately 50% of total energy, prioritizing low-glycemic-index sources with high dietary fiber to mitigate post-transplant hyperglycemia risks.30191-7/fulltext) Unlike pre-transplant renal diets, restrictions on potassium and phosphorus are typically lifted unless graft dysfunction recurs, allowing broader inclusion of fresh produce.[](https://www.ucsfbenioffchildrens.org/education/nutrition-after-kidney-transplant) Alcohol consumption should be limited to no more than one standard drink per day for women and two for men, with abstinence preferred during the early postoperative period due to interactions with immunosuppressants.00108-5/fulltext)\n\n- **Fruits and vegetables**: Aim for 5-7 servings daily to provide antioxidants and fiber, supporting immune function without excess potassium load in stable grafts.[](https://www.kidney.org/kidney-topics/diet-after-kidney-transplant)\n- **Lean proteins**: Include fish, poultry, and plant sources like legumes to minimize saturated fats linked to dyslipidemia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8258457/)\n- **Fats**: Favor unsaturated fats from nuts, seeds, and olive oil; plant sterols may help lower cholesterol levels elevated by calcineurin inhibitors.00108-5/fulltext)\n- **Hydration**: Maintain 2-3 liters of fluid daily unless contraindicated by edema or heart failure, to promote renal perfusion.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3540789/)\n\nLifestyle modifications focus on mitigating immunosuppression-related risks, including infection, malignancy, and cardiovascular diseaseâ€”the leading cause of death post-transplant.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3540789/) Regular physical activity is endorsed, with guidelines suggesting at least 150 minutes of moderate-intensity aerobic exercise per week, supplemented by resistance training twice weekly, to improve endothelial function, reduce fatigue, and enhance quality of life; randomized trials demonstrate feasibility and safety starting 4-6 weeks post-surgery.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf)[](https://karger.com/kbr/article/49/1/548/909773/Physical-Exercise-in-Kidney-Renal-Recipients-Where) Smoking cessation is critical, as continued tobacco use doubles the risk of graft loss and triples cardiovascular mortality within five years.[](https://newsnetwork.mayoclinic.org/discussion/lifestyle-changes-can-be-critical-for-kidney-transplant-patients-long-term-survival/) Sun protection measures, including broad-spectrum sunscreen and protective clothing, are essential due to heightened skin cancer incidence from azathioprine and cyclosporine.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf) Weight reduction through combined diet and exercise is prioritized for overweight recipients, targeting a BMI below 30 kg/mÂ² to lower allograft failure rates observed in obese cohorts.[](https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf)\n\n## Complications and Risks\n\n### Surgical and Perioperative Complications\n\nSurgical complications in kidney transplantation encompass vascular, urological, and wound-related issues that arise during or immediately after the procedure, with overall early complication rates (within 90 days) reported at approximately 36% across studies.[](https://pubmed.ncbi.nlm.nih.gov/40912061/) These events often necessitate reoperation and can jeopardize graft viability, particularly if vascular thrombosis occurs, which affects 2-3% of cases and typically leads to irreversible graft loss.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10276531/) Urological complications, such as urine leaks or ureteral strictures, occur in 3.4-11.2% of transplants, stemming from anastomotic failures or ischemia to the ureter.[](https://tau.amegroups.org/article/view/23349/html) Bleeding requiring transfusion is common, seen in up to 36% of patients, while symptomatic hematomas develop in about 10%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11098183/)\n\nVascular complications, occurring in 3-15% of renal transplants, include renal artery thrombosis (less than 1% incidence), venous thrombosis (around 1.4%), and transplant renal artery stenosis, which often manifests 3-6 months postoperatively but can originate perioperatively from technical errors or hypoperfusion.[](https://www.ectrx.org/detail/current/2022/20/4/0/333/0)[](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2023.1150331/full)[](https://journals.lww.com/transplantationdirect/fulltext/2022/06000/vascular_complications_in_renal_transplantation_.12.aspx) These arise causally from factors like prolonged cold ischemia time, donor hypotension, or anastomotic kinking, with early detection via Doppler ultrasound critical to salvage.[](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2023.1150331/full)\n\nPerioperative complications extend to non-surgical issues like delayed graft function (DGF), defined as the need for dialysis within the first week post-transplant, affecting 20-50% of deceased-donor recipients due to ischemia-reperfusion injury, acute tubular necrosis, or calcineurin inhibitor toxicity.[](https://www.kidney-international.org/article/S2157-1716%2815%2932257-7/fulltext)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9605016/) DGF prolongs hospitalization and heightens rejection risk, though its direct impact on long-term graft survival varies by duration and management.[](https://journals.lww.com/transplantationdirect/fulltext/2023/02000/effects_of_delayed_graft_function_on_transplant.6.aspx) Surgical site infections occur in about 3.7% of cases, often linked to wound contamination or immunosuppression, while incisional hernias develop in 2.5-10%, influenced by obesity and surgical technique.[](https://pubmed.ncbi.nlm.nih.gov/40429301/) Sepsis, at 3%, and urinary tract infections (8.6%) further compound perioperative morbidity, underscoring the need for vigilant monitoring and prophylactic antibiotics.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11098183/)\n\n### Rejection Mechanisms and Treatment\n\n![Renal graft biopsy showing acute cellular rejection](./_assets_/Acute_cellular_rejection%252C_renal_graft_biopsy.jpg)\n\nRejection of kidney transplants occurs when the recipient's immune system recognizes the donor graft as foreign, primarily due to mismatched human leukocyte antigens (HLA), triggering adaptive and innate immune responses.[](https://www.kidney-international.org/article/S0085-2538%2821%2901143-1/fulltext) Three main types are distinguished by timing and pathophysiology: hyperacute, acute, and chronic. Hyperacute rejection manifests within minutes to hours post-revascularization, mediated by preformed donor-specific antibodies (DSA) binding to vascular endothelium, activating complement and causing thrombosis, neutrophil infiltration, and rapid graft necrosis.[](https://www.ncbi.nlm.nih.gov/books/NBK553074/) This type is now rare, occurring in less than 1% of cases due to pre-transplant cross-matching via complement-dependent cytotoxicity or flow cytometry, which detects anti-HLA or anti-endothelial antibodies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4182006/)\n\nAcute rejection typically arises within days to months postoperatively and comprises two subtypes: T-cell-mediated (cellular) and antibody-mediated. T-cell-mediated rejection involves direct allorecognition by recipient CD4+ and CD8+ T cells, leading to cytokine release, macrophage recruitment, and tubulitis or vasculitis in the graft, confirmed histologically by Banff criteria showing lymphocytic infiltrates.[](https://emedicine.medscape.com/article/432209-overview) Antibody-mediated rejection (ABMR) results from de novo or anamnestic DSA targeting HLA or non-HLA antigens, causing C4d deposition in peritubular capillaries, endothelial injury, and microvascular inflammation.[](https://www.mdpi.com/2077-0383/12/12/4130) Incidence of acute rejection has declined to 10-15% in the first year with modern immunosuppression, but it remains a leading cause of early graft loss.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3808773/)\n\nChronic allograft injury, previously termed chronic rejection or chronic allograft nephropathy, develops over years through intertwined immune and non-immune mechanisms, culminating in interstitial fibrosis, tubular atrophy, and vascular changes. Immune factors include persistent low-level DSA-driven ABMR and T-cell activity, while non-immune contributors encompass calcineurin inhibitor nephrotoxicity, hypertension, recurrent glomerular disease, and donor-derived factors like ischemia-reperfusion injury.[](https://journals.lww.com/cjasn/fulltext/2021/11000/chronic_allograft_injury.16.aspx) This progressive process accounts for over 50% of long-term graft failures beyond the first decade.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12024747/)\n\nTreatment strategies prioritize prevention through induction with agents like basiliximab or antithymocyte globulin and maintenance regimens including tacrolimus, mycophenolate mofetil, and corticosteroids, which suppress T-cell activation and proliferation.[](https://www.ncbi.nlm.nih.gov/books/NBK553074/) For acute cellular rejection, first-line therapy involves high-dose intravenous methylprednisolone (250-500 mg daily for 3 days), achieving response rates of 70-80%; steroid-resistant cases receive lymphocyte-depleting agents such as rabbit antithymocyte globulin (ATG, 1.5 mg/kg daily for 7-14 days).[](https://www.uptodate.com/contents/kidney-transplantation-in-adults-treatment-of-acute-t-cell-mediated-cellular-rejection) Acute ABMR treatment combines plasmapheresis (to remove DSA), intravenous immunoglobulin (IVIG, 0.1-2 g/kg), and rituximab (375 mg/mÂ²), with adjuncts like bortezomib for plasma cell depletion or eculizumab for complement inhibition in severe cases, though evidence for long-term efficacy varies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10419508/) Hyperacute rejection mandates immediate graft nephrectomy, as no reversal is possible.[](https://www.ncbi.nlm.nih.gov/books/NBK553074/)\n\nChronic injury management focuses on risk factor modification rather than reversal, including minimization of calcineurin inhibitor doses, blood pressure control below 130/80 mmHg, proteinuria reduction with ACE inhibitors, and protocol biopsies for early detection.[](https://www.sciencedirect.com/science/article/abs/pii/S0955470X16300532) Emerging therapies target fibrosis pathways, but mTOR inhibitors like everolimus show mixed results in slowing progression.[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.660334/full) Overall, timely diagnosis via surveillance biopsies, DSA monitoring, and protocolized immunosuppression adjustments is critical, as untreated rejection episodes double the risk of graft loss.[](https://www.mdpi.com/2077-0383/12/12/4130)\n\n### Infectious and Malignancy Risks\n\nImmunosuppressive therapy in kidney transplant recipients substantially elevates the risk of opportunistic infections by impairing T-cell mediated immunity and neutrophil function, with bacterial infections occurring in approximately 41% of recipients and overall infection rates reaching 44% within two years post-transplant.[](https://academic.oup.com/ofid/article/9/7/ofac243/6585272)[](https://www.sciencedirect.com/science/article/pii/S1876034124002259) Urinary tract infections represent the most frequent complication, affecting 20-43% of patients, often linked to surgical site vulnerabilities and indwelling catheters, while asymptomatic bacteriuria complicates up to 53% of cases.[](https://www.mdpi.com/2077-0383/14/10/3307) Viral infections, particularly cytomegalovirus (CMV), pose significant threats, with incidence reduced to 17-37% through antiviral prophylaxis like valganciclovir, though disease can still emerge beyond six months in high-risk donor-positive/recipient-negative mismatches.[](https://journals.lww.com/cjasn/fulltext/2022/02000/long_term_infectious_complications_of_kidney.17.aspx)[](https://www.tandfonline.com/doi/full/10.2147/TRRM.S366213)\n\nBK polyomavirus nephropathy affects 1-10% of recipients, typically manifesting within the first year due to intense immunosuppression, leading to viruria in 30-40%, viremia in 10-20%, and graft loss in up to 35% of affected cases without intervention such as dose reduction of calcineurin inhibitors.[](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08043-z)[](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1309927/full) Fungal infections, including candidiasis and aspergillosis, occur less frequently but carry high mortality, often necessitating preemptive antifungal strategies in endemic areas or prolonged neutropenia. Prophylaxis protocols, including trimethoprim-sulfamethoxazole for Pneumocystis jirovecii, have curtailed certain infections, yet surveillance via PCR monitoring for CMV and BK remains essential to mitigate graft dysfunction.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12016247/)\n\nMalignancy risk post-kidney transplantation is nearly fourfold higher than in the general population, driven by chronic immunosuppression disrupting immune surveillance of oncogenic viruses and DNA repair mechanisms, with cumulative solid organ cancer incidence reaching 10-15% at 15 years.[](https://academic.oup.com/ckj/article/18/4/sfaf077/8088413)[](https://journals.lww.com/cjasn/fulltext/2022/03000/de_novo_malignancies_after_kidney_transplantation.16.aspx) Non-melanoma skin cancers predominate, alongside increased rates of post-transplant lymphoproliferative disorder (PTLD), which arises in EBV-seronegative recipients at elevated risk due to primary infection under immunosuppression, with overall de novo malignancy rates around 9% in large cohorts.[](https://www.mdpi.com/2227-9059/13/10/2346)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4831913/) Risk factors for PTLD include EBV mismatch, older recipient age, and potent induction therapies like antithymocyte globulin, contributing to mortality rates exceeding those of the general population by twofold.[](https://www.ajkd.org/article/S0272-6386%2821%2900501-1/pdf)[](https://www.sciencedirect.com/science/article/pii/S1600613525000413) Management involves immunosuppression minimization, rituximab for CD20-positive lesions, and enhanced screening such as annual dermatologic exams and EBV viral load monitoring to detect early oncogenic changes. Despite these measures, cancer remains a leading cause of long-term graft loss and death, underscoring the causal trade-off between rejection prevention and oncologic vulnerability.[](https://www.nature.com/articles/s41416-025-03086-2)\n\n### Cardiovascular and Other Systemic Issues\n\nCardiovascular disease constitutes the leading cause of death in kidney transplant recipients, responsible for a substantial proportion of both early and late mortality despite improvements in overall graft survival. In U.S. registry data, cardiovascular events predominate as the cause of death from 1 to 10 years post-transplant, with manifestations including coronary artery disease, heart failure, arrhythmias, and peripheral vascular disease. Transplant-specific factors exacerbate traditional risks such as age, diabetes, smoking, and dyslipidemia; these include acute and chronic rejection episodes, which in one cohort increased 10-year cardiovascular incidence threefold, delayed graft function, impaired renal allograft performance, new-onset diabetes after transplantation, and circulating donor-specific antibodies. Immunosuppressive agents like corticosteroids and calcineurin inhibitors contribute to hypertension, hyperlipidemia, and metabolic disturbances, accelerating atherosclerosis independently of pre-existing end-stage renal disease burdens.\n\nPost-transplant hyperglycemia and new-onset diabetes mellitus, occurring in 10-30% of recipients within the first year, further heighten cardiovascular vulnerability through endothelial dysfunction and insulin resistance, often linked to steroid use and tacrolimus. Elevated uric acid levels post-transplant, observed in up to 80% of recipients, correlate with congestive heart failure and graft loss, compounding ischemic risks. Management emphasizes aggressive modification of modifiable risksâ€”such as statin therapy for LDL reduction and blood pressure control below 130/80 mmHgâ€”alongside routine screening for donor-specific antibodies to mitigate rejection-related cardiovascular escalation, though outcomes vary with recipient age and comorbidity burden.\n\nBeyond cardiovascular concerns, posttransplant bone disease affects up to 50% of recipients, featuring rapid bone mineral density loss of 4-10% in the lumbar spine and femoral neck during the first 6-18 months, driven by persistent secondary hyperparathyroidism, corticosteroid-induced osteoporosis, and mineral metabolism dysregulation. This predisposes to fractures, with hip fracture rates 4-14 times higher than in the general population, correlating with increased morbidity and mortality independent of graft function. Anemia persists in 20-50% of patients early post-transplant, multifactorially arising from iron deficiency, erythropoietin hyporesponsiveness, and drug toxicities, and associates with allograft failure and reduced survival; severe cases (hemoglobin \u003c10 g/dL) heighten cardiovascular strain via left ventricular hypertrophy.\n\nHyperuricemia and gout emerge as prevalent metabolic issues, with gout incidence reaching 10-15% within five years, attributed to calcineurin inhibitors, diuretics, and reduced urate excretion, independently predicting allograft dysfunction and cardiovascular events. Other systemic complications encompass neurological effects from calcineurin inhibitor neurotoxicity, manifesting as tremors or posterior reversible encephalopathy in 5-15% of cases, and persistent electrolyte derangements like hypomagnesemia from proton pump inhibitors or tacrolimus. These issues underscore the need for vigilant monitoring, as they collectively impair long-term quality of life and survival beyond infectious or rejection pathways.[](https://journals.lww.com/kidney360/fulltext/2025/07000/cardiovascular_risk_after_renal_transplantation_.5.aspx)[](https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2024.1939)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10320602/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9904410/)[](https://journals.lww.com/kidney360/fulltext/2025/01000/high_post_kidney_transplant_serum_uric_acid_levels.18.aspx)\n\n## Prognosis and Outcomes\n\n### Graft Survival Metrics\n\nGraft survival in kidney transplantation refers to the duration from transplant to irreversible graft failure, typically defined as the need for chronic dialysis, retransplantation, or patient death with a functioning graft (unless death-censored analysis is specified).[](https://srtr.transplant.hrsa.gov/adr/Chapter?name=Kidney\u0026year=2023) Metrics are derived from large registries like the Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR), which track outcomes adjusted for recipient and donor factors. One-year graft survival rates have improved substantially, exceeding 95% overall, with living donor kidney transplants (LDKT) achieving 97.8-98.1% for recipients transplanted in recent cohorts (2014-2017).08680-4/fulltext)[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant)\n\nFive-year graft survival rates vary by donor type and recipient age, consistently higher for LDKT than deceased donor kidney transplants (DDKT). For adults aged 18-34 years, rates are approximately 90.0% for LDKT versus 82.2% for DDKT; for those aged 65 years and older, they drop to 80.2% versus 66.1%.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/) Death-censored analyses, excluding deaths with functioning grafts, yield higher figures, such as 92% for LDKT and 86% for DDKT at five years.[](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full) Long-term outcomes beyond five years show greater attrition, influenced by chronic allograft nephropathy, immunosuppression-related toxicities, and comorbidities, though exact 10-year metrics are less uniformly reported in recent data due to cohort maturity.[](https://www.sciencedirect.com/science/article/pii/S1600613522086804)\n\n| Metric                  | Living Donor (%) | Deceased Donor (%) | Notes/Source |\n|-------------------------|------------------|--------------------|-------------|\n| 1-Year Graft Survival  | 97.8-98.1       | 96                | Adjusted; recent cohorts (2014-2017)08680-4/fulltext)[](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full) |\n| 5-Year Graft Survival (18-34 yo) | 90.0            | 82.2              | OPTN/SRTR 2023[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/) |\n| 5-Year Graft Survival (â‰¥65 yo)   | 80.2            | 66.1              | OPTN/SRTR 2023[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/) |\n\nThese metrics reflect advancements in immunosuppression, donor selection, and perioperative care, but disparities persist due to donor quality (e.g., expanded criteria donors in DDKT) and recipient factors like diabetes or prior transplants.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant) Registry data indicate LDKT provides an additional 0.36 years of graft function over seven years compared to DDKT in matched cohorts.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12362070/)\n\n### Patient Survival and Quality of Life\n\nKidney transplantation confers a substantial survival advantage over maintenance dialysis for most end-stage renal disease patients, with adjusted life expectancy gains estimated at several years depending on age and comorbidities.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181) For recipients transplanted between 2016 and 2018, one-year patient survival reached 97.4%, while five-year survival was 86.6%.[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Introduction\u0026year=2023) These rates vary by donor type, with living donor kidney transplants yielding higher five-year patient survival of approximately 88% compared to 75-82% for deceased donor transplants.[](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full) Long-term outcomes show ten-year patient survival rates around 70-80% in select cohorts, though influenced by factors such as recipient age, with older patients (\u003e65 years) experiencing lower absolute survival but still outperforming dialysis equivalents.[](https://academic.oup.com/ndt/article/39/9/1483/7588854) [](https://www.ectrx.org/class/pdfPreview.php?year=2024\u0026volume=22\u0026issue=1\u0026supplement=1\u0026spage_number=263\u0026makale_no=0)\n\n| Time Post-Transplant | Patient Survival (All Donors, 2016-2018 Cohort) | Living Donor 5-Year | Deceased Donor 5-Year |\n|----------------------|------------------------------------------------|---------------------|-----------------------|\n| 1-Year              | 97.4%                                         | ~97%               | 92%                  |\n| 5-Year              | 86.6%                                         | 88%                | 75%                  |\n| 10-Year             | ~70-80% (cohort-specific)                     | N/A                | N/A                  |\n\nData derived from U.S. registry analyses; rates uncensored at graft failure.[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Introduction\u0026year=2023) [](https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full) [](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant)\n\nHealth-related quality of life (HRQoL) improves markedly post-transplantation relative to dialysis, with recipients reporting higher scores across physical, mental, and social domains in validated instruments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643597/) Meta-analyses and cohort studies confirm this elevation persists long-term, particularly in younger patients and those without heavy comorbidity burdens, enabling greater workforce participation and reduced symptom burden from uremia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11057459/) [](https://healthcare-bulletin.co.uk/article/quality-of-life-of-post-renal-transplant-patients-in-a-tertiary-corporate-hospital-in-bangalore-a-cross-sectional-study-3713/) However, immunosuppressive therapies introduce trade-offs, including fatigue, cosmetic changes, and heightened vulnerability to infections or malignancies, which can attenuate HRQoL gains in subsets like elderly recipients (\u003e70 years).[](https://www.amjtransplant.org/article/S1600-6135%2823%2900578-6/fulltext) [](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z) Overall, transplantation yields net positive HRQoL trajectories, with dialysis patients consistently scoring lower pre- and post-waitlist periods.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11057459/)\n\n### Determinants of Long-Term Success\n\nLong-term success in kidney transplantation is primarily measured by sustained allograft function, typically beyond 5â€“10 years, with median graft half-lives reported at approximately 12â€“15 years for deceased donor transplants and 15â€“20 years for living donor transplants in recent U.S. data from the Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR).[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2022) Key determinants encompass immunological compatibility, donor organ quality, recipient characteristics, and post-transplant management, where imbalances in any domain accelerate chronic allograft nephropathy or failure through mechanisms like antibody-mediated injury and fibrosis.[](https://www.sciencedirect.com/science/article/pii/S1600613522086804)\n\nHuman leukocyte antigen (HLA) matching remains a critical immunological factor, with each additional mismatch at HLA-A, -B, or -DR loci increasing the hazard ratio for graft loss by 7â€“10% over 20 years in first deceased donor transplants, based on analysis of over 100,000 U.S. cases.[](https://journals.lww.com/transplantjournal/fulltext/2016/05000/the_risk_of_transplant_failure_with_hla_mismatch.25.aspx) Poor matching heightens risks of chronic antibody-mediated rejection, particularly in sensitized recipients with preformed donor-specific antibodies, though modern immunosuppression has attenuated but not eliminated this effect.[](https://pubmed.ncbi.nlm.nih.gov/37302557/) Living donor transplants from HLA-identical siblings achieve superior 10-year graft survival rates exceeding 80%, compared to 60â€“70% for mismatched deceased donors.[](https://www.kidney-international.org/article/S0085-2538%2821%2900657-8/fulltext)\n\nDonor-specific factors, including age and procurement conditions, profoundly influence durability; kidneys from donors over 60 years exhibit 20â€“30% lower 10-year survival versus those from donors under 40, due to intrinsic nephrosclerosis and reduced regenerative capacity.[](https://www.sciencedirect.com/science/article/pii/S2589537021002601) Deceased donor grafts from expanded criteria (e.g., high Kidney Donor Profile Index \u003e85%) face heightened early ischemic injury, correlating with accelerated long-term decline, whereas living donors provide organs with lower cold ischemia times and better baseline function, extending median survival by 3â€“5 years.[](https://academic.oup.com/ndt/article/39/11/1846/7640868)\n\nRecipient variables such as pre-transplant dialysis duration, exceeding 5 years, independently doubles the risk of graft loss through endothelial damage and sensitization, per multivariate analyses of registry data.[](https://pubmed.ncbi.nlm.nih.gov/24138291/) Comorbidities like cardiovascular disease and diabetes mellitus impair outcomes, with adjusted hazard ratios for death-censored graft failure rising 1.5â€“2.0-fold in recipients with multiple conditions, underscoring the need for optimized pre-transplant risk stratification.[](https://bmjopen.bmj.com/content/12/5/e059631) Older recipients (\u003e65 years) experience comparable conditional survival post-engraftment but higher absolute failure rates due to cumulative frailty.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5120769/)\n\nPost-transplant adherence to immunosuppression regimens is paramount, with non-adherence accounting for up to 20% of late losses; protocolized monitoring of drug levels and biopsy surveillance detects subclinical rejection early, preserving function.[](https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx) Delayed graft function, occurring in 20â€“30% of deceased donor cases, triples the risk of chronic dysfunction via ischemia-reperfusion pathways, while vigilant infection prophylaxis mitigates opportunistic pathogens that exacerbate allograft stress.[](https://bmjopen.bmj.com/content/15/3/e087128) Overall, integrating these factors via refined allocation algorithms and personalized care has incrementally boosted 10-year graft survival from 50% in the 1990s to over 65% today, though non-immunological barriers like donor scarcity persist.[](https://www.sciencedirect.com/science/article/pii/S1600613522086804)\n\n## Ethical, Legal, and Societal Dimensions\n\n### The Organ Shortage Crisis and Waitlist Deaths\n\nThe persistent imbalance between the supply of donor kidneys and the demand from patients with end-stage renal disease constitutes a fundamental barrier to kidney transplantation in the United States. As of 2023, approximately 88,500 individuals were active on the kidney transplant waiting list, with 44,560 new candidates added that year, reflecting rising incidences of kidney failure driven by factors such as diabetes and hypertension.[](https://kidneytransplantcollaborative.com/new-kidney-transplant-collaborative-ktc-analysis-of-data-reveals-alarming-surge-in-kidney-transplant-waitlists-in-swing-states/)[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874) In contrast, only 27,332 kidney transplants were performed in 2023, including about 6,290 from living donors, leaving a net growth in the waitlist despite incremental increases in deceased donor recoveries.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874) This supply-demand gap has widened over time, as annual transplant volumes, while reaching records like 26,309 in 2022, fail to match the expanding pool of eligible patients added to the list each year.[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2022)\n\nWaitlist mortality underscores the human cost of this shortage, with thousands of patients dying annually while awaiting a transplant. In 2023, 4,002 individuals were removed from the kidney waitlist due to death, a decline from 5,371 in 2021 amid pandemic disruptions but still equating to roughly 11 deaths per day.[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2023) Estimates indicate 12 to 17 kidney candidates die daily across the U.S., often from complications of dialysis or disease progression, as median wait times exceed three to five years depending on blood type, tissue match, and geographic factors.[](https://kidneytransplantcollaborative.com/new-kidney-transplant-collaborative-ktc-analysis-of-data-reveals-alarming-surge-in-kidney-transplant-waitlists-in-swing-states/)[](https://www.kidney.org/kidney-topics/kidney-transplant-waitlist) One-year post-waitlisting survival data show that only about 16.6% receive a deceased donor kidney, while 1.7% die within that period, highlighting how prolonged dialysisâ€”while life-sustainingâ€”carries inferior outcomes compared to transplantation.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant)\n\nContributing to the shortage are multifaceted supply constraints, including insufficient deceased donor rates due to opt-in consent systems, cultural reluctance toward donation, and donor organ discard from perceived quality issues like extended ischemia or marginal viability.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4149736/)[](https://aopo.org/aopo-highlights-disturbing-crisis-thousands-of-kidney-patients-who-died-waiting-for-organs-in-2023-could-have-been-saved/) In 2023, organ procurement organizations recovered twice the kidneys needed to save waitlisted patients who died, yet many were discarded, pointing to inefficiencies in utilization alongside demographic shifts toward older donors with comorbidities.[](https://aopo.org/aopo-highlights-disturbing-crisis-thousands-of-kidney-patients-who-died-waiting-for-organs-in-2023-could-have-been-saved/) Living donation, which accounts for about 20-25% of transplants, has plateaued due to regulatory barriers and family-based limitations, failing to offset the deceased donor shortfall.[](https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961602-9/fulltext) These dynamics persist despite policy efforts like the 2014 Kidney Allocation System revisions, as demand continues to outpace even record donation levels.[](https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/)\n\n### Allocation Fairness and Geographic Disparities\n\nIn the United States, kidney allocation is managed by the Organ Procurement and Transplantation Network (OPTN) under policies designed to balance medical urgency, biological compatibility, and equitable access while maximizing graft utility. Priority is given first to zero human leukocyte antigen (HLA) mismatch candidates within a 250-nautical-mile radius of the donor hospital, followed by national zero-mismatch offers, pediatric candidates, highly sensitized patients (calculated panel reactive antibody \u003e98%), blood type compatibility, wait time, and other factors like donor-specific antibodies.[](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/) [](https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/removal-of-dsa-and-region-from-kidney-allocation-policy/) These criteria aim for fairness by prioritizing life-saving potential over geographic proximity, but longstanding debates question whether the system adequately weighs equity against efficiency, with critics arguing that local procurement inefficiencies exacerbate unequal outcomes without sufficient accountability for organ procurement organizations (OPOs).[](https://www.sciencedirect.com/science/article/pii/S0270929522000560) [](https://www.srtr.org/media/1234/gustafson_geogdisp.pdf)\n\nGeographic disparities in access to deceased donor kidney transplantation (DDKT) have persisted since the national system's inception, driven by variations in OPO performance, donor recovery rates, and local demand-supply imbalances. Median wait times for kidney transplant candidates exceed 3 years nationally but range up to 10 years in high-demand regions, with transplant rates per 100 dialysis patients varying more than twofold across donation service areas (DSAs).[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC5992006/) For instance, Scientific Registry of Transplant Recipients (SRTR) data indicate that areas with high end-stage kidney disease burdens, often urban centers, experience lower transplant rates post-policy updates due to constrained local supply and discard rates influenced by transport logistics.[](https://www.ajkd.org/article/S0272-6386%2821%2901041-6/fulltext) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC6933455/) In 2022, the OPTN/SRTR Annual Data Report highlighted stable but unequal graft survival metrics across regions, attributing part of the variance to OPO-level differences in deceased donor kidney recovery, where some DSAs recover kidneys from only 40-50% of eligible donors compared to over 70% in others.[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2022)\n\nPolicy reforms have targeted these inequities, notably the 2014 Kidney Allocation System (KAS), which expanded sharing for highly sensitized patients and prioritized longevity matching, and the 2021 KAS250 update, which eliminated DSA and regional boundaries in favor of distance-based circles to promote broader distribution.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5992006/) [](https://link.springer.com/article/10.1007/s40472-022-00384-z) The 2021 change increased cold ischemia times by an average of 1-2 hours but reduced geographic barriers, leading to a modest decline in waitlist mortality disparities in some analyses; however, SRTR evaluations show persistent unacceptably high variation, with the OPTN Board noting in 2012â€”and reaffirmed in subsequent reportsâ€”that access inequities remain a core failure mode tied to OPO metrics rather than allocation algorithms alone.[](https://www.srtr.org/media/1234/gustafson_geogdisp.pdf) [](https://www.sciencedirect.com/science/article/pii/S1600613524000777)\n\nFairness concerns extend to intersections with demographics, where geographic clustering of minority populations amplifies wait times; for example, non-Hispanic Black candidates, disproportionately in high-disparity DSAs, face 14% lower waitlisting odds even after KAS implementation, prompting 2023 waiting time modification policies that have awarded 1-3 years of credit to over 14,700 Black candidates to rectify historical HLA sensitization biases.[](https://www.kidneymedicinejournal.org/article/S2590-0595%2823%2900134-6/fulltext) [](https://optn.transplant.hrsa.gov/news/over-14-700-waiting-time-modifications-completed-for-black-kidney-patients-one-year-after-policy-implementation/) While these adjustments address calculable inequities, broader causal factors like variable OPO consent rates and discard practicesâ€”unmitigated by allocation tweaksâ€”underscore that fairness requires supply-side reforms, as evidenced by stagnant national waitlist growth despite record 28,142 transplants in 2023.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/) Empirical data from SRTR prioritize OPO accountability over further algorithmic shifts to achieve causal equity in outcomes.[](https://www.srtr.org/reports/opo-specific-reports/)\n\n### Debates on Organ Markets vs. Altruism\n\nThe debate over introducing regulated markets for kidneys versus relying solely on altruistic donation stems from persistent organ shortages, with over 100,000 patients awaiting kidneys in the United States as of 2023, leading to approximately 17 deaths per day on waitlists.[](https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/) Proponents argue that economic incentives would substantially increase supply by aligning human motivations with basic self-interest, as altruism alone has failed to meet demand despite public campaigns and opt-out policies in some countries.[](https://www.aeaweb.org/articles?id=10.1257/jep.21.3.3) In contrast, opponents contend that markets risk exploiting vulnerable sellers, commodifying human body parts, and eroding societal norms of gift-giving in medicine.[](https://meridian.allenpress.com/human-organization/article/77/4/323/72752/Against-a-Regulated-Market-in-Human-Organs-Ethical)\n\nEconomists Gary Becker and Julio Elias proposed in 2007 that payments of around $15,000 to $40,000 per kidney could eliminate U.S. transplant queues by boosting live donor supply fivefold or more, based on econometric modeling of willingness-to-donate under incentives.[](https://www.aeaweb.org/articles?id=10.1257/jep.21.3.3) This approach would also yield net savings of $100,000 or more per transplant by averting dialysis costs, which exceed $80,000 annually per patient.[](https://www.wsj.com/articles/SB10001424052702304149404579322560004817176) Empirical support draws from Iran's regulated compensated donation system, operational since 1988, where donors receive government-fixed payments of approximately $1,200 to $4,500 plus lifelong health insurance, resulting in over 40,000 kidney transplants by 2022 and the elimination of domestic waitlists.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9266983/) Studies of Iranian donors indicate high satisfaction rates (over 85%) and low regret (under 2%), with transplant volumes rising steadily without evidence of widespread coercion when regulated.[](https://ijkd.org/index.php/ijkd/article/download/9/8/8)\n\nCritics of organ markets emphasize ethical risks of exploitation, particularly for low-income individuals who may sell kidneys out of desperation rather than true voluntariness, potentially exacerbating global inequalities.[](https://pubmed.ncbi.nlm.nih.gov/28161761/) Bioethicists argue that even regulated payments undermine human dignity by treating organs as commodities, drawing parallels to historical bans on slavery or servitude, and warn of slippery slopes toward broader bodily commodification.[](https://plato.stanford.edu/entries/organs-sale/) Evidence from unregulated black markets, such as in Pakistan or via transplant tourism, shows higher infection rates and poorer graft survival (e.g., over 50% complication rates in some recipient cohorts), fueling concerns that incentives could incentivize substandard practices.[](https://europepmc.org/article/med/19469028) However, proponents counter that prohibition drives underground tradeâ€”estimated at 10% of global transplantsâ€”where sellers receive far less (often under $1,000) and face greater harms without oversight, suggesting regulation could mitigate these issues more effectively than altruism's status quo.[](https://journalofethics.ama-assn.org/article/veneer-altruism/2012-03)\n\nRecent analyses, including a 2022 review, highlight that while Iran's model has increased supply, donor long-term health outcomes remain understudied, with some evidence of higher hypertension risks among sellers, though not exceeding those in altruistic donors.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9266983/) Proposals for Western markets often include safeguards like fixed prices, independent oversight, and bans on foreign sales to prevent exploitation, with pilot studies suggesting public support rises to 70% if supply gains are projected.[](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12483/full) Despite these, opposition persists in institutions like the World Health Organization, which in 2023 reiterated bans on payments citing dignity over utilitarian gains, reflecting a preference for deontological ethics amid debates on whether altruism's moral framing truly enhances donation rates.[](https://jme.bmj.com/content/40/2/134) Causal evidence indicates that incentives outperform purely voluntary systems in high-demand contexts, as human behavior responds predictably to compensation, challenging assumptions that markets inherently corrupt benevolence.[](https://engagedscholarship.csuohio.edu/cgi/viewcontent.cgi?referer=\u0026httpsredir=1\u0026article=1056\u0026context=tdr)\n\n### Access Inequities and Systemic Biases\n\nRacial disparities persist in access to kidney transplantation in the United States, with Black patients facing lower rates of waitlisting and transplantation despite higher incidence of end-stage renal disease (ESRD). Black individuals are approximately 25% less likely to be waitlisted for transplant compared to White patients, even after adjusting for demographic, clinical, and socioeconomic factors. In 2020, White patients comprised 43% of kidney transplant recipients, while Black patients accounted for 26%, despite Blacks representing a disproportionate share of the ESRD population. Post-transplant, Black recipients experience worse graft survival rates compared to Whites. These patterns vary by age and region, with some studies indicating divergent trends where younger Black patients show narrowing gaps in waitlisting but persistent delays in transplantation.[](https://journals.lww.com/cjasn/fulltext/2021/02000/social_determinants_of_health_and_race_disparities.14.aspx)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12348215/)[](https://www.kidneyfund.org/sites/default/files/media/documents/addressing-disparities-in-transplantation_1.pdf)[](https://www.sciencedirect.com/science/article/abs/pii/S0966327425001170)\n\nGender inequities also affect transplant access, with women consistently less likely than men to receive kidneys at multiple stages of the process. Women with ESRD are up to 20% less likely to be referred for evaluation, activated on waitlists after referral, or receive living donor transplants. By 2017â€“2020, the disparity in living donor kidney transplantation had widened, with women 21% less likely to receive one compared to men (hazard ratio 0.79). Intersectional analyses reveal that White men exhibit the highest access across referral, waitlisting, and receipt of both living and deceased donor kidneys, while Black women face compounded barriers. Nephrologists have identified potential contributors including implicit biases in referral decisions and women's lower likelihood of pursuing living donation due to family roles, though empirical data underscores persistent gaps post-adjustment for clinical factors.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9174036/)[](https://www.ajkd.org/article/S0272-6386%2825%2900834-0/fulltext)[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03453-2)[](https://pubmed.ncbi.nlm.nih.gov/37471097/)\n\nSocioeconomic status exacerbates these inequities, correlating with reduced preemptive transplantation, prolonged dialysis dependence, and inferior graft outcomes. Patients from lower socioeconomic neighborhoods, as measured by indices like HOUSES, show significantly lower rates of preemptive kidney transplants, particularly among children. Low income, lack of private insurance, and residence in high-poverty areas independently predict delayed access, with Black patients disproportionately affected due to higher poverty prevalence (four-fold greater than Whites). Insurance status further influences outcomes, as publicly insured patients encounter barriers in evaluation and listing. These patterns hold after controlling for race, suggesting socioeconomic factors drive causal chains in referral and donor matching independent of, yet intertwined with, racial dynamics.[](https://pubmed.ncbi.nlm.nih.gov/39703725/)[](https://journals.lww.com/kidney360/fulltext/2025/07000/socioeconomic_disparities_in_preemptive_kidney.18.aspx)[](https://www.ajkd.org/article/S0272-6386%2899%2970404-X/fulltext)[](https://academic.oup.com/jamia/article/31/12/2781/7747707)\n\nGeographic disparities amplify access barriers through uneven organ supply and demand across United Network for Organ Sharing (UNOS) regions, resulting in wait times ranging from under 3 years in some areas to over 10 years in others. Regional variations account for a substantial portion of racial differences in waiting times, with minority-heavy areas like the Southeast exhibiting \"hot spots\" of prolonged delays. The 2014 Kidney Allocation System aimed to mitigate this by awarding points for multi-listing at distant centers, yet geographic mismatches persist, disproportionately impacting Black candidates whose distribution correlates with longer queues. Supply-demand imbalances, rather than solely policy flaws, underlie these inequities, as evidenced by modeling showing wait times extending to 52.6 months under expanded waitlists without supply increases.[](https://www.sciencedirect.com/science/article/pii/S0041134524004470)[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10078213/)[](https://www.amjtransplant.org/article/S1600-6135%2822%2925661-5/fulltext)\n\nSystemic biases manifest in allocation and evaluation processes, including historical use of race-adjusted glomerular filtration rate (eGFR) formulas that delayed Black patients' eligibility, now addressed by race-neutral alternatives. Disparities arise early, with Black patients less likely to receive timely referrals despite nephrologist awareness, potentially reflecting institutional inertia or unmeasured clinical hesitancy. Allocation prioritizes factors like wait time and expected post-transplant survival, inadvertently perpetuating inequities tied to dialysis duration and comorbidities more prevalent in disadvantaged groups. While some attribute gaps to overt discrimination, adjusted analyses reveal multifactorial origins, including HLA mismatch challenges in diverse populations and compliance variations, underscoring the need for causal dissection beyond correlative claims of bias. Peer-reviewed data from registries like UNOS provide robust evidence, though academic interpretations warrant scrutiny for overemphasizing social constructs over biological and logistical realities.[](https://www.nejm.org/doi/full/10.1056/NEJMp2512030?af=R\u0026rss=currentIssue)[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775070)[](https://www.kireports.org/article/S2468-0249%2823%2901419-5/fulltext)[](https://www.ncbi.nlm.nih.gov/books/NBK580030/)\n\n## Epidemiological Statistics\n\n### Global Transplant Trends and Volumes\n\nKidney transplantation accounts for the majority of solid organ transplants worldwide, comprising approximately 65% of the total in 2023.[](https://www.statista.com/topics/2389/organ-donations-and-transplants/) In that year, 111,135 kidney transplants were reported across 91 of 93 participating countries in the Global Observatory on Donation and Transplantation (GODT), reflecting data from regions covering a substantial portion of the global population.[](https://www.transplant-observatory.org/wp-content/uploads/2025/02/2023-data-global-report-20022025.pdf) This volume marked a notable rise from 102,090 kidney transplants in 2022, as documented in the prior GODT report covering 90 of 91 countries.[](https://www.transplant-observatory.org/wp-content/uploads/2023/11/2022-data-global-report_VF_2.pdf)\n\nGlobal volumes have shown consistent growth over the past decade, with kidney transplants increasing from around 80,000â€“90,000 annually in the mid-2010s to exceeding 100,000 by 2022, driven by expansions in both deceased and living donor programs.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/) Deceased donor kidney transplants constitute about 61% of the global total, though this proportion varies sharply by region: higher in high-income countries like the United States (where 28,142 kidney transplants occurred in 2023, predominantly deceased donor-derived) and lower in areas reliant on living donation, such as India, which performs 25% of worldwide living donor kidney transplants.[](https://journals.lww.com/transplantjournal/fulltext/2024/09001/405_5__the_need_for_rethinking_about_kidney.515.aspx) [](https://www.amjtransplant.org/article/S1600-6135%2825%2900026-7/fulltext) [](https://tts.org/news/tribune-pulse-weekly-newsletter/1520-tts-tribune-pulse-october-25-volume-viii-issue-42) Living donor rates average a median of 5 per million population globally, with extremes from near zero in some low-capacity nations to over 30 per million in outliers like Turkey.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9128615/)\n\nDespite the upward trend, coverage remains uneven, with Africa contributing only about 1% of global transplants in recent years due to infrastructural and regulatory limitations.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758520/) The overall 9% year-over-year increase in kidney transplant activity from 2022 to 2023 aligns with broader solid organ growth, attributed to policy enhancements in donor recruitment and allocation efficiency in reporting jurisdictions, though underreporting from non-participating or informal systems may underestimate true volumes.[](https://www.transplant-observatory.org/) Projections suggest continued modest expansion through 2030, contingent on addressing deceased donor shortages in developing regions, but empirical data indicate persistent gaps relative to the estimated 2â€“3 million annual end-stage kidney disease cases worldwide.[](https://pharm.ucsf.edu/kidney/need/statistics)\n\n### National Variations and Policy Impacts\n\nKidney transplant rates vary substantially across nations, influenced by policies on donor consent, allocation systems, and infrastructure. In 2023, Spain achieved the highest rate in Europe at 77.7 transplants per million population (pmp), attributed to its presumed consent (opt-out) system implemented since 1979, coupled with robust coordination via the National Transplant Organization.[](https://www.statista.com/statistics/537935/kidney-transplant-rate-in-europe/) In contrast, the United States recorded 77.0 pmp in 2021, leading globally in deceased donor rates at 38.0 pmp and deceased-donor kidney transplants at 55.6 pmp, driven by explicit consent (opt-in) policies but supported by advanced paired exchange programs and the Organ Procurement and Transplantation Network (OPTN).[](https://academic.oup.com/ndt/article/39/10/1593/7619140) [](https://unos.org/news/in-focus/us-world-leader-deceased-donor-rates/) Southeast Asian countries, however, averaged only 3.8 pmp in 2014, reflecting limited deceased donor frameworks and reliance on living donors amid cultural and regulatory barriers to posthumous donation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5481314/)\n\nOpt-out policies correlate with higher deceased donor rates in some analyses, yet causal evidence remains inconclusive, as confounding factors like public awareness campaigns and healthcare infrastructure play significant roles. For instance, opt-out nations exhibit elevated overall donation but lower living kidney donor transplants (4.5 pmp versus 15.2 pmp in opt-in countries), potentially due to greater emphasis on deceased procurement reducing incentives for living donation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9462118/) [](https://www.kidney-international.org/article/S0085-2538%2819%2930185-1/fulltext) Recent longitudinal studies, including evaluations post-policy shifts in countries like England (opting out since 2020), find no significant increase in donation rates attributable solely to defaults, underscoring that implementation quality and family override ratesâ€”often exceeding 40% even in opt-out systemsâ€”mitigate presumed consent effects.[](https://www.sciencedirect.com/science/article/pii/S003335062400355X) [](https://www.mpg.de/23726833/1113-bild-organ-donation-opt-out-defaults-do-not-increase-donation-rates-149835-x)\n\nPolicy reforms have demonstrably impacted access and equity. In the US, 2019â€“2021 OPTN revisions prioritizing longevity matching over wait time reduced geographic disparities and boosted transplants across demographics, with overall kidney transplants rising post-implementation without favoring specific groups.[](https://unos.org/news/in-focus/kidney-transplants-increase-across-all-populations-following-policy-changes/) European rates grew more modestly (+1.9% annually from 2012â€“2019) compared to the US (+4.3%), partly due to varied national allocation models emphasizing equity over utility in some regions.[](https://academic.oup.com/ndt/article/39/10/1593/7619140) In Asia, heterogeneous deceased donor lawsâ€”ranging from prohibition in some nations to regulated systems in othersâ€”constrain transplant volumes, particularly in lower-income settings where living donor chains predominate but raise ethical concerns over coercion.[](https://www.thelancet.com/journals/lansea/article/PIIS2772-3682%2823%2900172-5/fulltext) These variations highlight how policy design, independent of consent type, affects waitlist mortality, with higher-transplant nations like Spain and the US achieving lower per-capita dialysis burdens.[](https://www.transplant-observatory.org/wp-content/uploads/2025/02/2023-data-global-report-20022025.pdf)\n\n### Recent Data (2020â€“2025) and Projections\n\nIn the United States, kidney transplant volumes declined to 23,642 in 2020, primarily due to disruptions from the COVID-19 pandemic, which reduced deceased donor recoveries and elective procedures.[](https://pubmed.ncbi.nlm.nih.gov/35266618/) Recovery followed, with 25,549 transplants in 2021, rising to a record 26,309 in 2022 amid increased deceased donor activity.[](https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/7-transplantation)[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2022) Volumes peaked at 28,142 in 2023 before a slight dip to 27,759 in 2024, reflecting sustained growth in deceased donor kidneys (over 70% of totals) despite living donor numbers stabilizing around 6,000 annually.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/)[](https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/)\n\n| Year | Total Kidney Transplants (US) | Deceased Donor Share (Approx.) |\n|------|-------------------------------|-------------------------------|\n| 2020 | 23,642                       | ~80%                         |\n| 2021 | 25,549                       | ~77%                         |\n| 2022 | 26,309                       | ~75%                         |\n| 2023 | 28,142                       | ~75%                         |\n| 2024 | 27,759                       | ~75%                         |[](https://pubmed.ncbi.nlm.nih.gov/35266618/)[](https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/7-transplantation)[](https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2022)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/)[](https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/)\n\nGlobally, kidney transplants totaled approximately 102,149 in 2022, with kidneys comprising the majority of solid organ procedures amid uneven reporting from over 90 countries.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/) The transplant rate reached 18.5 per million population in 2023, up from 11 per million in 2011, driven by expansions in living and deceased donation in regions like Europe and Asia, though coverage remains limited to about 70% of countries with underdeveloped programs.[](https://www.statista.com/statistics/1083404/rate-of-kidney-transplant-activities-worldwide/) Living donor kidney transplants alone numbered 43,101 worldwide in 2023.[](https://www.transplant-observatory.org/wp-content/uploads/2024/12/2023-data-global-report-17122024.pdf)\n\nProjections indicate modest volume growth through 2030, constrained by persistent organ shortages; U.S. analyses suggest policy reforms in organ procurement could add up to 5,000 annual transplants by targeting underperforming centers.[](https://reconstrategy.com/2025/03/kidney-transplantation-improved-but-still-a-massive-missed-opportunity/) Globally, kidney replacement therapy needs are forecasted to affect 14.5 million people by 2030, with transplants meeting only a fraction due to supply limits, though conservative rate increases could avert 290,000 chronic kidney disease deaths yearly via expanded access.[](https://khi.asn-online.org/roadmap/kidney-diseases.aspx)00222-0/fulltext) Market analyses project the kidney transplant sector to grow at 4-6% CAGR to 2030, fueled by immunosuppression advances and paired exchange programs, but waitlist mortality underscores the need for supply-side innovations over demand-side expansions alone.[](https://www.grandviewresearch.com/industry-analysis/kidney-transplant-market-report)[](https://www.coherentmarketinsights.com/market-insight/kidney-transplant-market-4887)"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886979334,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Kidney Transplantation - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Furthermore, those who undergo transplantation often experience a better quality of life and a projected survival benefit of 10 years over those who remain onÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK567755/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Graft and Patient Survival Rates in Kidney Transplantation, and ...\",\"description\":\"In a study on 19 cases of kidney transplant patients in Germany, one-year graft survival rate was 94.7% (14). One-year graft survival rate was 85% in anotherÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8643514/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Joseph E. Murray â€“ Facts - NobelPrize.org\",\"description\":\"However, in 1954 Joseph Murray avoided rejection using radiotherapy and immunosuppressants, successfully transplanting a kidney between identical twins. ThisÂ ...\",\"url\":\"https://www.nobelprize.org/prizes/medicine/1990/murray/facts/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Joseph E. Murrayâ€”Nobel Prize for Organ Transplantation\",\"description\":\"He performed the first human kidney transplantation on December 23, 1954, in Boston, Mass. The transplantation occurred between identical twins.\",\"url\":\"https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962883-8/fulltext\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Acute Renal Transplantation Rejection - StatPearls - NCBI Bookshelf\",\"description\":\"Feb 9, 2023 Â· Renal transplant rejection, as stated earlier, is an immunological response that leads to inflammation with specific pathological changes in the allograft.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK553074/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Management of the patient with a failed kidney transplant - UpToDate\",\"description\":\"Aug 22, 2025 Â· ... kidney transplant is the increased risk of infection, malignancy, and complications associated with long-term immunosuppression use.\",\"url\":\"https://www.uptodate.com/contents/kidney-transplantation-in-adults-management-of-the-patient-with-a-failed-kidney-transplant\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Long-Term Infectious Complications of Kidney Transplantation - LWW\",\"description\":\"Worsening kidney allograft function after reduction of immunosuppression should prompt evaluation for possible graft rejection with a biopsy (19). AcuteÂ ...\",\"url\":\"https://journals.lww.com/cjasn/fulltext/2022/02000/long_term_infectious_complications_of_kidney.17.aspx\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Kidney Transplant | UCSF Department of Surgery\",\"description\":\"The success rate of kidney transplantation varies depending on whether the donated organ is from a living donor or a deceased donor as well as the medicalÂ ...\",\"url\":\"https://vascularsurgery.ucsf.edu/procedure/kidney-transplant-0\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Frequently asked questions about kidney transplant evaluation and ...\",\"description\":\"Waiting times for a deceased donor kidney transplant can vary greatly in different parts of the country, but waiting times of 4 to 5 years are common. SomeÂ ...\",\"url\":\"https://optn.transplant.hrsa.gov/patients/by-organ/kidney/frequently-asked-questions-about-kidney-transplant-evaluation-and-listing/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Historical Overview of Transplantation - PMC - PubMed Central - NIH\",\"description\":\"In 1933, the Soviet surgeon Yu Yu Voronoy performed the first human-to-human kidney transplant. That the kidney was not procured until 6 hours after the donor'sÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3684003/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Kidney transplantation: The journey across a century - PMC - NIH\",\"description\":\"The initial attempts of human to human kidney transplant were made by Yuri Voronoy, Jean Hamburger and several others between 1930 and 40s, but most of theseÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10654359/\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Review of the history of living donor solid organ transplants\",\"description\":\"May 15, 2024 Â· In 1906, the first two renal transplants in humans were performed by Jaboulay and colleagues using a pig donor for one and a goat donor for theÂ ...\",\"url\":\"https://www.eujtransplantation.com/article/view/403\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"The history of organ donation and transplantation - UNOS\",\"description\":\"In 1954, the kidney was the first human organ to be transplanted successfully. Until the early 1980s, the potential of organ rejection limited the number ofÂ ...\",\"url\":\"https://unos.org/transplant/history/\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Early Organ Transplant | LifeSource\",\"description\":\"Jun 16, 2020 Â· On June 17, 1950, Dr. Richard Lawler, Dr. James West and Dr. Raymond Murphy performed the first successful kidney transplant at Little Company of Mary Hospital.\u003c|separator|\u003e\",\"url\":\"https://www.life-source.org/latest/early-organ-transplant/\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"A transplant makes history - Harvard Gazette\",\"description\":\"Sep 22, 2011 Â· In 1954, Harvard surgeons at the Brigham performed the first successful organ transfer, a kidney exchanged between twins, opening a majorÂ ...\",\"url\":\"https://news.harvard.edu/gazette/story/2011/09/a-transplant-makes-history/\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"A Timeline of Kidney Transplantation - The Waring Historical Library\",\"description\":\"The first successful kidney transplanted from a deceased donor occurred in Boston - the kidney functioned for 21 months. This was the first use of the newÂ ...\",\"url\":\"https://waring.library.musc.edu/exhibits/kidney/Transplantation.php\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Immunosuppressants Used in Solid Organ Transplantation\",\"description\":\"Dec 22, 2006 Â· Azathioprine: Azathioprine (Imuran) was first used for transplantation in the early 1960s, initially in combination with steroids and laterÂ ...\",\"url\":\"https://www.uspharmacist.com/article/immunosuppressants-used-in-solid-organ-transplantation\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Kidney Transplantation: A History - Abdominal Key\",\"description\":\"Dec 26, 2019 Â· 1962, First use of tissue matching to select a donor and recipient ; 1966, Recognition that positive crossmatching leads to hyperacute rejection.Early Experiments Â· Human Kidney Transplants Â· The Middle YearsMissing:  milestones | Show results with:milestones\u003c|separator|\u003e\",\"url\":\"https://abdominalkey.com/kidney-transplantation-a-history/\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"History of kidney transplation - edren.org\",\"description\":\"Dec 19, 2018 Â· The first successful kidney transplant in UK was performed in Edinburgh by Sir Michael Woodruff and his team on 30th October, 1960.\",\"url\":\"https://edren.org/ren/unit/history/history-of-kidney-transplation/\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Cyclosporine: A Review - PMC - NIH\",\"description\":\"Oct 28, 2011 Â· Cyclosporine has no doubt revolutionized transplant medicine since its first clinical use in the late 1970s, improving rates of acute rejection and early graftÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3259474/\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Use of cyclosporine in renal transplantation - ScienceDirect.com\",\"description\":\"Since 1983, cyclosporine has been the backbone of immunosuppression in clinical organ transplantation. Cyclosporine is usually used in combination withÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0041134504001320\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"Modern Immunosuppression Regimens in Kidney Transplantation\",\"description\":\"The initial transplant armamentarium consisted only of azathioprine and steroids for maintenance immunosuppression in renal transplantation until the 1980's,Â ...\",\"url\":\"https://www.intechopen.com/chapters/41518\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"The role of tacrolimus in renal transplantation - PubMed - NIH\",\"description\":\"Tacrolimus gained FDA approval for use in liver transplantation in 1994 and ... approved for the prevention of acute rejection in kidney transplantation.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/18312164/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Evolution of Laparoscopic Donor Nephrectomy Techniques and ...\",\"description\":\"Feb 11, 2020 Â· In 1995, Ratner reported the first laparoscopic living-donor nephrectomy, which later became the accepted standard surgical technique for renalÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7034519/\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"The First 9 years of Kidney Paired Donation Through the National ...\",\"description\":\"The practice of kidney paired donation (KPD) is expanding annually, offering the opportunity for live donor kidney transplantation to more patients.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6165704/\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"Advances in Kidney Transplant, Machine Perfusion, and Viability ...\",\"description\":\"Combining perfusion technology with biomarkers has proven effective in predicting liver viability and increasing utilization rates. This innovative approach isÂ ...\",\"url\":\"https://www.mdpi.com/2673-8236/5/3/37\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"Machine Perfusion in Deceased Donor Kidney Transplantation\",\"description\":\"Jan 30, 2025 Â· Machine perfusion in deceased donor kidney transplantation: promises of improved outcomes but gaps in implementation.Missing:  innovations | Show results with:innovations\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2825%2900048-4/fulltext\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Normothermic Kidney Perfusion: Current Status and Future ...\",\"description\":\"Normothermic machine perfusion (NMP), the most recent advancement in solid organ preservation, enables ex situ maintenance of grafts in a physiologicallyÂ ...\",\"url\":\"https://www.kireports.org/article/S2468-0249%2825%2900413-9/fulltext\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Prolonged normothermic perfusion of the kidney prior to ... - Nature\",\"description\":\"May 17, 2025 Â· We successfully transplanted 36 kidneys after between two and 24 h normothermic machine perfusion following initial SCS, with a 100% 30-dayÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-025-59829-5\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Opportunities and challenges with the implementation of ... - Nature\",\"description\":\"Jul 25, 2025 Â· Kidney normothermic machine perfusion holds the promise to replace or shorten cold storage while enabling a thorough assessment of function andÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-025-60410-3\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Innovative immunosuppression in kidney transplantation - NIH\",\"description\":\"Due to the optimal results obtained in kidney transplantation and to the lack of interest of the industries, new innovative drugs in kidney transplantation are\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8968476/\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Kidney health innovations and research\",\"description\":\"Aug 11, 2025 Â· A new trial is testing a one-time cell therapy (MDR-101) that could help kidney transplant recipients live without anti-rejection drugs.\",\"url\":\"https://www.kidneyfund.org/kidney-health-innovations\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig ...\",\"description\":\"May 29, 2025 Â· Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation).\",\"url\":\"https://www.kidneymedicinejournal.org/article/S2590-0595%2825%2900077-9/fulltext\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Xenotransplantation of a Porcine Kidney for End-Stage Kidney ...\",\"description\":\"Feb 7, 2025 Â· The xenograft functioned immediately. The patient's creatinine levels decreased promptly and progressively, and dialysis was no longer needed.\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2412747\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"'We need this': Pig-to-human kidney transplants enter clinical trials\",\"description\":\"Jun 27, 2025 Â· A 3-year clinical trial with 50 patients is set to begin this year. In a first step toward FDA approval of kidney xenotransplantation, a livingÂ ...\",\"url\":\"https://www.healio.com/news/nephrology/20250627/we-need-this-pigtohuman-kidney-transplants-enter-clinical-trials\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Current Progress in Kidney Xenotransplantation: Time to Proceed to ...\",\"description\":\"Jul 9, 2025 Â· Although xenotransplantation, particularly from pigs, is a promising approach to address the donor shortage, significant challenges, such asÂ ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/iju.70173?af=R\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"End-Stage Renal Disease - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Jun 22, 2025 Â· The condition results from progressive loss of kidney function and is most commonly caused by diabetes mellitus, hypertension, and glomerularÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK499861/\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Systematic review: kidney transplantation compared with dialysis in ...\",\"description\":\"Individual studies indicate that kidney transplantation is associated with lower mortality and improved quality of life compared with chronic dialysis treatmentÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/21883901/\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"End Stage Renal Disease (Kidney Failure) | Columbia Surgery\",\"description\":\"The most common causes of kidney failure that necessitate kidney transplantation include: Diabetes, whether Type 1 (juvenile) or Type 2 (adult-onset), is theÂ ...\",\"url\":\"https://columbiasurgery.org/conditions-and-treatments/end-stage-renal-disease\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Kidney and Pancreas Patient Selection Criteria\",\"description\":\"Indications Â· Diabetes mellitus Â· Glomerular disease Â· Tubular and interstitial diseases Â· Renovascular and other vascular diseases Â· Congenital, rare familial andÂ ...\",\"url\":\"https://www.hopkinsmedicine.org/transplant/referring-physicians/kidney-pancreas-transplant-criteria\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"End Stage Kidney Disease and Transplant: General Information\",\"description\":\"ESRD is when the kidneys completely stop working and cannot filter and remove waste. ESRD can be caused by: Alport's Syndrome, infection, drug toxicity, heavyÂ ...\",\"url\":\"https://www.myast.org/caregiver-toolkit/end-stage-kidney-disease-and-transplant-general-information\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Am I a Candidate For a Kidney Transplant? - Cleveland Clinic\",\"description\":\"Initial Indications That I May Be a Candidate Â· Patients with End-Stage Kidney Disease on dialysis. Â· Patients with advanced chronic kidney disease (stage IV or VÂ ...\",\"url\":\"https://my.clevelandclinic.org/departments/transplant/programs/kidney/candidate\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Indications and contraindications of living-donor kidney transplantation\",\"description\":\"The principal indication of living kidney donor transplant is preemptive transplant. This will allow the patient to avoid the complications of dialysis.\u003c|separator|\u003e\",\"url\":\"https://www.revistanefrologia.com/en-indications-contraindications-living-donor-kidney-transplantation-articulo-X2013251410051408\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"End-Stage Renal Disease (ESRD) - Children's Hospital Colorado\",\"description\":\"ESRD is kidney (â€œrenalâ€) disease that has become so severe and irreversible that patients require dialysis and ultimately, a transplant. Learn more.\u003c|separator|\u003e\",\"url\":\"https://www.childrenscolorado.org/conditions-and-advice/conditions-and-symptoms/conditions/end-stage-renal-disease/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Kidney Transplantation: Background, Indications, Contraindications\",\"description\":\"Dec 17, 2021 Â· Kidney transplantation is the treatment of choice for a minority of patients with end-stage renal disease (ESRD).Background Â· Indications Â· Contraindications\",\"url\":\"https://emedicine.medscape.com/article/430128-overview\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"KDIGO Clinical Practice Guideline on the Evaluation and... - LWW\",\"description\":\"1.1.1: Refer potential kidney transplant candidates for evaluation at least 6 to 12 months before anticipated dialysis initiation to facilitate identification/Â ...\",\"url\":\"https://journals.lww.com/transplantjournal/fulltext/2020/04001/kdigo_clinical_practice_guideline_on_the.9.aspx\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Evaluation for Kidney Transplant\",\"description\":\"A medical and surgical history. The transplant team will review your medical history carefully. Â· A physical exam. Â· A psychosocial exam. Â· Compatibility tests.\",\"url\":\"https://www.kidney.org/kidney-topics/evaluation-kidney-transplant\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"KDIGO Clinical Practice Guideline on the Evaluation and Care of ...\",\"description\":\"Evaluation of candidates for living kidney donation requires balancing ethical principles of autonomy, beneficence, nonmaleficence, voluntarism and justice.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5540357/\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"The Evaluation of Kidney Function in Living Kidney Donor Candidates\",\"description\":\"This article reviews the different methods of GFR assessment, including eGFR, creatinine clearance, and measured GFR, and the current guidelines on GFRÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8786144/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Evaluation of Kidney Donors: Core Curriculum 2018\",\"description\":\"Jan 11, 2018 Â· This installment of AJKD's Core Curriculum in Nephrology provides readers with the tools necessary for proper evaluation of living kidney donor candidates.\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2817%2931078-8/fulltext\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Guidance for the Development of Program-Specific Living Kidney ...\",\"description\":\"The donor evaluation includes psychosocial and medical components. These evaluations should help determine if an individual is a suitable donor. TheÂ ...\",\"url\":\"https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/guidance-for-the-development-of-program-specific-living-kidney-donor-medical-evaluation-protocols/\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Long-Term Risks of Living Kidney Donation - Annual Reviews\",\"description\":\"Jan 27, 2025 Â· Available evidence supports small increases in the risks of end-stage kidney disease and hypertensive disorders of pregnancy in living donors.\",\"url\":\"https://www.annualreviews.org/content/journals/10.1146/annurev-med-050223-112648\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Updates to living donor exclusion criteria now in effect - UNOS\",\"description\":\"Jul 26, 2022 Â· Diabetes exclusion criterion. Policy maintains type 1 diabetes as an absolute contraindication to living kidney donation; Policy specifiesÂ ...\",\"url\":\"https://unos.org/news/policy-changes/updates-to-living-donor-exclusion-criteria-now-in-effect/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Living Kidney Donor - KDIGO\",\"description\":\"The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors is intended to assistÂ ...\",\"url\":\"https://kdigo.org/guidelines/living-kidney-donor/\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Thirty-Year Trends in Perioperative Mortality Risk for Living Kidney ...\",\"description\":\"Aug 28, 2024 Â· The best current estimate, 3.1 deaths within 90 days per 10 000 donations, comes from a study of donors from 1994 to 2009. Open donorÂ ...\",\"url\":\"https://jamanetwork.com/journals/jama/article-abstract/2822922\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Donor nephrectomy - Mayo Clinic\",\"description\":\"Jan 11, 2024 Â· In a living-donor laparoscopic nephrectomy, the surgeon uses a special camera called a laparoscope to view the internal organs and guide theÂ ...\",\"url\":\"https://www.mayoclinic.org/tests-procedures/donor-nephrectomy/about/pac-20384867\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Surgical Approaches and Outcomes in Living Donor Nephrectomy\",\"description\":\"To review different surgical techniques for living donor nephrectomy and compare complication rates, warm ischemia time, and delayed graft function.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S240545692200075X\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"UC Davis Health performs first robotic nephrectomy on living kidney ...\",\"description\":\"Apr 5, 2023 Â· Traditionally, living donor nephrectomies have been performed using either a laparoscopic technique or open surgery. Robotic-assisted proceduresÂ ...\u003c|separator|\u003e\",\"url\":\"https://health.ucdavis.edu/news/headlines/uc-davis-health-performs-first-robotic-nephrectomy-on-living-kidney-donor/2023/04\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Comparison of Surgical Techniques in Living Donor Nephrectomy\",\"description\":\"Oct 30, 2020 Â· We performed a meta-analysis to compare 4 surgical techniques: open LDN (OLDN), laparoscopic LDN (LLDN), hand-assisted LLDN (HALLDN), and robot-assisted LLDN (Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7607668/\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Long-Term Risks of Living Donation - National Kidney Foundation\",\"description\":\"Aug 27, 2024 Â· Research has shown that donating your kidney doesn't shorten your life. Some studies have found that living donors live longer than the averageÂ ...\",\"url\":\"https://www.kidney.org/kidney-topics/long-term-risks-living-donation\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Evaluating Risk in Kidney Living Donors - PMC - NIH\",\"description\":\"Feb 26, 2025 Â· Studies indicate that 86%â€“98% of kidney donors would choose to donate again [2, 5]. The health risks to the donor are minimal compared to theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11896807/\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"New Living Kidney Donor Program Requirements\",\"description\":\"The new donor follow-up policy requires that donor data be collected within 60 days of the 6 month, one-year, and two-year reporting periods.Missing:  criteria | Show results with:criteria\",\"url\":\"https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/new-living-kidney-donor-program-requirements-standardizing-patient-care/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Organ procurement in a deceased donor - PMC - PubMed Central\",\"description\":\"A proper surgical technique for the procurement of an organ graft from a deceased donor must be carried out to avoid any damage to it.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9186815/\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Management of the deceased organ donor - UpToDate\",\"description\":\"Management of the potential organ donor primarily involves the use of conventional therapeutic and supportive measuresÂ ...\",\"url\":\"https://www.uptodate.com/contents/management-of-the-deceased-organ-donor\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"New National Allocation Policy for Deceased Donor Kidneys in ... - NIH\",\"description\":\"The KDPI takes into account donor age, height, weight, ethnicity, history of hypertension and diabetes, cause of death, serum creatinine level, hepatitis CÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4116061/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Standard Criteria Donors (SCD) | Transplant Center - UC Davis Health\",\"description\":\"The standard criteria donor (SCD) is an organ donor who is under 50 years of age and suffered brain death from any number of causes.\",\"url\":\"https://health.ucdavis.edu/transplant/nonlivingdonors/standard-criteria-donors.html\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Increased Kidney Transplantation Utilizing Expanded Criteria ...\",\"description\":\"Expanded criteria deceased organ donors (ECD) are a source of kidneys that permit more patients to benefit from transplantation. ECD is defined as all deceasedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC1356277/\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Establish Minimum Kidney Donor Criteria to Require Biopsy - OPTN\",\"description\":\"OPOs will be required to perform a kidney biopsy on deceased organ donors who meet any of the following, excluding donors less than 18 years old.\",\"url\":\"https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/establish-minimum-kidney-donor-criteria-to-require-biopsy/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Implementation notice: Minimum kidney donor criteria established ...\",\"description\":\"Sep 6, 2022 Â· This policy establishes deceased kidney donor criteria for when OPOs are required to perform a procurement biopsy. OPOs must make a reasonableÂ ...\",\"url\":\"https://unos.org/news/implementation-minimum-kidney-donor-biopsy-criteria/\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Organ Retrieval - TeachMeSurgery\",\"description\":\"Aug 11, 2025 Â· Organs are retrieved from cadaveric donors who expressed their wish to donate in their life or if the donor's family decides to consent, as longÂ ...Deceased Donation Â· Expanding The Donor Pool For... Â· Retrieval Operation\",\"url\":\"https://teachmesurgery.com/transplant-surgery/core-concepts/organ-retrieval/\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Deceased Organ Donation Process - UNOS\",\"description\":\"The donor is taken to an operating room, where organs are surgically removed. After that, the organs are sent to the transplant hospitals where candidates areÂ ...Intensive Care Â· Placement Â· Organ Recovery\",\"url\":\"https://unos.org/transplant/deceased-donation/\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Transplantation Organ retrieval and preservation - ScienceDirect.com\",\"description\":\"Thoracic and abdominal organs from deceased donors are retrieved during a multi-organ procedure. The organs are flushed and cooled in situ with preservationÂ ...Transplantation Â· Types Of Donor Â· Deceased Donor Organ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0263931923001485\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"[PDF] OPTN Policies Effective as of October 1, 2025\",\"description\":\"A set of KPD matches that begins with a donation from a non-directed living donor to that KPD donor's matched candidate. This candidate's paired living donorÂ ...\",\"url\":\"https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Update Kidney Paired Donation Policy - OPTN - HRSA\",\"description\":\"Jul 25, 2022 Â· The OPTN's Kidney Paired Donation Pilot Program (KPDPP) is a national KPD program that is governed by OPTN Policy 13: Kidney Paired Donation.Missing:  opt- laws\",\"url\":\"https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/update-kidney-paired-donation-policy/\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"National Kidney Registry Reports Superior Transplant Outcomes\",\"description\":\"Apr 2, 2025 Â· Sensitized patients (\u003e 80% cPRA) experienced a 38% lower 3-year death-censored graft failure rate compared to non-NKR transplant recipients.\",\"url\":\"https://www.kidneyregistry.com/news/national-kidney-registrys-2025-outcomes-report-highlights-superior-kidney-transplant-success-rates/\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Quarterly Reports | National Kidney Registry\",\"description\":\"We are pleased to report strong growth with 760 KPD transplants facilitated in 2019, an increase of 22% or 141 KPD transplants over the prior year. NKRÂ ...\",\"url\":\"https://www.kidneyregistry.com/news-category/quarterly-reports/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Kidney Exchange Match Rates in a Large Multicenter Clearinghouse\",\"description\":\"Matching into a KPD transplant was the most frequent outcome among NKR registrants. At 3, 6, and 12 months, 32%, 38%, and 46% of candidates underwent NKR-Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6082363/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Opt-out legislations: the mysterious viability of the false\",\"description\":\"This is the case of Spain, the country with by far the highest organ donation rates since 1992, with 48 donors per million population in 2018 (Figure 1). It isÂ ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2819%2930298-4/fulltext\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Decadal Analysis of Deceased Organ Donation in Spain and the ...\",\"description\":\"After the foundation of the National Transplant Organization, Spanish rates of deceased donor donation rapidly outpaced. US growth over the decade from 1989Â ...\u003c|separator|\u003e\",\"url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23684\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"'Relative Consent' or 'Presumed Consent'? Organ donation attitudes ...\",\"description\":\"Using data from 28 European countries for the period 2002â€“2010, we found that presumed consent (PC) policies are associated with increased willingness to donateÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7822792/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Spain has a lesson for the rest of the world about organ donation\",\"description\":\"Jun 27, 2018 Â· In Spain policy, infrastructure and systems all combine to give it the highest organ donation rates in the world.\",\"url\":\"https://www.weforum.org/stories/2018/06/spain-leads-the-world-in-organ-donation-what-s-stopping-other-countries-catching-up/\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"NKF Applauds New Proposed Rules to Increase Organ Donation\",\"description\":\"Proposed rules include expanding financial aid for living donors, quality metrics for OPOs, and encouraging use of less than perfect deceased donor organs.Missing:  paired | Show results with:paired\",\"url\":\"https://www.kidney.org/press-room/nkf-applauds-new-proposed-rules-to-increase-organ-donation\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Use of Machine Perfusion to Increase the Number of Expanded ...\",\"description\":\"They found that using HMP for ECD kidneys and static cold storage (SCS) for standard criteria donors: Increased transplants by 1123. Decreased patients onÂ ...\",\"url\":\"https://www.organ-recovery.com/use-of-machine-perfusion-to-increase-the-number-of-expanded-criteria-deceased-donor-kidney-transplants-a-pharmacoeconomic-analysis/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Use of Machine Perfusion to Increase the ... - Transplantation Direct\",\"description\":\"Using machine perfusion may reduce the discard rate, increase the number of transplants, and reduce mortality on the waiting list.\",\"url\":\"https://journals.lww.com/transplantationdirect/fulltext/2024/08000/use_of_machine_perfusion_to_increase_the_number_of.3.aspx\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Normothermic machine perfusion expands kidney donor pool\",\"description\":\"Jun 17, 2024 Â· â€œNMP helps us check and use kidneys that might otherwise be declined, turning potential missed opportunities into life-saving transplants,â€ saidÂ ...\",\"url\":\"https://thelimbic.com/nephrology/normothermic-machine-perfusion-expands-kidney-donor-pool/\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"New technology could increase donor kidneys for transplants\",\"description\":\"Sep 18, 2024 Â· UC Davis Health researchers study novel technology to use kidneys previously considered unsuitable for transplant.\",\"url\":\"https://health.ucdavis.edu/news/headlines/new-technology-could-increase-donor-kidneys-for-transplants/2024/09\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Normothermic Kidney Perfusion: Current Status and Future ...\",\"description\":\"Jun 26, 2025 Â· Normothermic machine perfusion (NMP), the most recent advancement in solid organ preservation, enables ex situ maintenance of grafts in aÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12446984/\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Machine Perfusion in Deceased Donor Kidney Transplantation\",\"description\":\"Feb 6, 2025 Â· There is, however, growing evidence from retrospective studies that NRP appears to improve post-transplant kidney outcomes.\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2825%2900047-2/fulltext\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"The Individual Impact of Machine Perfusion on Liver and Kidney on ...\",\"description\":\"Sep 8, 2025 Â· Several MP technologies to optimize organ preservation, such as hypothermic machine perfusion (HMP) or normothermic machine perfusion (NMP) haveÂ ...\",\"url\":\"https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14807/full\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Xenotransplantation: Current Challenges and Emerging Solutions\",\"description\":\"The main obstacle facing xenotransplants is immunological reactions. Although the mechanism behind hyperacute rejection (HAR) in the xenograft is well defined,Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9846288/\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Surgeons Perform Second Pig Kidney Transplant at Massachusetts ...\",\"description\":\"Feb 7, 2025 Â· Team that performed first-of-its-kind surgery in 2024 has successfully transplanted another genetically edited pig kidney into a living person.\",\"url\":\"https://hms.harvard.edu/news/surgeons-perform-second-pig-kidney-transplant-massachusetts-general-hospital\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Massachusetts General Hospital Performs Second Groundbreaking ...\",\"description\":\"Feb 7, 2025 Â· eGenesis also provided the pig organ for the world's first kidney xenotransplant in 2024 conducted at MGH. Apellis Pharmaceuticals of Waltham,Â ...\",\"url\":\"https://www.massgeneral.org/news/press-release/mgh-performs-second-xenotransplant-of-genetically-edited-pig-kidney-into-living-recipient\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Gene-Edited Pig Kidney Gives Living Donor New Lease on Life\",\"description\":\"Dec 17, 2024 Â· Six human transgenes were added to make the gene-edited pig kidney more compatible with the human recipient and reduce the likelihood ofÂ ...\u003c|separator|\u003e\",\"url\":\"https://nyulangone.org/news/gene-edited-pig-kidney-gives-living-donor-new-lease-life\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"United Therapeutics Corporation Announces FDA Clearance of its ...\",\"description\":\"Feb 3, 2025 Â· United Therapeutics expects the first xenotransplant in this trial to be performed around mid-year 2025. According to the American Kidney Fund,Â ...\",\"url\":\"https://ir.unither.com/press-releases/2025/02-03-2025-120011819\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Opinions on the Future of Clinical Pig Kidney Xenotransplantation\",\"description\":\"Nov 25, 2024 Â· Using different variants of genetically modified pig kidneys, it has been demonstrated that pig xenotransplants can maintain renal function andÂ ...\",\"url\":\"https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13475/full\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Research on gene editing and immunosuppressants in kidney ...\",\"description\":\"This article mainly explores the effects of the NHP xenograft gene editing scheme and immunosuppressants on prolonging transplant survival time.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0966327425000127\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"A tipping point for kidney xenotransplantation | Nature Medicine\",\"description\":\"Jul 14, 2025 Â· Although kidney xenotransplantation has come a long way over the past few years, its clinical success is still far from assured. One lessonÂ ...\",\"url\":\"https://www.nature.com/articles/s41591-025-03855-9\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Vascularized Bioengineered Kidney Using Decellularized Scaffold ...\",\"description\":\"Jul 15, 2025 Â· We developed a vascularized bioengineered kidney by recellularizing DKS with hPASCs and KIO using a circulation perfusion culture system.Missing:  2024 | Show results with:2024\",\"url\":\"https://www.biorxiv.org/content/10.1101/2025.07.10.664023v1\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Surface modification of decellularized kidney scaffold with ... - PubMed\",\"description\":\"Dec 11, 2024 Â· This study underscores a recellularization strategy that addresses the challenges associated with constructing bio-artificial kidneys.Missing:  progress | Show results with:progress\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39674100/\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Current strategies on kidney regeneration using tissue engineering ...\",\"description\":\"Feb 11, 2025 Â· Kidney regeneration uses decellularization, often from whole organs, to create scaffolds. Recellularization with cells is then performed.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11816546/\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"Effective and new technologies in kidney tissue engineering - Frontiers\",\"description\":\"This article reviews recent advances in kidney tissue engineering, focusing on engineered structures such as hydrogels, electrospinning, 3D bioprinting, andÂ ...\",\"url\":\"https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1476510/full\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Application of decellularization methods for scaffold production\",\"description\":\"Decellularization is a technique that removes cells and immunogenic components from tissues and organs while maintaining the natural extracellular matrix (ECM)Â ...\u003c|separator|\u003e\",\"url\":\"https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1621641/full\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"HLA Matching Should Be Reconsidered in Modern Deceased Donor ...\",\"description\":\"Feb 21, 2022 Â· In particular, matching at the HLA-A, -B, and -DR loci has been shown to increase graft survival compared with nonmatched organs.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8966965/\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"HLA mismatch is important for 20-year graft survival in kidney ...\",\"description\":\"HLAs play a pivotal role in the cellular and humoral immune responses after renal transplantation and, therefore, in determining the outcome of the transplantsÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0966327423000783\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"High-resolution HLA genotyping improves PIRCHE-II assessment of ...\",\"description\":\"In kidney transplantation, HLA matching is associated with lower rates of de novo DSA (dnDSA) formation, reduced allograft rejection and improved allograftÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0198885924000739\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Clinical Applicability of 2â€Field Highâ€Resolution and Extended HLA ...\",\"description\":\"Dec 5, 2024 Â· HLA-compatibility remains an important triage test for deceased donor kidney allocation. Lowâ€“intermediate resolution donor HLA-typing isÂ ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/tan.15784\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Significance of HLA-DQ in kidney transplantation: time to reevaluate ...\",\"description\":\"Jul 7, 2021 Â· We address the implications of reduced HLA matching policies in kidney allocation. We highlight the observed diminished outcome data, the significant financialÂ ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2821%2900657-8/fulltext\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Maximizing matching, equity and survival in kidney transplantation ...\",\"description\":\"HLA matching improves long-term outcomes of kidney transplantation, yet implementation challenges persist, particularly within the African American (Black)Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0010482524005365\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"The Role of the Crossmatch in Kidney Transplantation\",\"description\":\"Immunogenetic characterization of the transplant recipient with crossmatch is used to minimize graft loss by detecting preformed antibodies.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7462663/\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"Overview of HLA sensitization and crossmatch testing - UpToDate\",\"description\":\"Sep 18, 2025 Â· (See \\\"Kidney transplantation in adults: HLA matching and outcomes\\\".) â—‹(See \\\"Kidney transplantation in adults: Prevention and treatment ofÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.uptodate.com/contents/kidney-transplantation-in-adults-overview-of-hla-sensitization-and-crossmatch-testing\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Principles of Virtual Crossmatch Testing for Kidney Transplantation\",\"description\":\"A crossmatch test is a test that determines the immunologic risk of a recipient with a potential donor by ensuring that there are no transplant-relevantÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9171621/\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Overcoming a Positive Crossmatch in Livingâ€Donor Kidney ...\",\"description\":\"Our results suggest that selected crossmatchâ€positive patients can be transplanted successfully with livingâ€donor kidney allografts, using a protocol ofÂ ...\",\"url\":\"https://www.amjtransplant.org/article/S1600-6135%2822%2907334-8/fulltext\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Crossmatch assays in transplantation: Physical or virtual?: A review\",\"description\":\"Dec 15, 2023 Â· The crossmatch tests in transplantation can be physical or virtual, each with its advantages and limitations.\",\"url\":\"https://journals.lww.com/md-journal/fulltext/2023/12150/crossmatch_assays_in_transplantation__physical_or.85.aspx\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Preventing hyperacute rejection in a deceased donor kidney ...\",\"description\":\"Virtual crossmatch (VXM) is a process of assessing HLA compatibility by evaluating donor HLA typing and recipient's pre-transplant anti-HLA antibody profile,Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0198885925000941\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Does HLA matching matter in the modern era of renal transplantation?\",\"description\":\"Dec 9, 2019 Â· In this review, we discuss the relative importance of HLA matching compared with donor quality; and long-term patient outcomes including re-transplantationÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7701071/\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"Kidney allocation system - OPTN - HRSA\",\"description\":\"KAS was developed in response to higher-than-necessary discard rates of kidneys, variability in access to transplants for candidates who are harder to match.Missing:  details | Show results with:details\",\"url\":\"https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"The New Kidney Allocation System (KAS) Frequently Asked Questions\",\"description\":\"In the new allocation system, prioritization points will be assigned based on a sliding scale, beginning with a CPRA score of 20%. Candidates with CPRA of 20%Â ...Why KAS is necessary; Key... Â· Waiting Time Â· Kidney Donor Profile Index... Â· EPTS\",\"url\":\"https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/the-new-kidney-allocation-system-kas-frequently-asked-questions/\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"[PDF] The New Kidney Allocation System (KAS): The First Six(+) Months\",\"description\":\"Dec 2, 2015 Â· Kidney discard rates increased by 1.7% points (about 10%). ... Post-KAS offer and accept. rates by EPTS score. â–« Surprisingly, offer ratesÂ ...\",\"url\":\"https://unos.org/kidney-allocation-system-kas-data_dec-2015/\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"Computational Eurotransplant kidney allocation simulations ...\",\"description\":\"Jul 27, 2021 Â· The EuroTransplant Kidney Allocation System (ETKAS) aims at allocating organs to patients on the waiting list fairly whilst optimizing HLAÂ ...\",\"url\":\"https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009248\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"The new French kidney allocation system for... - Ovid\",\"description\":\"In France, the Agence de la BiomÃ©decine is responsible for managing waiting lists and organ allocation. In recent decades, many countries have used stepwiseÂ ...\",\"url\":\"https://www.ovid.com/journals/ajtr/fulltext/10.1111/ajt.17180~the-new-french-kidney-allocation-system-for-donations-after\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Kidney Organ Allocation System: How to Be Fair - ScienceDirect.com\",\"description\":\"Jul 5, 2022 Â· The kidney organ allocation systems in the United States, Australia, and Hong Kong are used as illustrations.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0270929522000560\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"Global trends and challenges in deceased donor kidney allocation\",\"description\":\"This review examined the allocation schemes of several countries in which deceased donor kidney transplantation is an accepted and well-established practice. InÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0085253817300753\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Continuous Distribution of Kidneys, Winter 2025 - OPTN - HRSA\",\"description\":\"The continuous distribution of kidneys aims to provide a more equitable approach, remove hard boundaries, and improve kidney allocation efficiency.\",\"url\":\"https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/continuous-distribution-of-kidneys-winter-2025/\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"May 2025: Annual kidney allocation calculator updates\",\"description\":\"May 21, 2025 Â· The reference population used to calculate a deceased organ donor's kidney donor profile index (KDPI) has been updated, effective May 21, 2025.Missing:  algorithm details\",\"url\":\"https://optn.transplant.hrsa.gov/news/may-2025-annual-kidney-allocation-calculator-updates/\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"Modernizing the Design Process for US Organ Allocation Policy\",\"description\":\"Aug 22, 2025 Â· The new approach uses a faster simulation algorithm and multiobjective optimization to design continuous distribution policies for kidneys,Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12377324/\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"The New Distance-Based Kidney Allocation System - NIH\",\"description\":\"Oct 13, 2022 Â· The KAS 250 allocation policy changed the geographic basis of deceased donor kidney distribution in a manner that is intended to reduceÂ ...Missing:  points | Show results with:points\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9558035/\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Increasing Incidence of Out-of-Sequence Allocation of... - Kidney360\",\"description\":\"OOS allocation is increasingly common 2 , 3 because of regulatory pressure on OPOs to recover more kidneys, maximize organ use, 2 , 4 and address late turndownsÂ ...Missing:  details | Show results with:details\",\"url\":\"https://journals.lww.com/kidney360/fulltext/2025/01000/increasing_incidence_of_out_of_sequence_allocation.19.aspx\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Determinants of Long Waiting Time to Kidney Transplantation\",\"description\":\"Consequently, waiting times for kidney transplant are increasing with \u003e30% of candidates spending more than 3 years on the waiting list in 2021 [1].\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0041134524004470\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"The impact of systematic review of status 7 patients on the kidney ...\",\"description\":\"May 16, 2019 Â· Mortality is higher for inactive patients as compared to those active on the list [2, 3]. By the end of 2016, 30% of nearly 100,000 patientsÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1362-6\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Balancing Equity and Efficiency Considerations in Kidney Allocation\",\"description\":\"A concept document proposing changes to the kidney allocation algorithm, sparking a heated debate about priority-setting of scarce health resources andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3203330/\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Radical Transparency to Improve Equity in the Kidney Allocation ...\",\"description\":\"Transplants centers and OPOs typically cite the need for flexibility to deviate from algorithmic allocation priority to ensure that patients toward the topÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10833597/\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"The Effect of Donor-Recipient Pairing on Kidney Transplant Outcomes\",\"description\":\"It has been shown that patients might be negatively impacted by suboptimal HLA matching if their first kidney transplant fails, because this may cause increasedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6218811/\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Diminishing Significance of HLA Matching in Kidney Transplantation\",\"description\":\"Pooled censored and uncensored graft survival rates were 90.6% and 89.9% at 1 year, 85.8% and 84.5% at 2 years, and 80.7% and 78.6% at 3 years. HLA matchingÂ ...\",\"url\":\"https://www.amjtransplant.org/article/S1600-6135%2822%2907940-0/fulltext\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"The Progress and Challenges of Implementing HLA Molecular ...\",\"description\":\"Aug 12, 2025 Â· For deceased donor allocation, high resolution HLA typing is required at the time of allocation. Clinical studies with clear pre-definedÂ ...\",\"url\":\"https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14716/full\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Identify Priority Shares in Kidney Multi-Organ Allocation - OPTN\",\"description\":\"Considerations for kidney-alone prioritization should include highly sensitized patients, pediatric patients, medically urgent patients with exhausted accessÂ ...\",\"url\":\"https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/identify-priority-shares-in-kidney-multi-organ-allocation/\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Characterization of Transplant Center Decisions to Allocate Kidneys ...\",\"description\":\"Jun 5, 2023 Â· These findings suggest that transplant centers frequently skip over candidates to place kidneys with recipients with lower allocation priority, with limitedÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805570\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Navigating challenges in recipient selection for end-chain kidneys\",\"description\":\"Our strategy used to be selecting candidates at the top of waitlist, however, in addition to missing opportunities for longevity or HLA matching, we observedÂ ...\",\"url\":\"https://www.amjtransplant.org/article/S1600-6135%2824%2900678-6/fulltext\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"Navigating challenges in recipient selection for end-chain kidneys\",\"description\":\"We discuss 3 potential approaches for recipient selection: (1) adherence to the kidney allocation system, (2) utility maximization; and (3) priority to high-Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39490413/\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"The impact of multi-organ transplant allocation priority on waitlisted ...\",\"description\":\"Kidney-alone transplant (KAT) candidates may be disadvantaged by the allocation priority given to multi-organ transplant (MOT) candidates.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1600613522085914\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"Allocating organs through algorithms and equitable access to ...\",\"description\":\"At the transnational level, the Eurotransplant algorithm ensures a 'genuine distribution across the participating countries'. Disparities also exist at theÂ ...Missing:  major | Show results with:major\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10065754/\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"Operations Research to Solve Kidney Allocation Problems - NIH\",\"description\":\"Mar 6, 2023 Â· A blood-type-based matching scheme is also widely implemented, which entails the prioritization of transplant candidates with identical bloodÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10000664/\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Optimizing kidney allocation: challenges and solutions - PubMed\",\"description\":\"Challenges in designing a system assured to improve, not worsen, placement efficiency have hampered progress. OPO and transplant center practiceÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40040564/\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Kidney transplant - Mayo Clinic\",\"description\":\"Sep 5, 2025 Â· A kidney transplant can treat ongoing kidney disease or end-stage renal disease to help you feel better and live longer. Compared with dialysis,Â ...Deceased-donor kidney... Â· Preemptive kidney transplant\",\"url\":\"https://www.mayoclinic.org/tests-procedures/kidney-transplant/about/pac-20384777\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Surgical Strategies for Renal Transplantation: A Pictorial Essay - PMC\",\"description\":\"Jul 17, 2024 Â· Orthotopic RT is an alternative surgical technique for kidney transplantation in patients who are unsuitable for standard heterotopic RT in theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11278135/\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"Outcomes of Simultaneous Pancreas-Kidney Transplantation ... - NIH\",\"description\":\"Simultaneous pancreas-kidney transplantation (SPK) is one of the treatment options for type 1 diabetes mellitus (T1DM) patients with end-stage renal disease (Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3087789/\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"Clinical outcomes of simultaneous pancreas-kidney transplantation\",\"description\":\"This study evaluated the outcomes of simultaneous pancreas-kidney transplantation (SPK) at Fukushima Medical University between 2001 and 2024.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12079050/\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"Simultaneous pancreas-kidney transplantation for end-stage renal ...\",\"description\":\"Cardiovascular outcomes after simultaneous pancreas kidney transplantation compared to kidney transplantation alone: a propensity score matching analysisÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10514751/\",\"favicon\":\"\"},{\"id\":\"148\",\"title\":\"Improved surgical outcomes following simultaneous pancreas ...\",\"description\":\"Improved surgical outcomes following simultaneous pancreas-kidney transplantation in the contemporary era. Clin Transplant. 2022 Nov;36(11):e14792. doiÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/36029250/\",\"favicon\":\"\"},{\"id\":\"149\",\"title\":\"Long-term outcomes in simultaneous pancreas-kidney transplantation\",\"description\":\"In this limited retrospective analysis of outcomes after simultaneous pancreas-kidney transplantation, the importance of donor selection is re-emphasized. DonorÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/15387113/\",\"favicon\":\"\"},{\"id\":\"150\",\"title\":\"More than 25 years of pancreas graft survival after simultaneous ...\",\"description\":\"Simultaneous pancreas-kidney transplantation: The role in the treatment of type 1 diabetes and end-stage renal disease. Can Urol Assoc J. 2014;8(3â€“4):135Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8693781/\",\"favicon\":\"\"},{\"id\":\"151\",\"title\":\"Favorable Outcomes in Older Recipients Receiving Simultaneous ...\",\"description\":\"Favorable Outcomes in Older Recipients Receiving Simultaneous Pancreas Kidney Transplantation. Transplant Direct. 2022 Nov 17;8(12):e1413Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/36406897/\",\"favicon\":\"\"},{\"id\":\"152\",\"title\":\"Combined liver-kidney transplantation for rare diseases - PMC\",\"description\":\"Combined liver and kidney transplantation (CLKT) is indicated in patients with failure of both organs, or for the treatment of end-stage chronic kidney diseaseÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7643210/\",\"favicon\":\"\"},{\"id\":\"153\",\"title\":\"COMBINED LIVER-KIDNEY TRANSPLANTATION - NIH\",\"description\":\"Concerning the etiology of kidney failure, the main indications for renal replacement are diabetic nephropathy and chronic glomerular disease.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4675492/\",\"favicon\":\"\"},{\"id\":\"154\",\"title\":\"Dual-Organ Transplantation: Indications, Evaluation, and Outcomes ...\",\"description\":\"Jul 13, 2023 Â· Reviewing the experience of liver-kidney transplantation shows that staged KT is associated with improved kidney function and increased graftÂ ...\",\"url\":\"https://www.ahajournals.org/doi/10.1161/CIR.0000000000001155\",\"favicon\":\"\"},{\"id\":\"155\",\"title\":\"Perioperative and Long-Term Outcomes After Combined Liver and ...\",\"description\":\"Oct 17, 2024 Â· Survival was excellent in our cohort; all individuals were alive after a median follow-up of 23 months (range 13â€“123 months). Several studiesÂ ...\",\"url\":\"https://www.mdpi.com/2075-1729/14/10/1319\",\"favicon\":\"\"},{\"id\":\"156\",\"title\":\"Right-Sizing Multiorgan Allocation Involving Kidneys - PMC - NIH\",\"description\":\"Patients with multiorgan failure may be clinically ineligible for a single-organ transplant but eligible to receive two or more organs from the same deceasedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10637446/\",\"favicon\":\"\"},{\"id\":\"157\",\"title\":\"Multi-organ transplantation - OPTN - HRSA\",\"description\":\"The two organ combinations transplanted most frequently are kidney-pancreas and heart-lung. Accordingly, the OPTN adopted policies early in its operation toÂ ...What is multi-organ... Â· Evolution of multi-organ...\",\"url\":\"https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/multi-organ-transplantation/\",\"favicon\":\"\"},{\"id\":\"158\",\"title\":\"[PDF] KDIGO-2009-Transplant-Recipient-Guideline-English.pdf\",\"description\":\"management, and treatment of kidney transplant recipi- ents is intended to assist the practitioner caring for adults and children after kidney transplantation.\",\"url\":\"https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf\",\"favicon\":\"\"},{\"id\":\"159\",\"title\":\"Renal association clinical practice guideline in post-operative care ...\",\"description\":\"These guidelines cover the care of patients from the period following kidney transplantation until the transplant is no longer working or the patient dies.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5455080/\",\"favicon\":\"\"},{\"id\":\"160\",\"title\":\"Maintenance Immunosuppression in Kidney Transplantation\",\"description\":\"Mar 8, 2025 Â· This review evaluates contemporary immunosuppressive protocols, highlights existing challenges, and explores future directions for optimizing long-termÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11943253/\",\"favicon\":\"\"},{\"id\":\"161\",\"title\":\"[PDF] NEW OPTIONS IN MAINTENANCE IMMUNOSUPPRESSION:\",\"description\":\"Maintenance immunosuppression is a key component of post-transplant management, and it carries its own important benefits and known challenges. MaintenanceÂ ...Missing:  1980-2010 | Show results with:1980-2010\",\"url\":\"https://www.kidney.org/sites/default/files/2025-08/new-options-maintenance-immunosuppression_02-10-7138.pdf\",\"favicon\":\"\"},{\"id\":\"162\",\"title\":\"Efficacy and safety of single-dose anti-thymocyte globulin versus ...\",\"description\":\"Conclusions: These data suggest that induction therapy with a single 3 mg/kg dose of r-ATG is associated with higher efficacy for preventing acute rejection andÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/38553819/\",\"favicon\":\"\"},{\"id\":\"163\",\"title\":\"Basiliximab induction alone vs a dual ATG ... - Oxford Academic\",\"description\":\"Sep 12, 2024 Â· This study highlights the efficacy of a combined induction regimen comprising basiliximab and a single dose of anti-thymocyte globulin (ATG)Â ...\",\"url\":\"https://academic.oup.com/ckj/article/17/9/sfae236/7756426\",\"favicon\":\"\"},{\"id\":\"164\",\"title\":\"Efficacy and Safety of Low-Dose ATG Plus Basiliximab Induction in ...\",\"description\":\"Oct 12, 2025 Â· Clinical outcomes according to induction therapy in kidney transplant recipients: (A) Kaplanâ€“Meier curve for biopsy-proven acute rejectionÂ ...\",\"url\":\"https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15321/full\",\"favicon\":\"\"},{\"id\":\"165\",\"title\":\"Management of kidney transplant recipients for primary care ... - NIH\",\"description\":\"Mar 18, 2024 Â· The maintenance phase of immunosuppression consists of multiple agents across several medication classes: (1) CNIs (cyclosporine and tacrolimus)Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10946132/\",\"favicon\":\"\"},{\"id\":\"166\",\"title\":\"A PROSPECTIVE, RANDOMIZED TRIAL OF TACROLIMUS ... - NIH\",\"description\":\"In the triple-therapy patients who never discontinued MMF, the incidence of rejection and steroid-resistant rejection was 16% and 1.5%, whereas in those whoÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2952470/\",\"favicon\":\"\"},{\"id\":\"167\",\"title\":\"Belatacept and Long-Term Outcomes in Kidney Transplantation\",\"description\":\"Jan 28, 2016 Â· The use of prolonged maintenance immunosuppressive therapy after kidney transplantation has improved the short-term outcomes, but the effect onÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa1506027\",\"favicon\":\"\"},{\"id\":\"168\",\"title\":\"The Many Faces of Calcineurin Inhibitor Toxicity â€“ What the FK? - PMC\",\"description\":\"Chronic CNI nephrotoxicity commonly presents as an irreversible, progressive decline in allograft function, which is likely from a combination of chronicÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7080294/\",\"favicon\":\"\"},{\"id\":\"169\",\"title\":\"[PDF] KDIGO clinical practice guideline for the care of kidney transplant ...\",\"description\":\"The guideline makes recommendations for immunosuppression and graft monitoring, as well as prevention and treatment of infection, cardiovascular disease,.\",\"url\":\"https://kdigo.org/wp-content/uploads/2017/02/KITxpGL_summary.pdf\",\"favicon\":\"\"},{\"id\":\"170\",\"title\":\"[PDF] Practical Protocols - The Transplantation Society\",\"description\":\"Long-term Follow-up After Kidney Transplantation. The following are suggestions on timing and frequency of clinical and laboratory examinations after kidneyÂ ...\",\"url\":\"https://www.tts.org/images/stories/practical_protocols/Practical_Protocols_ENG.PDF\",\"favicon\":\"\"},{\"id\":\"171\",\"title\":\"Management of kidney transplant recipients for primary care ...\",\"description\":\"Mar 18, 2024 Â· This review aims to provide primary care practitioners with a practical blueprint for outpatient care of kidney transplant recipients.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03504-2\",\"favicon\":\"\"},{\"id\":\"172\",\"title\":\"Practical Recommendations for Long-term ... - Transplantation\",\"description\":\"Preoperative, perioperative, and postoperative factors may impact long-term outcomes; these include donor and organ factors as well as logistic factors. ForÂ ...\",\"url\":\"https://journals.lww.com/transplantjournal/fulltext/2017/04002/practical_recommendations_for_long_term_management.1.aspx\",\"favicon\":\"\"},{\"id\":\"173\",\"title\":\"A Narrative Review of Dietary Approaches for Kidney Transplant ...\",\"description\":\"A low sodium diet is already recommended for kidney transplant recipients, and the DASH diet extends this recommendation to an overall healthy eating pattern.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8258457/\",\"favicon\":\"\"},{\"id\":\"174\",\"title\":\"Nutrition After Kidney Transplant - UCSF Benioff Children's Hospitals\",\"description\":\"There is no longer a restriction on potassium, phosphorus, protein or dairy intake after a transplant. This applies to patients who were on a protein-restrictedÂ ...\",\"url\":\"https://www.ucsfbenioffchildrens.org/education/nutrition-after-kidney-transplant\",\"favicon\":\"\"},{\"id\":\"175\",\"title\":\"Diet after kidney transplant | National Kidney Foundation\",\"description\":\"After a kidney transplant, plan to follow a diet low in salt and high in fiber. A balanced diet includes a variety of fresh fruits and vegetables, lean meats,Â ...Missing:  KDIGO | Show results with:KDIGO\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.kidney.org/kidney-topics/diet-after-kidney-transplant\",\"favicon\":\"\"},{\"id\":\"176\",\"title\":\"Self-care strategies and barriers among kidney transplant recipients\",\"description\":\"Adequate hydration is important for overall renal health. Exercising is important to prevent cardiovascular disease, which is the primary cause of death amongÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3540789/\",\"favicon\":\"\"},{\"id\":\"177\",\"title\":\"Physical Exercise in Kidney Renal Recipients - Karger Publishers\",\"description\":\"Jun 27, 2024 Â· Based on recent evidence, a combined exercise program (aerobic and strength exercise) is largely proposed to kidney transplant recipients.Abstract Â· Introduction Â· Physical Activity and Transplant Â· Reference Guidelines\",\"url\":\"https://karger.com/kbr/article/49/1/548/909773/Physical-Exercise-in-Kidney-Renal-Recipients-Where\",\"favicon\":\"\"},{\"id\":\"178\",\"title\":\"Lifestyle changes can be critical for kidney transplant patients' long ...\",\"description\":\"Jan 17, 2022 Â· Those include losing weight, exercising and new strategies for managing diabetes,\\\" he says. \\\"Making those changes could potentially impact theÂ ...\",\"url\":\"https://newsnetwork.mayoclinic.org/discussion/lifestyle-changes-can-be-critical-for-kidney-transplant-patients-long-term-survival/\",\"favicon\":\"\"},{\"id\":\"179\",\"title\":\"Early surgical complications following kidney transplantation in adults\",\"description\":\"Sep 1, 2025 Â· In studies reporting on complications within 90 days of surgery the weighted overall complication rate was 36 % (range 12-60 %), the weightedÂ ...Missing:  perioperative | Show results with:perioperative\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40912061/\",\"favicon\":\"\"},{\"id\":\"180\",\"title\":\"Incidence of Thromboembolic Complications Following Kidney ... - NIH\",\"description\":\"Jun 13, 2023 Â· Graft thrombosis is an important early complication following kidney transplantation and occurs in up to 2â€“3% of cases, usually resulting inÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10276531/\",\"favicon\":\"\"},{\"id\":\"181\",\"title\":\"Urologic complications in renal transplants - Choate\",\"description\":\"The overall incidence ranges from 3.4â€“11.2% (4-13). Complications such as ureteral stricture, urine leak, symptomatic vesicoureteral reflux (VUR), urolithiasis,Â ...Missing:  vascular | Show results with:vascular\",\"url\":\"https://tau.amegroups.org/article/view/23349/html\",\"favicon\":\"\"},{\"id\":\"182\",\"title\":\"Surgical Complications Following Renal Transplantation in a Large ...\",\"description\":\"May 15, 2024 Â· The most common complications were postoperative need for blood transfusion (36%), symptomatic hematomas (10%), UTIs (8.6%), and sepsis (3.0%).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11098183/\",\"favicon\":\"\"},{\"id\":\"183\",\"title\":\"Update on Vascular Complications After Renal Transplantation\",\"description\":\"Apr 4, 2022 Â· Renal artery thrombosis is a rare but devastating complication of renal transplant. It occurs in less than 1% of all transplants.\",\"url\":\"https://www.ectrx.org/detail/current/2022/20/4/0/333/0\",\"favicon\":\"\"},{\"id\":\"184\",\"title\":\"Diagnostic and therapeutic strategies for vascular complications ...\",\"description\":\"May 10, 2023 Â· TRAS is the most common vascular complication after renal transplantation, often occurring 3â€“6 months after surgery, with an incidence of aboutÂ ...Abstract Â· Materials and methods Â· Results Â· Discussion\",\"url\":\"https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2023.1150331/full\",\"favicon\":\"\"},{\"id\":\"185\",\"title\":\"Vascular Complications in Renal Transplantation: Surgical... - LWW\",\"description\":\"Vascular complications in the setting of kidney transplantation occur in 3%â€“15% of patients. They include transplant renal artery stenosis, transplant renalÂ ...\",\"url\":\"https://journals.lww.com/transplantationdirect/fulltext/2022/06000/vascular_complications_in_renal_transplantation_.12.aspx\",\"favicon\":\"\"},{\"id\":\"186\",\"title\":\"Delayed graft function and the risk of acute rejection in the modern ...\",\"description\":\"It is most often defined as the need for dialysis within the first 7 days after kidney transplantation. The incidence of DGF ranges from 20% to 50% in deceasedÂ ...\",\"url\":\"https://www.kidney-international.org/article/S2157-1716%2815%2932257-7/fulltext\",\"favicon\":\"\"},{\"id\":\"187\",\"title\":\"Delayed Graft Function in Kidney Transplant: Risk Factors ... - NIH\",\"description\":\"Delayed graft function is a frequent complication of kidney transplantation that requires dialysis in the first week posttransplant.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9605016/\",\"favicon\":\"\"},{\"id\":\"188\",\"title\":\"Effects of Delayed Graft Function on Transplant Outcomes - LWW\",\"description\":\"Delayed graft function (DGF) is a frequent complication of kidney transplantation, but its impact on long- and short-term transplant outcomes is unclear.Results Â· Graft Failure Â· Acute Rejection\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://journals.lww.com/transplantationdirect/fulltext/2023/02000/effects_of_delayed_graft_function_on_transplant.6.aspx\",\"favicon\":\"\"},{\"id\":\"189\",\"title\":\"Surgical and Infectious Complications Following Kidney ... - PubMed\",\"description\":\"May 9, 2025 Â· Surgical site infections have a median incidence of 3.7%, and incisional hernias develop in 2.5-10% of cases, depending on follow-up duration.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40429301/\",\"favicon\":\"\"},{\"id\":\"190\",\"title\":\"Allorecognition and the spectrum of kidney transplant rejection\",\"description\":\"Dec 12, 2021 Â· Detection of mismatched human leukocyte antigens by adaptive immune cells is considered as the main cause of transplant rejection,Â ...Antibody-Mediated Immune... Â· Hla-Dsa--Mediated... Â· Abmr Mediated By Hla-Dsa...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2821%2901143-1/fulltext\",\"favicon\":\"\"},{\"id\":\"191\",\"title\":\"Hyperacute Rejection of a Living Unrelated Kidney Graft - PMC\",\"description\":\"Hyperacute rejection is a rare event in kidney transplantation. It is mediated by preformed antibodies that can usually be excluded by a pretransplant CDCÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4182006/\",\"favicon\":\"\"},{\"id\":\"192\",\"title\":\"Immunology of Transplant Rejection - Medscape Reference\",\"description\":\"Jul 11, 2023 Â· The immune response to a transplanted organ consists of both cellular (lymphocyte mediated) and humoral (antibody mediated) mechanisms. AlthoughÂ ...\",\"url\":\"https://emedicine.medscape.com/article/432209-overview\",\"favicon\":\"\"},{\"id\":\"193\",\"title\":\"Pathophysiology of Rejection in Kidney Transplantation - MDPI\",\"description\":\"Jun 19, 2023 Â· This review explains the interconnected mechanisms behind antibody-mediated and T-cell-mediated rejection and highlights how these processes contribute toÂ ...\",\"url\":\"https://www.mdpi.com/2077-0383/12/12/4130\",\"favicon\":\"\"},{\"id\":\"194\",\"title\":\"Effector Mechanisms of Rejection - PMC - PubMed Central\",\"description\":\"T cells and B cells mainly control the antigen-specific rejection and act either as effector, regulatory, or memory cells. On the other hand, nonspecific cellsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3808773/\",\"favicon\":\"\"},{\"id\":\"195\",\"title\":\"Chronic Allograft Injury : Clinical Journal of the American ... - LWW\",\"description\":\"Chronic allograft injury includes both immune-mediated and nonimmune-mediated injuries, which may involve the organ donor, the recipient, or both.\",\"url\":\"https://journals.lww.com/cjasn/fulltext/2021/11000/chronic_allograft_injury.16.aspx\",\"favicon\":\"\"},{\"id\":\"196\",\"title\":\"Chronic Allograft Nephropathyâ€”A Narrative Review of Its ...\",\"description\":\"Repeated episodes of acute rejection result in sustained immunologic activity against the allograft through both cellular and humoral mechanisms, including theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12024747/\",\"favicon\":\"\"},{\"id\":\"197\",\"title\":\"Treatment of acute T cell-mediated (cellular) rejection - UpToDate\",\"description\":\"May 19, 2025 Â· The use of potent immunosuppressive agents as part of induction and maintenance therapy for kidney transplantation has significantly reducedÂ ...\",\"url\":\"https://www.uptodate.com/contents/kidney-transplantation-in-adults-treatment-of-acute-t-cell-mediated-cellular-rejection\",\"favicon\":\"\"},{\"id\":\"198\",\"title\":\"Current Therapies in Kidney Transplant Rejection - PMC - NIH\",\"description\":\"Jul 27, 2023 Â· Plasmapheresis, or plasma exchange, is the most common treatment for ABMR. This technique has been used since 1979 in patients with ABMR.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10419508/\",\"favicon\":\"\"},{\"id\":\"199\",\"title\":\"Chronic allograft injury: Mechanisms and potential treatment targets\",\"description\":\"The causes of renal allograft loss are multifactorial, consisting of immunological and non-immunological factors such as chronic active antibody-mediatedÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0955470X16300532\",\"favicon\":\"\"},{\"id\":\"200\",\"title\":\"Chronic Kidney Allograft Disease: New Concepts and Opportunities\",\"description\":\"Its damage mechanisms have been characterized, with an acute reversible damage related to an imbalance between vasodilators and vasoconstrictors and tubularÂ ...\",\"url\":\"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.660334/full\",\"favicon\":\"\"},{\"id\":\"201\",\"title\":\"Incidences of Infectious Events in a Renal Transplant Cohort of the ...\",\"description\":\"Jul 14, 2022 Â· A bacterial infection was reported in 41.3% (332/804) of all recipients (male 36.3%, female 44.7%; P = .28), and the incidence increased withÂ ...\",\"url\":\"https://academic.oup.com/ofid/article/9/7/ofac243/6585272\",\"favicon\":\"\"},{\"id\":\"202\",\"title\":\"Incidence and risk factors of infections following kidney transplantation\",\"description\":\"The incidence of the infections was 44.2 % (19 individuals). The most common presented infections in the patients within two years post renal transplant wereÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1876034124002259\",\"favicon\":\"\"},{\"id\":\"203\",\"title\":\"Surgical and Infectious Complications Following Kidney ... - MDPI\",\"description\":\"The incidence of urinary tract infections ranges from 20 to 43%, while asymptomatic bacteriuria is reported in up to 53% of recipients. Surgical site infectionsÂ ...\",\"url\":\"https://www.mdpi.com/2077-0383/14/10/3307\",\"favicon\":\"\"},{\"id\":\"204\",\"title\":\"Full article: Prophylaxis of Cytomegalovirus Infection in Solid Organ ...\",\"description\":\"Jun 7, 2022 Â· Despite antiviral prophylaxis extending to 6 months following kidney transplantation, CMV disease commonly occurs in SOT recipients with CMV D+/Â ...\",\"url\":\"https://www.tandfonline.com/doi/full/10.2147/TRRM.S366213\",\"favicon\":\"\"},{\"id\":\"205\",\"title\":\"Characteristics, risk factors and outcome of BKV nephropathy in ...\",\"description\":\"Feb 6, 2023 Â· Following kidney transplantation, BK virus associated nephropathy (BKVN) occurs in 1 to 10% of kidney transplant recipients (KTR) andÂ ...\",\"url\":\"https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08043-z\",\"favicon\":\"\"},{\"id\":\"206\",\"title\":\"BK polyomavirus infection: more than 50 years and still a threat to ...\",\"description\":\"BKPyV reactivation can manifest as viruria in 30%â€“40%, viremia in 10%â€“20%, and BK polyomavirus-associated nephropathy (BKPyVAN) in 1%â€“10% of recipients.Abstract Â· Introduction Â· Discussion\u003c|separator|\u003e\",\"url\":\"https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1309927/full\",\"favicon\":\"\"},{\"id\":\"207\",\"title\":\"Incidence of cytomegalovirus infection after kidney transplantation in ...\",\"description\":\"Apr 22, 2025 Â· Cytomegalovirus (CMV) infection is a frequent complication following kidney transplantation that affects transplant outcomes.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12016247/\",\"favicon\":\"\"},{\"id\":\"208\",\"title\":\"Cancer risks in people on dialysis and kidney transplant recipients\",\"description\":\"Mar 20, 2025 Â· Cancer risk was more than two times higher in people on dialysis (SIR 2.11, 95% CI 2.02â€“2.19) and nearly four times higher in kidney transplantÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/18/4/sfaf077/8088413\",\"favicon\":\"\"},{\"id\":\"209\",\"title\":\"De Novo Malignancies after Kidney Transplantation - LWW\",\"description\":\"The cumulative incidence of solid organ cancer ranges between 10% and 15% (6,910â€“11) at around 15 years after transplantation. For skin cancers, the cumulativeÂ ...\",\"url\":\"https://journals.lww.com/cjasn/fulltext/2022/03000/de_novo_malignancies_after_kidney_transplantation.16.aspx\",\"favicon\":\"\"},{\"id\":\"210\",\"title\":\"Risk Factors for the Development of Malignancies Post ... - MDPI\",\"description\":\"From a total of 2986 kidney transplant recipients, 8.98% were diagnosed with a de novo malignancy, with PTLD, lung cancer and Kaposi sarcoma being the mostÂ ...\",\"url\":\"https://www.mdpi.com/2227-9059/13/10/2346\",\"favicon\":\"\"},{\"id\":\"211\",\"title\":\"Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors ...\",\"description\":\"Risk factors have been identified, including viral infections, degree of immunosuppression, recipient age and race, allograft type, and host genetic variations.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4831913/\",\"favicon\":\"\"},{\"id\":\"212\",\"title\":\"Posttransplant Lymphoproliferative Disorder Following Kidney ...\",\"description\":\"Mar 25, 2021 Â· Epstein-Barr virus infection is one of the most important risk factors for PTLD, even though 40% of PTLD cases in contemporary series are notÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2821%2900501-1/pdf\",\"favicon\":\"\"},{\"id\":\"213\",\"title\":\"Risk and prognosis of posttransplant lymphoproliferative disease in ...\",\"description\":\"Epstein-Barr virus (EBV)-seronegative recipients have a significantly increased risk of PTLD, but few studies have investigated risk factors for PTLD in EBV-Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1600613525000413\",\"favicon\":\"\"},{\"id\":\"214\",\"title\":\"Increased cancer risk in kidney transplant patients in Scotland - Nature\",\"description\":\"Jun 14, 2025 Â· This study examines the incidence of cancer in kidney transplant recipients (KTRs) in Scotland, compares this to the general population, and identifies factorsÂ ...\",\"url\":\"https://www.nature.com/articles/s41416-025-03086-2\",\"favicon\":\"\"},{\"id\":\"215\",\"title\":\"Cardiovascular Risk after Renal Transplantation - Kidney360\",\"description\":\"Cardiovascular complications are among the leading causes of both mortality and morbidity in renal transplant recipients (RTRs), although their incidence hasÂ ...\",\"url\":\"https://journals.lww.com/kidney360/fulltext/2025/07000/cardiovascular_risk_after_renal_transplantation_.5.aspx\",\"favicon\":\"\"},{\"id\":\"216\",\"title\":\"Bone Loss after Solid Organ Transplantation\",\"description\":\"Apr 25, 2024 Â· Bone loss rates are highest in the first 6 to 18 months post-transplantation, ranging from 4% to 10% in the lumbar spine and 5% to 8% in the femoral neck.ABSTRACT Â· PREVALENCE OF... Â· MULTIFACTORIAL... Â· ORGAN-SPECIFIC...\",\"url\":\"https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2024.1939\",\"favicon\":\"\"},{\"id\":\"217\",\"title\":\"Treatment Options for Anemia in Kidney Transplant Patients: A Review\",\"description\":\"Posttransplant anemia, particularly when severe, may be associated with adverse effects such as graft failure, mortality, and a decline in kidney function.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10320602/\",\"favicon\":\"\"},{\"id\":\"218\",\"title\":\"Risk factors and management of hyperuricemia after renal ... - NIH\",\"description\":\"Hyperuricemia (HUA) is a common complication after renal transplantation. Currently, there is no uniform consensus on factors which increase the risk forÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9904410/\",\"favicon\":\"\"},{\"id\":\"219\",\"title\":\"High Post-Kidney Transplant Serum Uric Acid Levels Are Associated ...\",\"description\":\"Key Points Â· Post-transplant increased serum uric acid levels are associated with congestive heart failure and graft failure for kidney transplant recipients.\",\"url\":\"https://journals.lww.com/kidney360/fulltext/2025/01000/high_post_kidney_transplant_serum_uric_acid_levels.18.aspx\",\"favicon\":\"\"},{\"id\":\"220\",\"title\":\"\",\"description\":\"\",\"url\":\"https://srtr.transplant.hrsa.gov/adr/Chapter?name=Kidney\u0026year=2023\",\"favicon\":\"\"},{\"id\":\"221\",\"title\":\"Kidney Transplant - Annual Data Report | USRDS - NIH\",\"description\":\"In this chapter, we examine access to kidney transplant and outcomes following a kidney transplant. Analyses span the beginning of the transplant journey.Missing:  guidelines | Show results with:guidelines\",\"url\":\"https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/7-kidney-transplant\",\"favicon\":\"\"},{\"id\":\"222\",\"title\":\"OPTN/SRTR 2023 Annual Data Report: Kidney - PMC - NIH\",\"description\":\"Five-year graft survival rates were 90.0% for LDKT compared with 82.2% for DDKT in recipients aged 18â€“34 years, and 80.2% for LDKT versus 66.1 % for DDKT inÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12414513/\",\"favicon\":\"\"},{\"id\":\"223\",\"title\":\"Outcomes of kidneys used for transplantation: an analysis of survival ...\",\"description\":\"Mar 4, 2024 Â· Death-censored DD and LDKT 1- and 5-year graft survival was 96%/86% and 98/92%, respectively (p \u003c 0.001) (Figure 1). The average DD recipientÂ ...\",\"url\":\"https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2024.1335999/full\",\"favicon\":\"\"},{\"id\":\"224\",\"title\":\"Long-term kidney transplant graft survivalâ€”Making progress when ...\",\"description\":\"In the case of living kidney donor transplant recipients, 1-year graft survival improved from 93.9% to 97.8% (4.2% improvement from era 1995â€“1999 to 2014â€“2017)Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1600613522086804\",\"favicon\":\"\"},{\"id\":\"225\",\"title\":\"Comparison of outcomes after living and deceased donor kidney ...\",\"description\":\"Aug 19, 2025 Â· Over 7 years, living donor recipients experienced an additional 0.36 (95% c.i. 0.29 to 0.43) years of graft survival. Benefits persisted acrossÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12362070/\",\"favicon\":\"\"},{\"id\":\"226\",\"title\":\"Survival Benefit of First Single-Organ Deceased Donor Kidney ...\",\"description\":\"Oct 7, 2022 Â· A recent French registry study reported a 6.8-month gain in life expectancy for patients who undergo transplant compared with transplant-Â ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181\",\"favicon\":\"\"},{\"id\":\"227\",\"title\":\"OPTN/SRTR 2023 Annual Data Report: Introduction\",\"description\":\"Among kidney transplant recipients in 2016-2018, 1-year and 5-year patient survival were 97.4% and 86.6%, respectively (Figure INT 8). Of note, a record numberÂ ...\",\"url\":\"https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Introduction\u0026year=2023\",\"favicon\":\"\"},{\"id\":\"228\",\"title\":\"Long-term outcome of kidney function in patients with ANCA ...\",\"description\":\"Jan 24, 2024 Â· Patient survival rates after the first kidney transplantation at 1, 5, 10 and 15 years, were 100%, 97.1%, 86.5% and 81.4%, respectively. PatientÂ ...\",\"url\":\"https://academic.oup.com/ndt/article/39/9/1483/7588854\",\"favicon\":\"\"},{\"id\":\"229\",\"title\":\"[PDF] Long-Term Kidney Transplant Graft Survival: Single-Center ...\",\"description\":\"Results:Graft survival rates at 3, 5, and 10 years were. 89.8%, 84.1%, and 81.3%, respectively. Main causes of graft loss were death with a functioning kidney.\",\"url\":\"https://www.ectrx.org/class/pdfPreview.php?year=2024\u0026volume=22\u0026issue=1\u0026supplement=1\u0026spage_number=263\u0026makale_no=0\",\"favicon\":\"\"},{\"id\":\"230\",\"title\":\"Mapping health-related quality of life after kidney transplantation by ...\",\"description\":\"KTRs reported a higher HRQOL after KT compared with pre-transplantation and compared with patients receiving dialysis with or without being on the WL.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8643597/\",\"favicon\":\"\"},{\"id\":\"231\",\"title\":\"Kidney Transplantation Improves Health-Related Quality of Life in ...\",\"description\":\"Apr 15, 2024 Â· In conclusion, HRQoL is significantly higher among older KTR after kidney transplantation compared to older waitlisted patients.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11057459/\",\"favicon\":\"\"},{\"id\":\"232\",\"title\":\"Quality of Life of Post-Renal Transplant Patients in a Tertiary ...\",\"description\":\"Jul 4, 2025 Â· Conclusion: QoL following renal transplantation was observed to be high, especially among younger recipients and those further along in the postÂ ...\u003c|separator|\u003e\",\"url\":\"https://healthcare-bulletin.co.uk/article/quality-of-life-of-post-renal-transplant-patients-in-a-tertiary-corporate-hospital-in-bangalore-a-cross-sectional-study-3713/\",\"favicon\":\"\"},{\"id\":\"233\",\"title\":\"Survival after kidney transplantation compared with ongoing dialysis ...\",\"description\":\"Jul 15, 2023 Â· Kidney transplantation offers improved survival and quality of life compared to dialysis for most recipients; however, benefits for elderly patients (\u003e70 yearsÂ ...\",\"url\":\"https://www.amjtransplant.org/article/S1600-6135%2823%2900578-6/fulltext\",\"favicon\":\"\"},{\"id\":\"234\",\"title\":\"Quality of life for kidney transplant recipients and hemodialysis ...\",\"description\":\"Jun 3, 2021 Â· The literature has shown mixed evidence about whether kidney transplantation improves HRQOL compared with other renal replacement modalities.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z\",\"favicon\":\"\"},{\"id\":\"235\",\"title\":\"OPTN/SRTR 2022 Annual Data Report: Kidney\",\"description\":\"Five-year graft survival after LDKT compared with DDKT was 90.0% versus 81.4% for recipients aged 18-34 years and 80.8% versus 67.8% for recipients aged 65Â ...Figure KI 1: New adult... Â· Figure KI 7: Distribution of...\",\"url\":\"https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2022\",\"favicon\":\"\"},{\"id\":\"236\",\"title\":\"The Risk of Transplant Failure With HLA Mismatch in First... - LWW\",\"description\":\"We examined the effect of HLA compatibility on kidney allograft survival by studying all first adult kidney transplants in the United States from a deceasedÂ ...\",\"url\":\"https://journals.lww.com/transplantjournal/fulltext/2016/05000/the_risk_of_transplant_failure_with_hla_mismatch.25.aspx\",\"favicon\":\"\"},{\"id\":\"237\",\"title\":\"HLA mismatch is important for 20-year graft survival in kidney ...\",\"description\":\"Conclusions: A greater number of HLA mismatches was associated with progressively worse long-term graft survival for patients. Our analysis reinforces theÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/37302557/\",\"favicon\":\"\"},{\"id\":\"238\",\"title\":\"Estimated GFR, donor age and KDPI association with graft survival\",\"description\":\"Analysis of the US donor and transplant database demonstrated that the durability of kidney transplants from deceased donors \u003e 65 years was similar to youngerÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2589537021002601\",\"favicon\":\"\"},{\"id\":\"239\",\"title\":\"Better kidney allograft survival despite higher-risk donor and ...\",\"description\":\"Apr 4, 2024 Â· This study aimed to characterize trends in recipient and donor characteristics and in medium- and long-term graft failure in Australia and NewÂ ...\",\"url\":\"https://academic.oup.com/ndt/article/39/11/1846/7640868\",\"favicon\":\"\"},{\"id\":\"240\",\"title\":\"Factors influencing long-term outcome after kidney transplantation\",\"description\":\"The key factors related to the recipient include their age as well as disease recurrence, HLA matching, HLA immunization, ethnic background, time on dialysis,Â ...Missing:  UNOS SRTR data\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/24138291/\",\"favicon\":\"\"},{\"id\":\"241\",\"title\":\"Long-term outcomes and prognostic factors in kidney transplant ...\",\"description\":\"The survival rates of KT recipients are prognosticated by pretransplant dialysis duration, cardiovascular disease, DGF, post-transplant infection and acuteÂ ...\",\"url\":\"https://bmjopen.bmj.com/content/12/5/e059631\",\"favicon\":\"\"},{\"id\":\"242\",\"title\":\"Survival Benefit in Renal Transplantation Despite High Comorbidity\",\"description\":\"The overall survival benefit was 62% versus 70% in deceased versus living donor transplanted patients. Conclusions. Poor health and old age reduced the chanceÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5120769/\",\"favicon\":\"\"},{\"id\":\"243\",\"title\":\"Risk factors for delayed graft function in patients with kidney ...\",\"description\":\"Delayed graft function (DGF) is one of the most common early complications following kidney transplantation. Current diagnostic criteria define DGF as the needÂ ...\",\"url\":\"https://bmjopen.bmj.com/content/15/3/e087128\",\"favicon\":\"\"},{\"id\":\"244\",\"title\":\"New Kidney Transplant Collaborative (KTC) Analysis of Data ...\",\"description\":\"Oct 23, 2024 Â· As of 2023, approximately 88,500 Americans are on the kidney transplant waitlist, with 12-17 individuals dying every day while waiting. In justÂ ...\u003c|separator|\u003e\",\"url\":\"https://kidneytransplantcollaborative.com/new-kidney-transplant-collaborative-ktc-analysis-of-data-reveals-alarming-surge-in-kidney-transplant-waitlists-in-swing-states/\",\"favicon\":\"\"},{\"id\":\"245\",\"title\":\"Supply, Demand, and a Growing US Kidney Transplant Waiting List\",\"description\":\"Mar 24, 2025 Â· In 2023, there were 44 560 new patients added to a kidney transplant waiting list, but only 27 332 kidney transplants were performed (6290Â ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831874\",\"favicon\":\"\"},{\"id\":\"246\",\"title\":\"Kidney - Scientific Registry of Transplant Recipients - HRSA\",\"description\":\"There were 4,002 waitlist removals due to death in 2023, a significant decrease from 5,371 in 2021 during the COVID-19 pandemic. However, the 4,855 waitlistÂ ...\",\"url\":\"https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Kidney\u0026year=2023\",\"favicon\":\"\"},{\"id\":\"247\",\"title\":\"The Kidney Transplant Waitlist | National Kidney Foundation\",\"description\":\"The waitlist is only for organs from deceased donors. Deceased donors are people who donate organs at the time of their death. When a deceased donor kidney isÂ ...\",\"url\":\"https://www.kidney.org/kidney-topics/kidney-transplant-waitlist\",\"favicon\":\"\"},{\"id\":\"248\",\"title\":\"Challenges of Organ Shortage for Transplantation - NIH\",\"description\":\"This decline can be attributed to increases in the number and percentage of ECDs and DCDs [14]. The shift in the distribution of recovered kidneys from standardÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4149736/\",\"favicon\":\"\"},{\"id\":\"249\",\"title\":\"AOPO Highlights Disturbing Crisis: Thousands of Kidney Patients ...\",\"description\":\"Sep 12, 2024 Â· Organ Procurement Organizations recovered 2X the kidneys needed for dying patients, but the organs went to waste; underscoring the rise in organ nonuse in theÂ ...\",\"url\":\"https://aopo.org/aopo-highlights-disturbing-crisis-thousands-of-kidney-patients-who-died-waiting-for-organs-in-2023-could-have-been-saved/\",\"favicon\":\"\"},{\"id\":\"250\",\"title\":\"The Problems of Organ Donor Shortage - Mayo Clinic Proceedings\",\"description\":\"However, living related donation has been the single reason for the increased number of kidney transplants in the United States in the past 10 years.\",\"url\":\"https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961602-9/fulltext\",\"favicon\":\"\"},{\"id\":\"251\",\"title\":\"a 3.3 percent increase from the transplants performed in 2023 - OPTN\",\"description\":\"Jan 15, 2025 Â· A total of 41,119 transplants were made possible through deceased organ donation in 2024. This is the first year the threshold of 40,000Â ...\",\"url\":\"https://optn.transplant.hrsa.gov/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/\",\"favicon\":\"\"},{\"id\":\"252\",\"title\":\"Removal of DSA and region from kidney allocation policy - OPTN\",\"description\":\"Background. At its December 2019 meeting, the OPTN Board of Directors approved a policy to remove DSA, and region from kidney allocation.\",\"url\":\"https://optn.transplant.hrsa.gov/professionals/by-organ/kidney-pancreas/kidney-allocation-system/removal-of-dsa-and-region-from-kidney-allocation-policy/\",\"favicon\":\"\"},{\"id\":\"253\",\"title\":\"[PDF] Geographic Variations in Access to Kidney Transplant - SRTR.org\",\"description\":\"November 2012: The OPTN/UNOS Board of Directors agreed that geographic disparities in candidate access to transplant are unacceptably high. â€¢ Various efforts toÂ ...\",\"url\":\"https://www.srtr.org/media/1234/gustafson_geogdisp.pdf\",\"favicon\":\"\"},{\"id\":\"254\",\"title\":\"Geographic Disparity in Kidney Transplantation under KAS - PMC\",\"description\":\"Considerable geographic inequity in access to deceased donor kidney transplantation (DDKT) in the United States has persisted since the creation of the nationalÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5992006/\",\"favicon\":\"\"},{\"id\":\"255\",\"title\":\"Effect of Policy on Geographic Inequities in Kidney Transplantation\",\"description\":\"Dec 29, 2021 Â· Association of high burden of end-stage kidney disease with decreased kidney transplant rates with the updated US kidney allocation policy.\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2821%2901041-6/fulltext\",\"favicon\":\"\"},{\"id\":\"256\",\"title\":\"Geographic Variation in the Availability of Deceased Donor Kidneys ...\",\"description\":\"We aimed to describe regional and DSA-level differences in deceased donor kidney recovery to assess whether improving deceased donor kidney recovery fromÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6933455/\",\"favicon\":\"\"},{\"id\":\"257\",\"title\":\"The New Distance-Based Kidney Allocation System - SpringerLink\",\"description\":\"Oct 13, 2022 Â· The KAS 250 allocation policy changed the geographic basis of deceased donor kidney distribution in a manner that is intended to reduce geographic disparitiesÂ ...Missing:  algorithms | Show results with:algorithms\u003c|separator|\u003e\",\"url\":\"https://link.springer.com/article/10.1007/s40472-022-00384-z\",\"favicon\":\"\"},{\"id\":\"258\",\"title\":\"OPTN/SRTR 2022 Annual Data Report: Kidney - ScienceDirect.com\",\"description\":\"The year 2022 had continued successes and challenges for the field of kidney transplantation, as the community adapted to ongoing surges of the COVID-19Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1600613524000777\",\"favicon\":\"\"},{\"id\":\"259\",\"title\":\"Persistent Disparities in Waitlisting After the Kidney Allocation System\",\"description\":\"Aug 26, 2023 Â· There was a significant disparity in kidney transplant waitlisting, with non-Hispanic Black individuals being 14% less likely to be waitlistedÂ ...\",\"url\":\"https://www.kidneymedicinejournal.org/article/S2590-0595%2823%2900134-6/fulltext\",\"favicon\":\"\"},{\"id\":\"260\",\"title\":\"Over 14,700 waiting time modifications completed for Black kidney ...\",\"description\":\"May 8, 2024 Â· Approximately 50% of all modified registrations received between 1-3 years of waiting time; 2,709 candidates with a waiting time modificationÂ ...\",\"url\":\"https://optn.transplant.hrsa.gov/news/over-14-700-waiting-time-modifications-completed-for-black-kidney-patients-one-year-after-policy-implementation/\",\"favicon\":\"\"},{\"id\":\"261\",\"title\":\"Organ Procurement Organization Statistics - SRTR.org\",\"description\":\"SRTR supports the transplant community with analyses, in an effort to better patient results and experience. Data driven, improving patient outcomes is ourÂ ...Missing:  geographic | Show results with:geographic\",\"url\":\"https://www.srtr.org/reports/opo-specific-reports/\",\"favicon\":\"\"},{\"id\":\"262\",\"title\":\"National data - OPTN - HRSA\",\"description\":\"Survival by Recipient Age; Survival by Recipient Birth Sex; Survival by Primary vs. Repeat Transplant; Survival by Recipient UNOS Status at Transplant. SurvivalÂ ...\",\"url\":\"https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/\",\"favicon\":\"\"},{\"id\":\"263\",\"title\":\"Introducing Incentives in the Market for Live and Cadaveric Organ ...\",\"description\":\"We show that monetary incentives would increase the supply of organs for transplant sufficiently to eliminate the very large queues in organ markets.\",\"url\":\"https://www.aeaweb.org/articles?id=10.1257/jep.21.3.3\",\"favicon\":\"\"},{\"id\":\"264\",\"title\":\"Against a Regulated Market in Human Organs: Ethical Arguments ...\",\"description\":\"Dec 1, 2018 Â· This article explains how organ trade results in violence, exploitation, and suffering against the vulnerable, who sell their live organs on the black marketÂ ...\",\"url\":\"https://meridian.allenpress.com/human-organization/article/77/4/323/72752/Against-a-Regulated-Market-in-Human-Organs-Ethical\",\"favicon\":\"\"},{\"id\":\"265\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.wsj.com/articles/SB10001424052702304149404579322560004817176\",\"favicon\":\"\"},{\"id\":\"266\",\"title\":\"Kidneys for Sale: Empirical Evidence From Iran - PMC\",\"description\":\"Jun 24, 2022 Â· As a result of the Iranian system of compensated donation, the number of renal transplants conducted has substantively enhanced such that fromÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9266983/\",\"favicon\":\"\"},{\"id\":\"267\",\"title\":\"[PDF] Compensated Living Kidney Donation in Iran\",\"description\":\"Their feelings before discharge were complete satisfaction in 519 (86.5%), relative satisfaction in 69. (11.5%), regret in 9 (1.5%), and indifference in 3 (0.5Â ...Missing:  empirical | Show results with:empirical\",\"url\":\"https://ijkd.org/index.php/ijkd/article/download/9/8/8\",\"favicon\":\"\"},{\"id\":\"268\",\"title\":\"Reconsidering Exploitation Arguments Against Organ Markets\",\"description\":\"It is often argued that concerns about exploitation should be addressed by increasing the price paid to organ sellers, not by banning the trade outright. IÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/28161761/\",\"favicon\":\"\"},{\"id\":\"269\",\"title\":\"The Sale of Human Organs - Stanford Encyclopedia of Philosophy\",\"description\":\"Oct 17, 2011 Â· This difference between kidneys and blood reveals a general structural difficulty for altruism arguments against sale. For altruism argumentsÂ ...\",\"url\":\"https://plato.stanford.edu/entries/organs-sale/\",\"favicon\":\"\"},{\"id\":\"270\",\"title\":\"Regulated compensated donation in Pakistan and Iran. - Europe PMC\",\"description\":\"More than half of recipients were foreigners who paid US$20,000-30,000. Recipients of vendor kidneys had poor outcome and high infectious complications.\",\"url\":\"https://europepmc.org/article/med/19469028\",\"favicon\":\"\"},{\"id\":\"271\",\"title\":\"The Veneer of Altruism - AMA Journal of Ethics\",\"description\":\"American patients pay brokers upwards of $150,000 for kidneys and as much as $250,000 for hearts [11]. Rather than waiting more than 6 years for a kidney,Â ...\",\"url\":\"https://journalofethics.ama-assn.org/article/veneer-altruism/2012-03\",\"favicon\":\"\"},{\"id\":\"272\",\"title\":\"Public Opinions on Removing Disincentives and Introducing ...\",\"description\":\"Apr 2, 2024 Â· On average, 57% of respondents supported a paid-donor system with no kidney supply gains, and about 70% supported a paid-donor system when theÂ ...Missing:  peer- | Show results with:peer-\",\"url\":\"https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12483/full\",\"favicon\":\"\"},{\"id\":\"273\",\"title\":\"Altruism in organ donation: an unnecessary requirement?\",\"description\":\"We argue that, despite this prominent role, altruism has been poorly defined in policy and position documents, and used confusingly and inconsistently.\",\"url\":\"https://jme.bmj.com/content/40/2/134\",\"favicon\":\"\"},{\"id\":\"274\",\"title\":\"[PDF] Organ Donation: A Comparison of Altruistic and Market-Based ...\",\"description\":\"For kidney donations there is the risk of hypertension, kidney failure, and proteinuria; for liver donations, there is the possibility of bile leakage,Â ...\",\"url\":\"https://engagedscholarship.csuohio.edu/cgi/viewcontent.cgi?referer=\u0026httpsredir=1\u0026article=1056\u0026context=tdr\",\"favicon\":\"\"},{\"id\":\"275\",\"title\":\"Social Determinants of Health and Race Disparities in Kidney... - LWW\",\"description\":\"Recently, we found significant racial disparities in waitlisting for transplant (13). Black individuals were 25% less likely to be waitlisted, even afterÂ ...\",\"url\":\"https://journals.lww.com/cjasn/fulltext/2021/02000/social_determinants_of_health_and_race_disparities.14.aspx\",\"favicon\":\"\"},{\"id\":\"276\",\"title\":\"Divergent Trends by Patient Age in Racial Disparities in Kidney ...\",\"description\":\"Jun 4, 2025 Â· We identified 1,091,206 White or Black adults initiating dialysis (cohort 1) and 226,703 adults waitlisted (cohort 2) in the United States RenalÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12348215/\",\"favicon\":\"\"},{\"id\":\"277\",\"title\":\"[PDF] Addressing disparities in kidney transplantation\",\"description\":\"Among patients who were initially waitlisted for a kidney transplant in 2013 (most recent data available), the median wait time was 5 years for Black patientsÂ ...Missing:  OPO | Show results with:OPO\",\"url\":\"https://www.kidneyfund.org/sites/default/files/media/documents/addressing-disparities-in-transplantation_1.pdf\",\"favicon\":\"\"},{\"id\":\"278\",\"title\":\"Racial and ethnic disparities in kidney transplantation - ScienceDirect\",\"description\":\"Sep 10, 2025 Â· Post kidney transplant mortality is lowest in Hispanics and Asians. ... Kidney graft survival is worse in African Americans compared to Whites.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0966327425001170\",\"favicon\":\"\"},{\"id\":\"279\",\"title\":\"Gender Disparities in Access to Kidney Transplant - NIH\",\"description\":\"Compared with men, women are less likely to be referred for kidney transplant, less likely to be activated on the waitlist once referred, and less likely toÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9174036/\",\"favicon\":\"\"},{\"id\":\"280\",\"title\":\"Sex Inequities in Kidney Transplantation: A Persistent and ...\",\"description\":\"May 21, 2025 Â· By 2017-2020, this disparity had intensified, with women being 21% less likely to receive an LDKT than men (HR, 0.79; 95% CI, 0.76-0.82). TheÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2825%2900834-0/fulltext\",\"favicon\":\"\"},{\"id\":\"281\",\"title\":\"Intersectional race and gender disparities in kidney transplant ...\",\"description\":\"Jan 25, 2024 Â· Overall, we found that White men have the greatest access at all steps of the transplant process, from referral to eventual living or deceasedÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03453-2\",\"favicon\":\"\"},{\"id\":\"282\",\"title\":\"Perspectives of Nephrologists on Gender Disparities in Access to ...\",\"description\":\"Oct 1, 2023 Â· Background: Gender disparities in access to kidney transplantation are apparent, with women being up to 20% less likely to receive kidneyÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/37471097/\",\"favicon\":\"\"},{\"id\":\"283\",\"title\":\"Socioeconomic Inequities in Preemptive Kidney Transplantation and ...\",\"description\":\"Dec 18, 2024 Â· We observed significant socioeconomic disparities in kidney transplant access, dialysis duration, and graft survival.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39703725/\",\"favicon\":\"\"},{\"id\":\"284\",\"title\":\"Socioeconomic Disparities in Preemptive Kidney Transplant... - LWW\",\"description\":\"Conclusions. Using the HOUSES index, we found significant socioeconomic disparities in preemptive kidney transplantation rates among children. Visual Abstract.Missing:  inequities | Show results with:inequities\",\"url\":\"https://journals.lww.com/kidney360/fulltext/2025/07000/socioeconomic_disparities_in_preemptive_kidney.18.aspx\",\"favicon\":\"\"},{\"id\":\"285\",\"title\":\"Kidney transplantation: Racial or socioeconomic disparities?\",\"description\":\"The percentage of blacks with income below the poverty level is four-fold greater than for whites. The number of one-adult households is three-fold greater.Missing:  inequities | Show results with:inequities\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2899%2970404-X/fulltext\",\"favicon\":\"\"},{\"id\":\"286\",\"title\":\"Socioeconomic disparities in kidney transplant access for patients ...\",\"description\":\"Sep 2, 2024 Â· Our findings reveal the influence of insurance status and socioeconomic factors on access to kidney transplantation among ESKD patients.Missing:  inequities | Show results with:inequities\",\"url\":\"https://academic.oup.com/jamia/article/31/12/2781/7747707\",\"favicon\":\"\"},{\"id\":\"287\",\"title\":\"Geographic hot spots of kidney transplant candidates waitâ€listed ...\",\"description\":\"Novel subâ€regional hot spots were identified in the southeast, southwest, Appalachia, and California, with a majority existing in the southeast.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10078213/\",\"favicon\":\"\"},{\"id\":\"288\",\"title\":\"The Role of Minority Geographic Distribution in Waiting Time for ...\",\"description\":\"In the US, African Americans and other minority groups have longer wait times to deceased donor kidney transplantation than Caucasians. To date, the role ofÂ ...\",\"url\":\"https://www.amjtransplant.org/article/S1600-6135%2822%2925661-5/fulltext\",\"favicon\":\"\"},{\"id\":\"289\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMp2512030?af=R\u0026rss=currentIssue\",\"favicon\":\"\"},{\"id\":\"290\",\"title\":\"Systemic Kidney Transplant Inequities for Black Individuals\",\"description\":\"Jan 14, 2021 Â· For instance, Black individuals are disproportionately harmed by delayed referrals to kidney care and transplant evaluation. Studies suggestÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775070\",\"favicon\":\"\"},{\"id\":\"291\",\"title\":\"Geographic Differences in Racial Disparities in Access to Kidney ...\",\"description\":\"Aug 10, 2023 Â· The extent and predictors of waiting time geographic disparity in kidney transplantation in the United States\",\"url\":\"https://www.kireports.org/article/S2468-0249%2823%2901419-5/fulltext\",\"favicon\":\"\"},{\"id\":\"292\",\"title\":\"Confronting and Eliminating Inequities in the Organ Transplantation ...\",\"description\":\"Disproportionately fewer racial and ethnic minority patients receive organ transplants than are represented on the transplant waiting list. These inequitiesÂ ...STRIVING FOR HEALTH... Â· STRUCTURAL BARRIERS TO...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK580030/\",\"favicon\":\"\"},{\"id\":\"293\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.statista.com/topics/2389/organ-donations-and-transplants/\",\"favicon\":\"\"},{\"id\":\"294\",\"title\":\"[PDF] 2023-data-global-report-20022025.pdf - transplant-observatory.org\",\"description\":\"Dec 31, 2024 Â· Total Kidney transplants pmp. 91/93 countries reported kidney transplant activities (living or deceased) in 2023. âœ“111 135 kidney transplants.\u003c|separator|\u003e\",\"url\":\"https://www.transplant-observatory.org/wp-content/uploads/2025/02/2023-data-global-report-20022025.pdf\",\"favicon\":\"\"},{\"id\":\"295\",\"title\":\"[PDF] 2022 Global Report - transplant-observatory.org\",\"description\":\"This database collects data on global donation and transplantation practices, and it is recognized as a tool for ensuring transparency, equity and monitoringÂ ...\",\"url\":\"https://www.transplant-observatory.org/wp-content/uploads/2023/11/2022-data-global-report_VF_2.pdf\",\"favicon\":\"\"},{\"id\":\"296\",\"title\":\"Global transplantation: Lessons from organ ... - PubMed Central - NIH\",\"description\":\"The Americas lead with 62153 organ transplants, followed by Europe and the Western Pacific with 40337 and 29014 transplants, respectively[12]. Africa lagsÂ ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/\",\"favicon\":\"\"},{\"id\":\"297\",\"title\":\"405.5: The need for rethinking about kidney donation systems. - LWW\",\"description\":\"The numbers demonstrate that the rate of kidney transplants from deceased donors was 61.19% globally, 77.71% in the United States, and 7.76% in Turkiye.Missing:  statistics | Show results with:statistics\",\"url\":\"https://journals.lww.com/transplantjournal/fulltext/2024/09001/405_5__the_need_for_rethinking_about_kidney.515.aspx\",\"favicon\":\"\"},{\"id\":\"298\",\"title\":\"OPTN/SRTR 2023 Annual Data Report: Kidney\",\"description\":\"Five-year graft survival rates were 90.0% for LDKT compared with 82.2% for DDKT in recipients aged 18-34 years, and 80.2% for LDKT versus 66.1% for DDKT inÂ ...\",\"url\":\"https://www.amjtransplant.org/article/S1600-6135%2825%2900026-7/fulltext\",\"favicon\":\"\"},{\"id\":\"299\",\"title\":\"Tribune Pulse - ISODP Issue - October 25 - Volume VIII - Issue 42\",\"description\":\"Oct 21, 2024 Â· According to 2022 data from the GODT, India accounted for 25% of living donor kidney transplants worldwide but only 3% of deceased donor kidneyÂ ...\",\"url\":\"https://tts.org/news/tribune-pulse-weekly-newsletter/1520-tts-tribune-pulse-october-25-volume-viii-issue-42\",\"favicon\":\"\"},{\"id\":\"300\",\"title\":\"Global Estimates of Capacity for Kidney Transplantation in World ...\",\"description\":\"The median global incidence of living donor KT was 5 pmp (IQR: 3â€“11), ranging from 0.04 pmp in Myanmar to 33 pmp in Turkey (Table 1; Figure S2, SDC, http://Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9128615/\",\"favicon\":\"\"},{\"id\":\"301\",\"title\":\"Kidney Transplantation in Sub-Saharan Africa: History and Current ...\",\"description\":\"Table 1. ... The General Observatory on Donation and Transplantation reports that in 2021, Africa was responsible for only 1% of the total number of transplantsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10758520/\",\"favicon\":\"\"},{\"id\":\"302\",\"title\":\"Home - GODT\",\"description\":\"WHO-ONT ; 172.409 Organs transplanted annually (2023) ; 9.5 Â· of increase over 2022 ; 45.861 actual deceased organ donors in 2023 ; 18 transplants/hour in 2023.\",\"url\":\"https://www.transplant-observatory.org/\",\"favicon\":\"\"},{\"id\":\"303\",\"title\":\"Statistics Â· The Kidney Project Â· UCSF\",\"description\":\"Nearly 750,000 patients per year in the United States and an estimated 2 million patients worldwide are affected by kidney failure.\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://pharm.ucsf.edu/kidney/need/statistics\",\"favicon\":\"\"},{\"id\":\"304\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.statista.com/statistics/537935/kidney-transplant-rate-in-europe/\",\"favicon\":\"\"},{\"id\":\"305\",\"title\":\"2021 data of the ERA Registry and the USRDS - Oxford Academic\",\"description\":\"Mar 4, 2024 Â· In the US, 17 357 kidney transplantations were performed, corresponding to a kidney transplantation rate of 77.0 pmp (Table 1, Fig. 1C). TheseÂ ...\",\"url\":\"https://academic.oup.com/ndt/article/39/10/1593/7619140\",\"favicon\":\"\"},{\"id\":\"306\",\"title\":\"U.S. leads world in rates of deceased donors, key transplant ... - UNOS\",\"description\":\"World leader: 38.0* deceased donor rate. *Rates per million population. World leader: 55.6* kidney transplant rate from deceased donors. *Rates per million.\",\"url\":\"https://unos.org/news/in-focus/us-world-leader-deceased-donor-rates/\",\"favicon\":\"\"},{\"id\":\"307\",\"title\":\"A Comprehensive Analysis of the Current Status and Unmet Needs ...\",\"description\":\"In 2014, in Southeast Asia, the rate of organ tx was 3.8 patients per million population (ppmp), compared to 31.6 ppmp in the US and 27.9 ppmp in Europe (6).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5481314/\",\"favicon\":\"\"},{\"id\":\"308\",\"title\":\"Differential impact of opt-in, opt-out policies on deceased organ ...\",\"description\":\"Sep 8, 2022 Â· Although opt-out countries tend to have higher donation rates, there is no conclusive evidence that this is caused by the policy itself. TheÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9462118/\",\"favicon\":\"\"},{\"id\":\"309\",\"title\":\"Comparison of organ donation and transplantation rates between ...\",\"description\":\"Mar 15, 2019 Â· However, we did observe significantly less living donor kidney transplants among opt-out versus opt-in countries (4.5 vs. 15.2, respectively; PÂ ...\",\"url\":\"https://www.kidney-international.org/article/S0085-2538%2819%2930185-1/fulltext\",\"favicon\":\"\"},{\"id\":\"310\",\"title\":\"Opt-out defaults do not increase organ donation rates - ScienceDirect\",\"description\":\"Our longitudinal analysis suggests that changing to an opt-out default does not increase organ donation rates.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S003335062400355X\",\"favicon\":\"\"},{\"id\":\"311\",\"title\":\"Organ donation: Opt-out defaults do not increase donation rates\",\"description\":\"Nov 14, 2024 Â· â€œSimply switching to an opt-out system does not automatically lead to more organ donations,â€ states author Mattea Dallacker, who led the projectÂ ...\",\"url\":\"https://www.mpg.de/23726833/1113-bild-organ-donation-opt-out-defaults-do-not-increase-donation-rates-149835-x\",\"favicon\":\"\"},{\"id\":\"312\",\"title\":\"Kidney transplants increase across all populations following policy ...\",\"description\":\"The new policies were projected to increase equity in access to kidney transplant by distributing organs more fairly to people waiting for an organ. KidneyÂ ...Missing:  Europe Asia\",\"url\":\"https://unos.org/news/in-focus/kidney-transplants-increase-across-all-populations-following-policy-changes/\",\"favicon\":\"\"},{\"id\":\"313\",\"title\":\"Deceased donor kidney transplant policies in Asia - The Lancet\",\"description\":\"Nov 8, 2023 Â· Variations in transplant policy and practice in many Asian countries have affected access to transplantation, especially in lower incomeÂ ...\",\"url\":\"https://www.thelancet.com/journals/lansea/article/PIIS2772-3682%2823%2900172-5/fulltext\",\"favicon\":\"\"},{\"id\":\"314\",\"title\":\"OPTN/SRTR 2020 Annual Data Report: Kidney - PubMed\",\"description\":\"The total number of kidney trans- plants decreased slightly, to 23642, in 2020. The decrease in total kidney transplants was due to a decrease in living donorÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/35266618/\",\"favicon\":\"\"},{\"id\":\"315\",\"title\":\"Transplantation - Annual Data Report | USRDS - NIH\",\"description\":\"By Year 2, 51% were alive and still awaiting transplantation, 16% had received a living donor kidney transplant, 21% had received a deceased donor kidneyÂ ...\",\"url\":\"https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/7-transplantation\",\"favicon\":\"\"},{\"id\":\"316\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.statista.com/statistics/1083404/rate-of-kidney-transplant-activities-worldwide/\",\"favicon\":\"\"},{\"id\":\"317\",\"title\":\"[PDF] international report on organ donation and transplantation activities\",\"description\":\"Dec 31, 2024 Â· Total number of LD transplants: 43 101 kidney transplants. 10 ... Patients dead on Kidney WL pmp. Total Kidney transplants pmp. PatientsÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.transplant-observatory.org/wp-content/uploads/2024/12/2023-data-global-report-17122024.pdf\",\"favicon\":\"\"},{\"id\":\"318\",\"title\":\"Kidney transplantation, improved but still a significant missed ...\",\"description\":\"Mar 4, 2025 Â· This increase in donation rate would amount to a ~5K increase in total kidney transplants per year by 2030. Increasing total kidney transplantsÂ ...\",\"url\":\"https://reconstrategy.com/2025/03/kidney-transplantation-improved-but-still-a-massive-missed-opportunity/\",\"favicon\":\"\"},{\"id\":\"319\",\"title\":\"KRT Roadmap | Kidney Diseases\",\"description\":\"By 2030, it is estimated that 14.5 million people will need KRT, but only 5.4 million will receive it. Â· Estimated that over 2 million people die each year dueÂ ...\",\"url\":\"https://khi.asn-online.org/roadmap/kidney-diseases.aspx\",\"favicon\":\"\"},{\"id\":\"320\",\"title\":\"Kidney Transplant Market Size \u0026 Share| Industry Report, 2030\",\"description\":\"The global kidney transplant market size was estimated at USD 9,235.7 million in 2024 and is projected to reach USD 13,790.7 million by 2030, growing at a CAGRÂ ...\",\"url\":\"https://www.grandviewresearch.com/industry-analysis/kidney-transplant-market-report\",\"favicon\":\"\"},{\"id\":\"321\",\"title\":\"Kidney Transplant Market Size \u0026 Opportunities, 2025-2032\",\"description\":\"Jun 17, 2025 Â· The kidney transplant market size is estimated to be valued at USD 9.96 Bn in 2025 and is expected to reach USD 13.65 Bn by 2032, exhibiting a compound annualÂ ...\",\"url\":\"https://www.coherentmarketinsights.com/market-insight/kidney-transplant-market-4887\",\"favicon\":\"\"}],\"images\":[{\"id\":\"cd4fee5e24de\",\"caption\":\"Kidney transplant procedure\",\"url\":\"./_assets_/Kidtransplant.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"f5b9f366c3f4\",\"caption\":\"The Herrick twins' kidney transplant in 1954\",\"url\":\"./_assets_/Herrick_kidney_transplant.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"4e71fc61e332\",\"caption\":\"Kidney for transplant from live donor\",\"url\":\"./_assets_/Kidney_for_transplant_from_live_donor.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"cd4fee5e24de\",\"caption\":\"Kidney transplant implantation\",\"url\":\"./_assets_/Kidtransplant.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"333574724237\",\"caption\":\"Schema of pancreas-kidney transplantation\",\"url\":\"./_assets_/lossy-page1-250px-Schema_der_Pankreas-Nierentransplantation_mit_portalven%C3%B6ser_Anastomose_des_Pankreastransplantats.tif.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"140c21b76267\",\"caption\":\"Renal graft biopsy showing acute cellular rejection\",\"url\":\"./_assets_/Acute_cellular_rejection%252C_renal_graft_biopsy.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Kidney_transplantation\",\"title\":\"Kidney transplantation\",\"content\":\"$1f\",\"description\":\"Kidney transplantation\\n\\nKidney transplant procedure \\nKidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with...\",\"metadata\":{\"categories\":[\"kidney transplant\",\"renal transplantation\",\"renal transplant\",\"KT\"],\"lastModified\":\"1761582967\",\"contentLength\":\"149601\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"85174\",\"recentViews\":\"85174\",\"dailyAvgViews\":2839.13330078125,\"qualityScore\":1,\"lastViewed\":\"1761886978\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886979327,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Kidney_transplantation\"],\"queryHash\":\"[\\\"page\\\",\\\"Kidney_transplantation\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Kidney transplantation\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis. The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"kidney transplant, renal transplantation, renal transplant, KT\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Kidney_transplantation\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Kidney transplantation\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis. The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Kidney_transplantation\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Kidney transplantation\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:42.967Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Kidney transplantation\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Kidney transplantation is a surgical procedure in which a healthy kidney from a living or deceased donor is implanted into a patient with end-stage renal disease to restore renal function, offering superior long-term survival and quality of life compared to dialysis. The first successful human kidney transplant occurred on December 23, 1954, when surgeon Joseph E. Murray transplanted a kidney between identical twins Ronald and Richard Herrick at Peter Bent Brigham Hospital in Boston, avoiding...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NGYyZWRmODUtYzEyYi00YzBhLWFiZmEtOGJiZjY3MWFkMWQ1">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Kidney_transplantation\"}]}]\n"])</script></body></html>